VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 15 (1-12 agosto / 2024)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

La vacuna nasal contra la COVID-19 detiene la infección en ensayos con animales

1 ago. Una vacuna nasal de próxima generación contra COVID-19 parece hacer lo que las vacunas inyectables no pueden: en realidad detener la propagación del virus de persona a persona.

Los hámsters que recibieron la vacuna nasal no transmitieron el virus a otros si se infectaban, rompiendo el ciclo de transmisión, informaron los investigadores en la edición del 31 de julio de la revista Science Advances.

El estudio con animales proporciona más evidencias de que las vacunas administradas en la nariz o la boca podrían ser la clave para controlar la propagación de infecciones respiratorias como la influenza y COVID, dijeron los investigadores.

"Para prevenir la transmisión, hay que mantener baja la cantidad de virus en las vías respiratorias superiores", señaló el investigador sénior, Jacco Boon, profesor de medicina, microbiología molecular y patología e inmunología de la Facultad de Medicina de la Universidad de Washington, en St. Louis.

"Para empezar, cuanto menos virus haya, menos probabilidades hay de infectar a otra persona si tose o estornuda, o incluso si simplemente respira sobre ellos", añadió Boon en un comunicado de prensa de la universidad. "Este estudio muestra que las vacunas contra la mucosa son superiores a las vacunas inyectables en términos de limitar la replicación viral en las vías respiratorias superiores y prevenir la propagación al siguiente individuo".

"En una situación epidémica o pandémica, este es el tipo de vacuna que se va a querer", concluyó Boon.

Aunque las primeras vacunas contra el COVID lograron reducir la enfermedad grave y la muerte, las inyecciones no pudieron prevenir la propagación del virus. Una persona vacunada levemente enferma aún podría transmitir el virus a otra persona.

Los virus como la gripe, COVID y VRS se multiplican rápidamente en la nariz, lo que permite que se propaguen de persona a persona a través de la tos, los estornudos e incluso la respiración, apuntaron los investigadores.

Las vacunas inyectables tradicionales son mucho menos potentes en la nariz que en el torrente sanguíneo, lo que deja a la nariz relativamente desprotegida contra los virus que se multiplican rápidamente y se propagan fácilmente.

Los investigadores han teorizado durante mucho tiempo que una vacuna administrada por la nariz o la boca a través de aerosoles o gotitas podría reducir la transmisión de enfermedades al desencadenar una respuesta inmunitaria justo donde más se necesita.

Para este estudio, los investigadores utilizaron un proceso de dos pasos para probar una vacuna nasal contra COVID utilizada en la India contra la vacuna inyectable de Pfizer en un grupo de hámsters.

Los hámsters son naturalmente susceptibles a COVID, a diferencia de los ratones, lo que los convierte en un mejor animal de laboratorio con el que estudiar la transmisión del virus, explicaron los investigadores.

Después de dar a los hámsters vacunados unas semanas para desarrollar una respuesta inmunitaria

completa, los investigadores infectaron a otros hámsters con COVID y los juntaron a todos durante ocho horas.

La mayoría de los hámsters vacunados se infectaron, y el coronavirus se encontró después en las narices de 12 de 14 que recibieron la vacuna nasal y 15 de 16 que recibieron la inyección, dijeron los investigadores.

Sin embargo, los hámsteres que recibieron la vacuna nasal tenían niveles de virus en las vías respiratorias que eran de 100 a 100,000 veces más bajos que los de los hámsteres vacunados con una inyección, muestran los resultados.

En el segundo paso, los investigadores tomaron hámsters vacunados que se infectaron y los colocaron con otros hámsteres sanos durante ocho horas.

Ninguno de los hámsters expuestos a hámsters vacunados por la nariz se infectó, independientemente de si los nuevos hámsters habían sido vacunados o no, según muestran los resultados.

Por otro lado, alrededor de la mitad de los nuevos hámsters expuestos a los vacunados por inyección se infectaron, apuntaron los investigadores.

La vacunación por vía nasal rompió el ciclo de transmisión, concluyeron los investigadores.

"Las vacunas contra las mucosas son el futuro de las vacunas contra las infecciones respiratorias", dijo Boon. "Históricamente, el desarrollo de este tipo de vacunas ha sido un reto. Todavía hay mucho que no sabemos sobre el tipo de respuesta inmunitaria que necesitamos y cómo provocarla. Creo que vamos a ver muchas investigaciones muy interesantes en los próximos años que podrían conducir a grandes mejoras en las vacunas contra las infecciones respiratorias".

Fuente: infobae. Disponible en https://acortar.link/L0KtAo

Swissmedic authorises dengue fever vaccine

Aug 2. Qdenga (powder and solvent for solution for injection in a pre-filled syringe) can be placed on the market in Switzerland.

To date, no vaccine against dengue fever was authorised in Switzerland. At the end of July 2024, Swissmedic authorised the vaccine Qdenga, from manufacturer Takeda Pharma AG, after assessing its efficacy, safety and quality.

The vaccine is authorised for people aged 4 years and older who are travelling to regions in which dengue fever is prevalent. These primarily include subtropical and tropical regions in Central Africa, Latin America, India and Southeast Asia. The disease is also present in the south of the USA (Texas).

Qdenga helps to protect against dengue fever. The vaccine can be administered to adults, adolescents and children aged 4 years and older. It contains attenuated (weakened) versions of dengue virus variants 1, 2, 3 and 4. They cannot cause the disease but trigger the immune system (the body's natural defences) to defend the body against the virus. When a person receives the vaccine, their immune system recognises the attenuated variants as being foreign and forms antibodies against them. When they come into contact with the virus again, the body rapidly produces more antibodies to neutralise it before the person contracts dengue fever.

Dengue fever is a viral disease that is spread by infected mosquitoes (mainly yellow fever mosquitoes and Asian tiger mosquitoes). It usually develops between four and seven days after the person is bitten.

Symptoms include fever, headache, pain behind the eyes, muscle and joint pain, nausea or vomiting, swollen glands and rash.

Fuente: Swissmedic. Disponible en https://acortar.link/QHSzqW

Ante la preocupación por una nueva pandemia, un laboratorio argentino desarrollará la vacuna contra la gripe aviar

3 ago. El laboratorio argentino Sinergium Biotech comenzó la investigación para el desarrollo de una vacuna contra la gripe aviar dentro de un programa de la Organización Mundial de la Salud (OMS) que permitirá prepararse contra una posible pandemia. El proyecto trabaja con la tecnología del ARN mensajero (ARNm), usada contra la COVID-19, y se inicia en un contexto de crecientes contagios de virus H5N1 (de gripe aviar) en mamíferos. En junio se confirmó la primera muerte humana, un hombre en México sin antecedentes de contacto directo con aves silvestres.

Esta semana, la OMS anunció el nuevo proyecto de desarrollo y accesibilidad de vacunas experimentales de ácido ribonucleico mensajero (ARNm) contra la gripe aviar (H5N1) para los fabricantes de países de ingresos medianos y bajos. Forma parte del programa de Transferencia de Tecnología de ARNm de la OMS y el Medicines Patent Pool (MPP) y el laboratorio Sinergium Biotech desarrollará la vacuna para después compartir el conocimiento con otras empresas para agilizar la fabricación ante una posible pandemia. Este laboratorio forma parte del grupo Insud, fundado por Hugo Sigman y Silvia Gold. Otra empresa del grupo, mAbxience, estuvo a cargo de la producción del principio activo de la vacuna contra la COVID-19 de AstraZeneca, desarrollada por la Universidad de Oxford, para América Latina.

“Tenemos 14 diseños de candidatos vacunales, estamos en la etapa de descubrimiento y prueba de concepto. Son ensayos en animales en curso y ensayos in vitro. Los resultados vienen muy bien”, le dijo a elDiarioAR Germán Sánchez, gerente de I+D de la empresa argentina.

Una de las preocupaciones de los investigadores es la extensión acelerada del virus, no solo en aves sino también en mamíferos. En Estados Unidos se registraron brotes en vacas de ocho estados y se detectó el virus en leche no pasteurizada, que derivó en trabajadores con la enfermedad. En 2022, la gripe produjo mortalidad en lobos y elefantes marinos de Perú, Chile y Argentina. También está presente en la Antártida. Si bien en Europa la gripe aviar se mantiene solo en aves silvestres, están en alerta por la rapidez con la que se mueve el virus.

“Realmente lo que está ocurriendo a nivel animales es un brote, una pandemia a nivel zoonótico. Hay mucha potencialidad de que eso pueda seguir avanzando y el problema es cuando la influenza se empieza a mezclar. Principalmente porque este virus se puede llegar a mezclar con un virus estacional y de esa forma adquirir capacidades de ingresar al humano. Hoy en día no ingresa fácilmente al humano a menos que tenga algún evento de recombinación con otro virus como puede ser un virus estacional”, detalló Sánchez.

En junio de este año, la OMS confirmó la primera muerte por gripe aviar H5N2. Se trata de una persona de 59 años que murió el 24 de abril en México después de tener fiebre, dificultad respiratoria, diarrea, náuseas y malestar general. Se trata del primer caso humano confirmado en un laboratorio de una infección por el subtipo A(H5N2) de la gripe aviar notificado en todo el mundo. La víctima no tenía antecedentes de exposición a aves de corral u otros animales.

“Venimos detectando el comportamiento desde el 2002 y ahora se ha extendido a mamíferos. Esto nos

alentó a seguir incursionando en el desarrollo de la vacuna. Teniendo experiencia en la tecnología de la ARN, buscamos las secuencias de los genomas de los virus que estaban circulando. Lo que hicimos fue modificar la secuencias, extraer unas porciones del genoma del virus de influenza, de una proteína de superficie del virus que se llama hemaglutinina", explicó Sánchez.

El laboratorio estima que para el 2025 tendrán los estudios preclínicos y toxicológicos y en lo que resta de este año buscan reducir los candidatos vacunales, que hoy son 14, en función de la inmunogenicidad y de los rendimientos de producción. El desarrollo de la vacuna podría estar listo para el año 2026, aunque los tiempos dependen también de la construcción de una nueva planta de tecnología de ARN que Sinergium Biotech comenzó en Argentina, una de las primeras en la región. "Es una vacuna que está pensada inicialmente para humanos, pero no quita que con pequeñas modificaciones se pueda llegar a vacunar animales. Arrancamos con H5N1 y después este programa va a migrar a otros tipos de influenza estacionales, como la vacuna de gripe", anticipó el investigador.

Una vez que el laboratorio obtenga los datos preclínicos suficientes, va a compartir la información sobre técnicas y materiales con otros fabricantes que integran el Programa de Transferencia de Tecnología de ARNm para que puedan agilizar la fabricación de esas vacunas y reforzar la preparación contra una posible pandemia. Son empresas públicas, privadas o mixtas de países de ingresos medianos y bajos del Hemisferio Sur como Egipto, Kenia, Nigeria, Senegal, Túnez, Bangladesh, Indonesia, India, Pakistán, Serbia, Sudáfrica, Ucrania y Vietnam. La idea es que tengan la capacidad para producir vacunas de ARNm no solo para COVID-19, sino también para la producción de otras inmunizaciones críticas para el sistema de salud.

"Esta iniciativa ilustra a la perfección el motivo por el que la OMS creó el programa, que no es otro que el de impulsar la investigación, el desarrollo y la producción en países de ingresos medianos y bajos con el fin de prepararnos mejor para actuar eficaz y equitativamente en el caso de que se declare una pandemia", dijo el director General de la OMS, Tedros Adhanom Ghebreyesus, durante la presentación del proyecto de gripe aviar.

"El programa intenta democratizar esta tecnología ARN, que en la pandemia estaba segmentada en Estados Unidos o en Alemania, con compañías que no transfirieron su tecnología. Lo que se vio es que así se logran respuestas más rápidas en pandemia. Tiene un rol muy importante a nivel social. Mientras más rápido sacás la vacuna, más vidas terminás salvando", explicó Sánchez.

Fuente: el Diario AR. Disponible en https://acortar.link/JgpzSu

SK Bioscience's Investments Charge Momentum for Vaccine Production

Aug 5. SK Bioscience, which acquired Germany's IDT Biologika in June, announced on July 25th that it has entered into a conditional equity purchase agreement (SAFE) to invest approximately $2.1 million in the U.S. biotech company Sunflower Therapeutics. This partnership is expected to create significant technological synergies between the two companies.

Founded in 2018, Sunflower Therapeutics is a biotech firm that has developed the 'Yeast Expression System,' a protein manufacturing technology essential for the development of antigens and antibodies.

This system simplifies the vaccine production process, reducing the time required and enhancing overall efficiency, thereby lowering manufacturing costs.

Through this SAFE investment, SK Bioscience aims to optimize its vaccine production processes using Sunflower's technology. The company anticipates that incorporating Sunflower's Yeast Expression System into the vaccine production line at its Andong L House facility could improve yield by up to 7.7 times compared to current methods. This enhancement is projected to reduce production costs per dose by 88.7%.

The two companies first established their relationship in 2023 while collaborating on the research and development of a human papillomavirus (HPV) vaccine. SK Bioscience plans to explore various strategies to maximize the value of its investment during Sunflower's potential future IPO and third-party mergers and acquisitions, while also expanding their technological collaboration.

An SK Bioscience representative stated, "We have been continuously collaborating with Sunflower since last year. Due to the potential changes in our equity stake depending on Sunflower's IPO and other related events, we cannot disclose the specific percentage of our holdings in Sunflower."

Meanwhile, in June, SK Bioscience invested approximately $250 million to acquire IDT Biologika, a German contract development and manufacturing organization (CDMO) for biopharmaceuticals. IDT Biologika has an impressive track record recognized by regulatory agencies in the U.S., Europe, and more than ten other key pharmaceutical markets.

At a press conference on June 27th, Ahn Jae-yong, CEO of SK Bioscience, stated, "From SK Bioscience's perspective, the acquisition of IDT Biologika is a 'perfect fit.' There are complementary aspects between the company's Andong L House vaccine plant and IDT Biologika. By combining the software and hardware of both companies, we aim to create immediate synergies and expand our revenue."

SK Bioscience has expanded its production capacity with the acquisition of IDT Biologika and aims to optimize its vaccine processes through its investment in Sunflower Therapeutics. This move is seen as an effort to seek synergies in the field of vaccine development.

An SK Bioscience representative commented, "The investment in Sunflower considers the potential synergies with the acquisition of Germany's IDT. Regardless of the synergies from the IDT acquisition, various technologies from Sunflower can be utilized in multiple aspects at the Andong L House vaccine plant."

Fuente: Hit News. Disponible en https://acortar.link/D7arta

Las vacunas COVID reducen el riesgo de infarto y ACV, concluyó un estudio que evaluó a 46 millones de personas

5 ago. Las vacunas son un hito histórico en el sistema de salud global y cada año salvan entre 3,4 y 5 millones de vidas en todo el mundo. Al vacunarse, el sistema inmunológico de una persona se activa, por lo que se reduce el riesgo de contraer enfermedades prevenibles por inmunización.

Además, la inmunización brinda beneficios integrales para la salud, al proteger al organismo de diversas patologías

asociadas. En ese sentido, una nueva investigación mostró evidencia contundente sobre el papel de las vacunas contra el SARS-CoV-2 como escudo protector contra las enfermedades del corazón.

La incidencia de los infartos de miocardio y accidentes cerebrovasculares (ACV) ha disminuido significativamente tras la vacunación contra la COVID-19, según el estudio publicado en la revista *Nature Communications*. El trabajo fortalece la evidencia sobre los beneficios de la vacunación, no solo en términos de prevención de COVID-19, sino también en la reducción de incidentes cardiovasculares.

La investigación, que fue dirigida por las universidades británicas de Cambridge, Bristol y Edimburgo, junto con Centro de Ciencia de Datos de la Fundación Británica del Corazón (BHF, por sus sigla en inglés), analizó un vasto conjunto de datos pertenecientes a 46 millones de personas en Inglaterra -casi toda la población adulta del país- durante el periodo comprendido entre el 8 de diciembre de 2020 y el 23 de enero de 2022.

De acuerdo al análisis, la incidencia de trombosis arteriales, incluyendo infartos de miocardio y accidentes cerebrovasculares (ACV), se redujo hasta en un 10% en las 24 semanas posteriores a la administración de la primera dosis de la vacuna contra la COVID-19.

Este descenso fue aún más pronunciado tras la segunda dosis, alcanzando una disminución del 27% con la vacuna de AstraZeneca y del 20% con la vacuna de Pfizer/Biotech. “La vacunación demostró ser una herramienta clave no sólo en la prevención de la enfermedad grave por COVID-19, sino también en la reducción de complicaciones cardiovasculares”, afirmaron los investigadores en el mencionado estudio.

Además, el estudio analizó la incidencia de episodios trombóticos venosos, como la embolia pulmonar y la trombosis venosa profunda de las extremidades inferiores, trastornos que siguieron un patrón similar de reducción post-vacunación. “Estos hallazgos subrayan la eficacia del programa de vacunación en la protección integral contra diversas complicaciones de salud”, añadieron los investigadores.

El equipo de investigación del Centro de Ciencia de Datos de la Fundación Británica del Corazón (BHF) utilizó datos no identificados de consultas médicas, ingresos hospitalarios y registros de defunciones, asegurando que el análisis se realizara dentro de un entorno de datos seguro.

Complicaciones cardiovasculares raras post vacunación



Algunos estudios previos habían identificado una incidencia mayor de complicaciones cardiovasculares raras en ciertas vacunas contra la COVID-19, como la miocarditis y pericarditis (inflamación del corazón) asociada a las vacunas basadas en ARNm o la trombocitopenia trombótica inducida por vacunas basadas en adenovirus, como la de AstraZeneca.

Los científicos del estudio remarcaron que estas complicaciones fueron eventuales, confirmaron que los beneficios de la vacunación superan los riesgos asociados a efectos secundarios extremadamente raros y a las secuelas que deja en el organismo la infección por COVID-19.

En ese mismo sentido, la investigación publicada en *Nature Communications* suma tranquilidad al no identificar nuevas afecciones cardiovasculares adversas vinculadas a la vacunación. Este estudio refuerza la percepción de que los beneficios de la vacunación superan ampliamente los riesgos, incluso en grupos con preexistencias cardiovasculares.

Además, uno de los puntos clave del trabajo es la observación de que la incidencia de enfermedades cardiovasculares es mayor tras sufrir COVID-19, especialmente en los casos graves. Esta podría ser una de las razones por las que la vacunación resulta en una menor incidencia de infartos de miocardio y accidentes cerebrovasculares comparado con las personas no vacunadas.

El profesor Nicholas Mills, coautor del estudio y profesor de Cardiología en la Universidad de Edimburgo, manifestó: “Nuestros hallazgos confirman que la vacunación contra COVID-19 no solo es crucial para prevenir la enfermedad en sí, sino que también tiene un impacto positivo significativo en la reducción de complicaciones cardiovasculares”.

Por otro lado, el doctor Steven Liu de la Universidad de Cambridge, remarcó: “Este enorme estudio nos proporciona la evidencia más robusta disponible hasta la fecha sobre la relación entre la vacunación y la reducción de riesgos cardiovasculares”.

El especialista de Cambridge dijo que el trabajo representó un gran esfuerzo que mostró la importancia de las iniciativas de datos a gran escala para comprender mejor los efectos secundarios de las vacunas y resaltar sus beneficios adicionales. “Analizar datos de casi toda la población adulta de Inglaterra nos permite hacer observaciones muy amplias y representativas sobre los efectos de la vacunación”, afirmó el doctor Liu.

Los investigadores esperan que estos resultados incrementen la confianza pública en las vacunas y ayuden a mitigar cualquier reticencia frente a la vacunación.

El profesor William Whiteley, director asociado del Centro de Ciencias de Datos de BHF y profesor de Neurología y Epidemiología de la Universidad de Edimburgo, dijo: “El lanzamiento del programa de vacunación COVID-19 comenzó con fuerza en el Reino Unido, con más del 90% de la población mayor de 12 años vacunada con al menos una dosis en enero de 2022. Este estudio realizado en toda Inglaterra ofrece a los pacientes la tranquilidad de que la primera, segunda y dosis de refuerzo de las vacunas contra la COVID-19 son seguras para el sistema cardiovascular. Demuestra que los beneficios de la segunda dosis y de las dosis de refuerzo, con menos eventos cardiovasculares comunes (infartos de miocardio y accidentes cerebrovasculares) después de la vacunación, superan las complicaciones cardiovasculares muy poco frecuentes”.

La coautora principal, la Dra. Venexia Walker, investigadora asociada de la Universidad de Bristol, afirmó: “Dado el papel fundamental que desempeñan las vacunas contra la COVID-19 en la protección de las personas contra la COVID-19, es importante que sigamos estudiando los beneficios y los riesgos asociados a ellas. La disponibilidad de datos de toda la población nos ha permitido estudiar diferentes combinaciones de vacunas contra la COVID-19 y considerar complicaciones cardiovasculares poco frecuentes. Esto no habría sido posible sin la gran cantidad de datos a los que tenemos el privilegio de acceder y nuestras estrechas colaboraciones entre instituciones”.

Fuente: Infobae. Disponible en https://acortar.link/hfvEKs

Los casos de COVID-19 van al alza en el mundo y existe el riesgo de aparición de nuevas variantes

7 ago. La agencia sanitaria mundial alerta del aumento de contagios y estima poco probable que la oleada disminuya en el corto plazo. Asimismo, expresa preocupación por la baja en la cobertura de vacunación, sobre todo ante la posibilidad de que surja una cepa más virulenta que pudiera causar enfermedad grave.

Las infecciones por COVID-19 están aumentando en todo el mundo y es poco probable que disminuyan en el corto plazo, advirtió este martes la Organización Mundial de la Salud (OMS), que también destacó el riesgo de que pronto aparezcan variantes más graves del coronavirus.

"La COVID-19 todavía está muy presente" y circula en todos los países, dijo la directora de Prevención de Pandemias de la OMS, la doctora Maria Van Kerkhove.

En conferencia de prensa en Ginebra, la epidemióloga indicó que los datos del sistema de vigilancia de la agencia sanitaria, basados en centinelas en 84 países, informan en este momento que el porcentaje de pruebas positivas para SARS-CoV-2 ha aumentado durante varias semanas.

“Las pruebas con resultado positivo rebasan el 10%, pero la cifra fluctúa según la región. En Europa, ese porcentaje es superior al 20%", detalló.

Además, se han registrado nuevas olas de infección en América, Europa y el Pacífico occidental.

La vigilancia de las aguas residuales sugiere que la circulación del SARS-CoV-2 es de dos a 20 veces mayor que las cifras documentadas.

Circulación atípica durante el verano

Las tasas de circulación de infecciones tan elevadas en los meses de verano boreal son atípicas para los virus respiratorios, que tienden más bien a propagarse principalmente en temperaturas frías.

Sin embargo, en los últimos meses, muchos países han experimentado oleadas de COVID-19, independientemente de la temporada.

Esto está ocurriendo ahora mismo en los Juegos Olímpicos, “donde al menos 40 atletas dieron positivo”, dijo Van Kerkhove.

Riesgo creciente de nuevas cepas

La experta subrayó que a medida que el virus continúa evolucionando y propagándose, existe el riesgo creciente de que aparezca una cepa más grave del virus que pueda evadir los sistemas de detección y no responder a la intervención médica.

“Estoy preocupada”, enfatizó la especialista de la OMS, argumentando que con una cobertura de vacunación tan baja y una circulación tan grande, “si tuviéramos una variante que fuera más virulenta, la susceptibilidad de las poblaciones en riesgo a desarrollar una enfermedad grave sería enorme”, acotó.

Fortalecer las campañas de vacunación

Si bien las admisiones hospitalarias, incluidas las de cuidados intensivos, siguen siendo mucho menores que durante el pico de la pandemia, la OMS instó a los gobiernos a fortalecer las campañas de vacunación, garantizando que los grupos de mayor riesgo reciban las vacunas al menos una vez cada doce meses.

“Como individuos, es importante tomar medidas para reducir el peligro de infección y enfermedad grave, incluyendo asegurarse de haber recibido una dosis de la vacuna contra el COVID-19 en los últimos doce

meses, especialmente si se pertenece a un grupo de riesgo", enfatizó Van Kerkhove.

La OMS detalló que la disponibilidad de vacunas ha disminuido sustancialmente en los últimos 18 meses porque el número de productores de vacunas contra el coronavirus se ha reducido.

La doctora Van Kerkhove señaló que es muy difícil para los fabricantes mantener el ritmo de producción, al margen de que no hace falta que mantengan el paso de 2021 y 2022. "Pero seamos muy claros: existe un mercado para las vacunas contra la COVID-19 que ya están hechas.

En cuanto a las vacunas nasales, precisó que aún están en desarrollo y explicó que podrían abordar la transmisión, reduciendo así el riesgo de más variantes, infecciones y enfermedad grave.

Fuente: reliefweb. Disponible en https://acortar.link/slVALx

VAX-31 is the Broadest Spectrum Pneumococcal Conjugate Vaccine in the Clinic Today

Aug 7. Vaxcyte, Inc. today announced financial results for the second quarter ended June 30, 2024, and provided a business update.

"We continue to make significant strides toward building the potentially best-in-class pneumococcal conjugate vaccine (PCV) franchise and expect to announce the VAX-31 adult Phase 1/2 study topline safety, tolerability and immunogenicity data in September," said Grant Pickering, Chief Executive Officer and Co -founder of Vaxcyte, in a press release on August 6, 2024.

"Our clinical program assessing VAX-31, the broadest-spectrum PCV in the clinic today, will provide significant insights into the full potential of this vaccine candidate across the adult population."

"Following the VAX-31 adult data readout, we plan to advance either VAX-24 or VAX-31 into Phase 3 clinical development in adults."

Mr. Pickering continued, "Additionally, we look forward to delivering the topline data from the primary immunization series of the VAX-24 infant Phase 2 study by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025."

"We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market today."

The Company also confirmed cash, cash equivalents, and investments were $1,851.9 million as of June 30, 2024, compared to $1,242.9 million as of December 31, 2023.

Fuente: Precision Vaccinations. Disponible en https://acortar.link/tHxKr5

MSD Korea introduces Vaxneuvance: The first pneumococcal vaccine with proven immunogenicity

Aug 7. "Vaxneuvance, a pneumococcal protein conjugate vaccine introduced after 13 years, has demonstrated either superior immunogenicity or at least comparable effectiveness to the existing PCV13 vaccine in all 15 serotypes, including the newly added 22F and 33F."

MSD Korea, the Korean branch of the multinational pharmaceutical company MSD (Merck, USA), hosted a media seminar on August 6 at Seoul Square in Jung-gu District, Seoul. The event, themed “Vaxneuvance: Opening the Era of Pneumococcal Vaccine Immunogenicity,” highlighted the vaccine’s strengths. Key speakers included Cho Min-hee, Head of the External Cooperation Division of MSD Korea, Cho Jae-yong, Executive Director of the Vaccine Business Division of MSD Korea, and Professor Kang Hyun-mi of the Department of Pediatrics at the Catholic University of Korea Seoul St. Mary's Hospital.

By adding the two important serotypes, 22F and 33F, identified as major serotypes causing pneumococcal diseases worldwide, into the 13 serotypes, Vaxneuvance has expanded its scope of protection. The vaccine has shown immunogenicity that aligns with all World Health Organization (WHO) standards for each of the 15 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F).

At the seminar, Professor Kang Hyun-mi of the Department of Pediatrics at the Catholic University of Korea Seoul St. Mary's Hospital delivered a presentation on “A Time of Great Change in the Pneumococcal Vaccine Market, Vaccine Selection Criteria, and the Clinical Value of Vaxneuvance.” She noted that 34% of Korean invasive pneumococcal disease cases were caused by serotypes 19A, 19F, and 3, while 66% were caused by 23A. Although the incidence of invasive pneumococcal disease in Korea has significantly decreased since the introduction of PCV13, the incidence of disease caused by 23A has remained unchanged.

"When developing a new PCV, there is a risk that including additional serotypes could reduce the vaccine’s immunogenicity against the common ones," Kang stated. This suggests that the effectiveness of the vaccine in preventing invasive pneumococcal disease might be reduced.

In fact, an analysis of the main phase 3 clinical trial results revealed that immunogenicity for common serotypes decreased as the number of serotypes in the PCV increased. Consequently, the WHO defines 'immunogenicity' as the capacity of a vaccine to produce a measurable immune response.

Vaxneuvance, which includes 15 pneumococcal serotypes, has been proven safe and immunogenic in over 20,000 subjects. In particular, the phase 3 clinical trial (PNEU-PED) demonstrated Vaxneuvance’s non-inferior immunogenicity for the 13 common serotypes and stronger immunogenicity for serotypes 3, 22F, and 33F.

Since April, Vaxneuvance has been part of the National Immunization Program (NIP) for children, allowing free administration at hospitals and clinics nationwide. The NIP targets all children aged 2 months to under 5 years, including those who have not yet been vaccinated with the pneumococcal conjugate vaccine or have not completed their vaccination schedule.

Clinical studies on children have confirmed that Vaxneuvance can be cross-vaccinated with the existing PCV13. Thus, children who have received at least one dose of PCV13 can cross-vaccinate with Vaxneuvance for the remaining recommended vaccinations. "Since its inclusion in the NIP, Seoul St. Mary's Hospital has started vaccinating with the 15-valent vaccine," Professor Kang expressed. "The vaccination rate is high," she added.

Fuente: THE BIO NEWS. Disponible en https://acortar.link/azUISE

El VRS suele preceder a las infecciones bacterianas por neumococo

El virus respiratorio sincitial (VRS) y el neumococo son dos de los patógenos respiratorios (el primero, un virus; el segundo, una bacteria) más comunes que afectan tanto a niños como a adultos mayores. Su interacción es muy relevante en el contexto de las infecciones respiratorias, pues, tal y como destaca Federico Martinón-Torres, jefe de Pediatría y director de Pediatría Traslacional y Enfermedades Infecciosas en el Hospital Clínico Universitario de Santiago de Compostela, en declaraciones a GM, "el VRS suele preceder a las infecciones bacterianas por neumococo.

"Este fenómeno se debe a que el VRS puede dañar el epitelio respiratorio, lo que facilita la adhesión y colonización del neumococo", explica. De hecho, a nivel molecular, se ha demostrado su interacción directa. "El VRS aumenta la expresión de receptores en las células epiteliales respiratorias que el neumococo utiliza para adherirse e invadir los tejidos; la coinfección es frecuente y puede conducir a complicaciones severas como la neumonía y la sepsis", apunta Martinón-Torres.

Interacción entre VRS y neumococo



En este sentido, la interacción entre este virus y esta bacteria quedó patente durante la pandemia de COVID-19. El experto afirma que, al dejar de circular el VRS y, por tanto, reducirse las infecciones a consecuencia del virus, también cayó la incidencia de la enfermedad neumocócica. Eso sí, Martinón-Torres aclara que, aunque se redujeron los casos de enfermedad, no disminuyó la transmisión de neumococo de persona a persona, es decir, la "tasa de portadores de neumococo era similar a la pre-pandemia".

Estas interacciones entre VRS y neumococo "varían con la edad". En niños, las infecciones son "más frecuentes y severas" debido a la "inmadurez" de su sistema inmunológico, mientras que en los adultos, especialmente en aquellos que padecen comorbilidades o tienen una edad avanzada, "la severidad de las infecciones puede ser alta" por la disminución de la respuesta inmunitaria y la presencia de enfermedades crónicas como la diabetes o la enfermedad pulmonar obstructiva crónica (EPOC).

"La diferencia en la respuesta inmunitaria se debe principalmente a la ontogenia del sistema inmunológico en los niños y la inmunosenescencia en los adultos mayores", resume Martinón-Torres. "Durante la pandemia, se observó que las infecciones respiratorias en adultos mayores tenían peores desenlaces, resaltando la necesidad de entender las diferencias inmunológicas por edad, entre otros factores", agrega.

La importancia de la inmunización

Ante este hecho, el experto apunta a la importancia de la inmunización, "herramienta clave para prevenir infecciones respiratorias". "La vacuna neumocócica, especialmente la vacunación conjugada, ha reducido significativamente la incidencia de enfermedades invasivas por neumococo en todas las edades", asegura. También recuerda que está disponible la inmunización frente al VRS en lactantes con el anticuerpo monoclonal nirsevimab o protección pasiva a través de vacunas VRS para la gestante, así como en adultos con "tres vacunas disponibles que han demostrado una gran eficacia".

Respecto a una posible inmunización cruzada, Martinón-Torres es precavido: "Es pronto para sacar

conclusiones sobre su interacción, sin embargo, sabemos que la vacunación frente a neumococo, reduce la incidencia de infecciones respiratorias de cualquier etiología y específicamente de infecciones virales graves". "Y en el caso del nirsevimab, hemos visto también una reducción de las infecciones respiratorias de cualquier causa, y no solo del VRS", añade.

"De algún modo esto apunta a la interrelación que existe entre virus y bacterias y más específicamente entre neumococo y VRS, reforzando el papel de protección sinérgica que estas medidas de prevención pueden tener", concluye el experto.

Además, la prevención es más importante si cabe en el contexto de la conocida como 'tripledemia', es decir, circulación simultánea de VRS, gripe y COVID-19. "Para abordar esta situación, se recomienda una estrategia integral en la que, sin duda, la vacunación es un pilar fundamental", asevera. Porque, "al margen de las interacciones especificas entre estos patógenos y con otros patógenos, no debemos olvidar que la infección secuencial también tiene consecuencias muy graves", explica Martinón-Torres.

De este modo, de cara a la próxima temporada de infecciones respiratorias, la vacunación es "la clave más potente". "Es esencial tener el calendario vacunal al día, siguiendo las recomendaciones oficiales e independientemente de la edad", destaca el experto, quien insiste especialmente en los más vulnerables y susceptibles a estos tres virus y también frente al neumococo: personas de edad avanzada, personas con enfermedades de base cardiacas, respiratorias o metabólicas, inmunodeprimidos, etc.

"Los cuatro (VRS, gripe, COVID-19 y neumococo) explican la gran mayoría de las infecciones respiratorias graves que podemos padecer y hoy son prevenibles mediante vacunación en la mayor parte de los casos", concluye.

Fuente: Gaceta Médica. Disponible en https://acortar.link/DUN0jw

V116 Vaccine Supported for Adult Pneumococcal Disease Prevention in Phase 3 Trial

Aug 9. For adult patients, V116, an investigational 21-valent pneumococcal conjugate vaccine (PCV21) is noninferior to PCV20 for serotypes shared by both vaccines and superior to PCV20 for all serotypes unique to V116, aside from 15C, according to study results published in The Lancet Infectious Diseases.

Researchers conducted a randomized, double-blind, active comparator controlled, international phase 3 trial (ClinicalTrials.gov Identifier: NCT05425732) to evaluate the safety, tolerability, and immunogenicity of V116. Adults with no history of pneumococcal vaccination were eligible for the analysis and enrolled across 2 cohorts. Cohort 1 was stratified by age (50-64, 65-74, 75-84, and ≥85 years) and comprised patients aged 50 years and older who were randomly assigned 1:1 to receive 1 dose of either V116 or PCV20. Cohort 2 comprised patients aged between 18 and 49 years who were randomly assigned 2:1 to receive 1 dose of either V116 or PCV20. The primary safety outcomes were the percentage of patients with solicited injection-site and systemic adverse events (AEs) through day 5 and vaccine-related severe AEs up to 6 months after vaccination. The primary immunogenicity outcomes were as follows:

⇒ Noninferiority of V116 to PCV20 was tested using serotype-specific opsonophagocytic activity geometric mean titers (GMT) ratios for serotypes common to both vaccines (cohort 1);

⇒ Superiority of V116 to PCV20 was tested for opsonophagocytic GMT ratios for the serotypes unique to V116 (cohort 1);

⇒ Superiority of V116 to PCV20 was tested by the percentage of patients with at least a 4-fold rise from day 1 to day 30 for serotypes unique to V116 (cohort 1); and

⇒ Immunobridging for all 21 serotypes in V116 for adults aged 18 to 49 and 50 to 64 years (cohort 2).

A total of 2663 patients (women, 58.7%; resident of US, 47.4%) were included in the analysis and received V116 (cohort 1, n=1181; cohort 2, n=201) or PCV20 (cohort 1, n=1181; cohort 2, n=100). Among patients in the first cohort, 1179 (99.8%) and 1177 (99.7%) received V116 and PCV20, respectively. Among patients in the second cohort, 200 (99.5%) and 100 (100%) received V116 and PCV20, respectively.

In cohort 1, V116 vs PCV20 met noninferiority criteria for all 10 serotypes common to both vaccines (all P <.0001), as well as superiority criteria for 10 of the 11 serotypes unique to V116 (P <.0001 for all unique serotypes except 15C, which was P =.41).

Further, V116 vs PCV20 met superiority criteria for 10 of 11 serotypes unique to V116 based on the percentage of patients with at least a 4-fold rise in opsonophagocytic activity from day 1 to day 30 (P <.0001 for all unique serotypes except 15C, which was P =.67). Moreover, immune responses among V116 recipients were noninferior between those aged 18 to 49 vs 50 to 64 years for all V116 serotypes (all P <.0001).

"Real-world evidence will be needed to assess vaccine effectiveness for the prevention of vaccine-type pneumococcal disease."

In regard to safety, 685 (58.2%) V116 recipients and 778 (66.2%) PCV20 recipients in cohort 1 and 164 (82.0%) V116 recipients and 79 (79.0%) PCV20 recipients in cohort 2 reported at least 1 AE.

In cohort 1, mortality occurred among 4 patients who received V116 and 2 patients who received PCV20. No deaths were considered related to vaccination. For V116 recipients, mortality was attributed to sepsis (n=1), cerebrovascular accident (n=1), myocardial infarction (n=1), and hepatic cirrhosis plus hepatic encephalopathy (n=1). For PCV20 recipients, mortality was attributed to cardiac arrest (n=1) and abdominal abscess (n=1). There were no vaccine-related severe AEs reported.

Study limitations include the lack of data on frailty status, the inability to assess the effect of V116 vaccination on nasopharyngeal pneumococcal carriage, and the exclusion of older patients (≥75 years), those with a history of pneumococcal vaccination, and those with immunocompromising conditions.

"Real-world evidence will be needed to assess vaccine effectiveness for the prevention of vaccine-type pneumococcal disease," the researchers concluded.

Disclosure: This research was supported by Merck Sharp & Dohme, and multiple study authors declared affiliations with biotech and pharmaceutical companies. Please see the original reference for a full list of disclosures.

Fuente: Infectious Disease Advisor. Disponible en https://acortar.link/LJZBMj

22nd Country Authorizes Second-Gen Dengue Vaccine

Aug 11. At the end of July 2024, Swissmedic authorized Takeda Pharma AG's QDENGA® (TAK-003) Tetravalent Vaccine (Live, Attenuated) vaccine after assessing its efficacy, safety, and quality.

To date, Switzerland has not authorized a dengue fever prevention vaccine. However, about 21 other countries have issued QDENGA authorization.

According to Swissmedic's statement on August 2, 2024, QDENGA is authorized for people aged four years and older who travel to regions where dengue fever is prevalent. These areas primarily include subtropical and tropical regions in Central Africa, Latin America, India, and Southeast Asia.

The U.S. Centers for Disease Control and Prevention (CDC) recently announced that the global incidence of dengue this year is the highest in recent history, with about 100 countries reporting higher-than-usual dengue cases.

In 2024, dengue infections, both travel-related and locally transmitted, were confirmed in the south of the USA, in states such as Florida (335) and Texas (18).

Swissmedic says QDENGA cannot cause the disease, but vaccination triggers the immune system to defend the body against the virus. When a person receives the vaccine, their immune system recognizes the attenuated variants as foreign and forms antibodies against them. When they come into contact with the virus again, the body rapidly produces more antibodies to neutralize it before the person contracts dengue fever.

Dengue fever is a viral disease spread by infected mosquitoes. It usually develops between four and seven days after the person is bitten. Symptoms include fever, headache, pain behind the eyes, muscle and joint pain, nausea or vomiting, swollen glands, and rash.

As of August 11, 2024, QDENGA is unavailable in the USA.

Fuente: Precision Vaccinations. Disponible en https://acortar.link/PGQFwO

New vaccine for respiratory disease rolls out in Scotland

Aug 12. A new vaccination programme aimed at protecting newborn babies and older adults against a dangerous respiratory disease is now being rolled out in Scotland.

The Respiratory Syncytial Virus (RSV) immunisation programme begins on Monday morning, and will be offered in the other UK nations from September.

RSV is common and highly infectious. It affects the breathing system and can cause severe illness in vulnerable groups, including infants and older people.

It is the leading cause of emergency respiratory admissions to hospital in infants.

In 2022-23, more than 1,500 infants under the age of one and more than 500 people aged 75 and over were

hospitalised with RSV, according to Public Health Scotland.

Across the UK as a whole it results in 25-30 infant deaths each year.

While for many the symptoms are mild, the infection is easily spread and 90% of children will catch it within the first two years of their lives.

Winter pressures on NHS

The vaccine is being administered on the advice of the UK's Joint Committee on Vaccination and Immunisation (JCVI).

Doses are being offered to women from 28 weeks into their pregnancies, to protect newborns, as well as those aged 75 and as a one-off catch up for those aged 75 to 79.

Dr Sam Ghebrehewet, head of immunisation and vaccination at Public Health Scotland, said: "RSV can be very serious for those who are more vulnerable, such as newborns, infants and older adults.



"If you are eligible, getting vaccinated is the best and simplest thing you can do to protect yourself or your newborn baby from RSV."

First Minister John Swinney said Scotland's early rollout of the vaccination programme could help relieve winter pressures on the NHS.

He added: “It is equally important that those aged 75-79 take up their offer of this vaccine."

What are the symptoms of RSV?

Symptoms of RSV usually start within a few days of getting infected.

According to the NHS, most people only get cold-like symptoms, such as:

⇒ a runny or blocked nose

⇒ sneezing

⇒ a cough

⇒ tiredness

⇒ a high temperature

Babies with RSV may also be irritable and feed less than usual.

If RSV leads to a more serious infection (such as bronchiolitis) it may also cause:

⇒ a cough that gets worse

⇒ faster breathing or long gaps between breaths

⇒ difficulty feeding or eating

⇒ noisy breathing (wheezing)

Fuente: BBC. Disponible en https://acortar.link/NTMXyt

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2024/08/01"[Date - Publication] : "2024/08/12"[Date - Publication])) 694 records.

The convergent model of coagulation.

Yong J, Toh CH.J Thromb Haemost. 2024 Aug;22(8):2140-2146. doi: 10.1016/j.jtha.2024.05.014. Epub 2024 May 28.PMID: 38815754

Vaccine design via antigen reorientation.

Xu D, Carter JJ, Li C, Utz A, Weidenbacher PAB, Tang S, Sanyal M, Pulendran B, Barnes CO, Kim PS.Nat Chem Biol. 2024 Aug;20(8):1012-1021. doi: 10.1038/s41589-023-01529-6. Epub 2024 Jan 15.PMID: 38225471

Biomarkers of immunotherapy in glioblastoma.

Savage WM, Yeary MD, Tang AJ, Sperring CP, Argenziano MG, Adapa AR, Yoh N, Canoll P, Bruce JN.Neurooncol Pract. 2024 Apr 1;11(4):383-394. doi: 10.1093/nop/npae028. eCollection 2024 Aug.PMID: 39006524

Biotech's role in advancing HIV vaccine development.

Tatoud R, Brander C, Hwang C, Kennelly J, Lu S, O'Neil K, Safrit JT, Benhayoun I, Firmat J, Barriere N.Emerg Microbes Infect. 2024 Dec;13(1):2384460. doi: 10.1080/22221751.2024.2384460. Epub 2024 Aug 12.PMID: 39042015

The mRNA vaccine platform for veterinary species.

Fazel F, Doost JS, Raj S, Boodhoo N, Karimi K, Sharif S.Vet Immunol Immunopathol. 2024 Aug;274:110803. doi: 10.1016/j.vetimm.2024.110803. Epub 2024 Jul 4.PMID: 39003921

Vaccine Science Diplomacy and "The Phenomenon of Man".

Hotez P.Linacre Q. 2024 Aug;91(3):254-264. doi: 10.1177/00243639241245105. Epub 2024 Apr 11.PMID: 39104467

A landscape review of malaria vaccine candidates in the pipeline.

Tajudeen YA, Oladipo HJ, Yusuff SI, Abimbola SO, Abdulkadir M, Oladunjoye IO, Omotosho AO, Egbewande OM, Shittu HD, Yusuf RO, Ogundipe O, Muili AO, Afolabi AO, Dahesh SMA, Gameil MAM, El-Sherbini MS.Trop Dis Travel Med Vaccines. 2024 Aug 1;10(1):19. doi: 10.1186/s40794-024-00222-3.PMID: 39085983

Acinetobacter baumannii subunit vaccines: recent progress and challenges.

Lau YT, Tan HS.Crit Rev Microbiol. 2024 Aug;50(4):434-449. doi: 10.1080/1040841X.2023.2215303. Epub 2023 May 21.PMID: 37211625

COVID-19 Vaccine Decision-Making Among Black Pregnant and Postpartum Women.

Avorgbedor F, Gondwe KW, Aljarrah A, Bankole AO.J Racial Ethn Health Disparities. 2024 Aug;11(4):2073-2082. doi: 10.1007/s40615-023-01675-6. Epub 2023 Jun 19.PMID: 37335424

Intestinal mucosal immunity is unimportant for polio eradication: the failure of oral polio vaccination.

John TJ, Dharmapalan D, Hirschhorn N.Infect Dis (Lond). 2024 Aug;56(8):669-677. doi: 10.1080/23744235.2024.2367742. Epub 2024 Jun 18.PMID: 38889538

Current mRNA-based vaccine strategies for glioma treatment.

Mao M, Yang W, Zhang X.Crit Rev Oncol Hematol. 2024 Aug 7;202:104459. doi: 10.1016/j.critrevonc.2024.104459. Online ahead of print.PMID: 39097247

Immunoinformatic-guided novel mRNA vaccine designing to elicit immunogenic responses against the endemic Monkeypox virus.

Aiman S, Ali Y, Malik A, Alkholief M, Ahmad A, Akhtar S, Ali S, Khan A, Li C, Shams S.J Biomol Struct Dyn. 2024 Aug;42(12):6292-6306. doi: 10.1080/07391102.2023.2233627. Epub 2023 Jul 9.PMID: 37424185

Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024.

Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, Gaglani M, Columbus C, Gottlieb RL, Ghamande S, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Saeed S, Prekker ME, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Khan A, Hough CL, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Kwon JH, Parikh B, Exline MC, Vaughn IA, Ramesh M, Safdar B, Mosier J, Harris ES, Shapiro NI, Felzer J, Zhu Y, Grijalva CG, Halasa N, Chappell JD, Womack KN, Rhoads JP, Baughman A, Swan SA, Johnson CA, Rice TW, Casey JD, Blair PW, Han JH, Ellington S, Lewis NM, Thornburg N, Paden CR, Atherton LJ, Self WH, Dawood FS, DeCuir J.Clin Infect Dis. 2024 Aug 6:ciae405. doi: 10.1093/cid/ciae405. Online ahead of print.PMID: 39107255

HTLV-1 vaccination Landscape: Current developments and challenges.

Letafati A, Bahari M, Salahi Ardekani O, Nayerain Jazi N, Nikzad A, Norouzi F, Mahdavi B, Aboofazeli A, Mozhgani SH.Vaccine X. 2024 Jul 16;19:100525. doi: 10.1016/j.jvacx.2024.100525. eCollection 2024 Aug.PMID: 39105133

A decavalent composite mRNA vaccine against both influenza and COVID-19.

Wang Y, Ma Q, Li M, Mai Q, Ma L, Zhang H, Zhong H, Mai K, Cheng N, Feng P, Guan P, Wu S, Zhang L, Dai J, Zhang B, Pan W, Yang Z.mBio. 2024 Aug 6:e0066824. doi: 10.1128/mbio.00668-24. Online ahead of print.PMID: 39105586

Strategies used to improve vaccine uptake among healthcare providers: A systematic review.

de Koning R, Gonzalez Utrilla M, Spanaus E, Moore M, Lomazzi M.Vaccine X. 2024 Jul 2;19:100519. doi: 10.1016/j.jvacx.2024.100519. eCollection 2024 Aug.PMID: 39105135

Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine.

Klein NP, Wiesner A, Bautista O, Group T, Kanu K, Li ZL, McCauley J, Saxena K, Tota J, Luxembourg A, Bonawitz R.Pediatrics. 2024 Aug 1;154(2):e2023064693. doi: 10.1542/peds.2023-064693.PMID: 38978512

Using curiosity to render the invisible, visible.

Cheung K.Theor Med Bioeth. 2024 Aug;45(4):251-259. doi: 10.1007/s11017-024-09665-3. Epub 2024 May 20.PMID: 38767830

Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19.

Tartof SY, Slezak JM, Frankland TB, Puzniak L, Hong V, Ackerson BK, Stern JA, Zamparo J, Simmons S, Jodar L, McLaughlin JM.JAMA Intern Med. 2024 Aug 1;184(8):932-940. doi: 10.1001/jamainternmed.2024.1640.PMID: 38913355

State Medicaid Coverage and Reimbursement of Adult Vaccines Administered by Physicians and Pharmacists.

Polaris JJZ, Eiden AL, DiFranzo AP, Pfister HR, Itzkowitz MC, Bhatti AA.AJPM Focus. 2024 Jun 13;3(4):100252. doi: 10.1016/j.focus.2024.100252. eCollection 2024 Aug.PMID: 39070136

The Immunomodulatory Effects and Applications of Probiotic Lactiplantibacillus plantarum in Vaccine Development.

He G, Long H, He J, Zhu C.Probiotics Antimicrob Proteins. 2024 Aug 5. doi: 10.1007/s12602-024-10338-9. Online ahead of print.PMID: 39101975

Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.

Bouazzaoui A, Abdellatif AAH.Vaccine X. 2024 May 24;19:100500. doi: 10.1016/j.jvacx.2024.100500. eCollection 2024 Aug.PMID: 38873639

Factors associated with COVID-19 vaccine uptake among south African health care workers.

George G, Strauss M, Lansdell E, Nota P, Peters RPH, Brysiewicz P, Nadesan-Reddy N, Wassenaar D.Vaccine. 2024 Aug 5;42(21):126181. doi: 10.1016/j.vaccine.2024.126181. Online ahead of print.PMID: 39111155

Vaccine patterns among older adults with Guillain-Barre syndrome and matched comparators, 2006-2019.

Eiffert SR, Kinlaw AC, Sleath BL, Thorpe CT, Traub R, Raman SR, Stürmer T.J Am Geriatr Soc. 2024 Aug 1. doi: 10.1111/jgs.19110. Online ahead of print.PMID: 39090827

Exploring COVID-19 vaccine hesitancy among young adults in Australia. A qualitative study.

Sum Z, Sofija E, Sebar B.Vaccine X. 2024 Jun 22;19:100515. doi: 10.1016/j.jvacx.2024.100515. eCollection 2024 Aug.PMID: 39040885

FDA approves 21-valent pneumococcal vaccine.

Mullard A.Nat Rev Drug Discov. 2024 Aug;23(8):572. doi: 10.1038/d41573-024-00108-1.PMID: 38906987

Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches.

Peter J, Takalani A, Meyer J, Semete-Makokotlela B, Collie S, Seocharan I, Goga A, Garrett N, Gail-Bekker L, Gray G.Expert Opin Drug Saf. 2024 Aug 8. doi: 10.1080/14740338.2024.2387322. Online ahead of print.PMID: 39115010

A recombinant multi-epitope trivalent vaccine for foot-and-mouth disease virus serotype O in pigs.

Shao J, Liu W, Gao S, Chang H, Guo H.Virology. 2024 Aug;596:110103. doi: 10.1016/j.virol.2024.110103. Epub 2024 May 10.PMID: 38781710

Development of a novel multi-epitope vaccine based on capsid and envelope protein against Chikungunya virus.

Ma S, Zhu F, Wen H, Rao M, Zhang P, Peng W, Cui Y, Yang H, Tan C, Chen J, Pan P.J Biomol Struct Dyn. 2024 Aug;42(13):7024-7036. doi: 10.1080/07391102.2023.2240059. Epub 2023 Aug 1.PMID: 37526203

To give or not to give? Pandemic vaccine donation policy.

Holleran A, Martonosi SE, Veatch M.Public Health. 2024 Aug;233:164-169. doi: 10.1016/j.puhe.2024.05.011. Epub 2024 Jun 19.PMID: 38897068

Influenza epidemiology and vaccine effectiveness during the 2023/2024 season in Italy: A test-negative case-control study.

Domnich A, Icardi G, Panatto D, Scarpaleggia M, Trombetta CS, Ogliastro M, Stefanelli F, Bruzzone B, Orsi A.Int J Infect Dis. 2024 Aug 7:107202. doi: 10.1016/j.ijid.2024.107202. Online ahead of print.PMID: 39122207

Spatial Accessibility and Uptake of Pediatric COVID-19 Vaccinations by Social Vulnerability.

Khazanchi R, Rader B, Cantor J, McManus KA, Bravata DM, Weintraub R, Whaley C, Brownstein JS.Pediatrics. 2024 Aug 1;154(2):e2024065938. doi: 10.1542/peds.2024-065938.PMID: 39028301

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Costa Clemens SA, Jepson B, Bhorat QE, Ahmad A, Akhund T, Aley PK, Bansal H, Bibi S, Kelly EJ, Khan M, Lambe T, Lombaard JJ, Matthews S, Pipolo Milan E, Olsson U, Ramasamy MN, Moura de Oliveira Paiva MS, Seegobin S, Shoemaker K, Szylak A, Villafana T, Pollard AJ, Green JA; AZD2816 Study Group.Lancet Microbe. 2024 Aug;5(8):100863. doi: 10.1016/S2666-5247(24)00078-8. Epub 2024 Jun 12.PMID: 38878794

Review of current perspectives and future outlook on bacterial disease prevention through vaccination in Asian seabass (Lates calcarifer).

Lan NGT, Dong HT, Shinn AP, Vinh NT, Senapin S, Salin KR, Rodkhum C.J Fish Dis. 2024 Aug;47(8):e13964. doi: 10.1111/jfd.13964. Epub 2024 May 26.PMID: 38798108

Reasons for COVID-19 Vaccine Hesitancy Among Patients Listed for Solid Organ Transplants.

Kalavacherla S, Goldhaber NH, Chen KY, Li VM, Mou Z, Taj R, Mekeel KL.Transplant Proc. 2024 Aug 2:S0041-1345(24)00342-7. doi: 10.1016/j.transproceed.2024.05.031. Online ahead of print.PMID: 39097516

The role of the gut microbiota in regulating responses to vaccination: current knowledge and future directions.

Rossouw C, Ryan FJ, Lynn DJ.FEBS J. 2024 Aug 5. doi: 10.1111/febs.17241. Online ahead of print.PMID: 39102299

Advanced strategies in improving the immunotherapeutic effect of CAR-T cell therapy.

Wang M, Jia L, Dai X, Zhang X.Mol Oncol. 2024 Aug;18(8):1821-1848. doi: 10.1002/1878-0261.13621. Epub 2024 Mar 8.PMID: 38456710

A qualitative assessment of influenza vaccine uptake among children in Kenya.

Liku N, Mburu C, Lafond KE, Ebama M, Athman M, Swaleh S, Jewa I, Ngware E, Njenga V, Kiptoo E, Munyao C, Miano C, Anyango E, Thuo S, Matini W, Mirieri H, Otieno N, Athman M, Chanzera P, Awadh Z, Muthoni M, Kingori P, Kariuki Njenga M, Emukule GO, Osoro E, Tabu C, Dawa J.Vaccine X. 2024 May 27;19:100507. doi: 10.1016/j.jvacx.2024.100507. eCollection 2024 Aug.PMID: 38873637

Motives for Vaccination Against COVID-19 Among the Ultra-orthodox Jewish Community in Israel.

Schiff M, Sharon-Lavi N.J Relig Health. 2024 Aug;63(4):2654-2670. doi: 10.1007/s10943-024-02018-3. Epub 2024 Mar 26.PMID: 38530581

Biomimetic functionalized metal organic frameworks as multifunctional agents: Paving the way for cancer vaccine advances.

Tousian B, Khosravi AR, Ghasemi MH, Kadkhodaie M.Mater Today Bio. 2024 Jun 20;27:101134. doi: 10.1016/j.mtbio.2024.101134. eCollection 2024 Aug.PMID: 39027676

Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.

D'souza S, Ghatole B, Raghuram H, Sukhija S, Singh S, Shaikh A, Bandewar SS, Bhan A.Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174. Online ahead of print.PMID: 39117525

mRNA vaccine development and applications: A special focus on tumors (Review).

Chen B, Yang Y, Wang X, Yang W, Lu Y, Wang D, Zhuo E, Tang Y, Su J, Tang G, Shao S, Gu K.Int J Oncol. 2024 Aug;65(2):81. doi: 10.3892/ijo.2024.5669. Epub 2024 Jul 12.PMID: 38994758

Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.

Pan HX, Qiu LX, Liang Q, Chen Z, Zhang ML, Liu S, Zhong GH, Zhu KX, Liao MJ, Hu JL, Li JX, Xu JB, Fan Y, Huang Y, Su YY, Huang SJ, Wang W, Han JL, Jia JZ, Zhu H, Cheng T, Ye XZ, Li CG, Wu T, Zhu FC, Zhang J, Xia NS.Lancet Infect Dis. 2024 Aug;24(8):922-934. doi: 10.1016/S1473-3099(24)00159-2. Epub 2024 Apr 10.PMID: 38614117 Clinical Trial.

Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.

Garrett N, Dintwe O, Monaco CL, Jones M, Seaton KE, Church EC, Grunenberg N, Hutter J, deCamp A, Huang Y, Lu H, Mann P, Robinson ST, Heptinstall J, Jensen RL, Pantaleo G, Ding S, Koutsoukos M, Hosseinipour MC, Van Der Meeren O, Gilbert PB, Ferrari G, Andersen-Nissen E, McElrath MJ, Tomaras GD, Gray GE, Corey L, Kublin JG; HVTN 108 and HVTN 111 Study Teams.J Acquir Immune Defic Syndr. 2024 Aug 1;96(4):350-360. doi: 10.1097/QAI.0000000000003438. Epub 2024 Jun 21.PMID: 38916429

Trusted Information Sources About the COVID-19 Vaccine Vary in Underserved Communities.

Benson BR, Rahman SA, Bleasdale J, Win S, Townsend-Kensinger K, Cole M, Jalal K, Yu J, Morse GD, Mohler JL, Ward RL.J Community Health. 2024 Aug;49(4):598-605. doi: 10.1007/s10900-023-01319-0. Epub 2024 Feb 1.PMID: 38300477

The effect of stress on the antibody response after vaccination in children aged 0-18 years: A systematic review.

Svensson R, Malon M, Stensballe LG, Thorsen SU, Svensson J.Scand J Immunol. 2024 Aug;100(2):e13394. doi: 10.1111/sji.13394. Epub 2024 Jun 24.PMID: 38924129

Lipid nanoparticle-encapsulated DNA vaccine confers protection against swine and human-origin H1N1 influenza viruses.

Nguyen TN, Lai DC, Sillman S, Petro-Turnquist E, Weaver EA, Vu HLX.mSphere. 2024 Aug 1:e0028324. doi: 10.1128/msphere.00283-24. Online ahead of print.PMID: 39087764

A novel subunit vaccine based on Fiber1/2 knob domain provides full protection against fowl adenovirus serotype 4 and induces stronger immune responses than a Fiber2 subunit vaccine.

Liu S, Dong X, Lei B, Zhang W, Wang X, Yuan W, Zhao K.Poult Sci. 2024 Aug;103(8):103888. doi: 10.1016/j.psj.2024.103888. Epub 2024 May 23.PMID: 38851180

An integrated in silico approach for the identification of novel potential drug target and chimeric vaccine against Neisseria meningitides strain 331401 serogroup X by subtractive genomics and reverse vaccinology.

Asad M, Hassan A, Wang W, Alonazi WB, Khan MS, Ogunyemi SO, Ibrahim M, Bin L.Comput Biol Med. 2024 Aug;178:108738. doi: 10.1016/j.compbiomed.2024.108738. Epub 2024 Jun 10.PMID: 38870724

Postexposure prophylaxis for occupational exposure to selected pathogens for healthcare personnel.

Han A, Henderson DK.Curr Opin Infect Dis. 2024 Aug 1;37(4):296-303. doi: 10.1097/QCO.0000000000001029. Epub 2024 Jun 7.PMID: 38899948

A natural experiment during lockdown and on-going care-home COVID-19 outbreaks showed a single dose of vaccine reduced hospitalisation and deaths of care-home residents in North West England.

Ghebrehewet S, Stewart AG, MacPherson P.Public Health. 2024 Aug;233:60-64. doi: 10.1016/j.puhe.2024.05.002. Epub 2024 Jun 7.PMID: 38850602

A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models.

Warner NL, Archer J, Park S, Singh G, McFadden KM, Kimura T, Nicholes K, Simpson A, Kaelber JT, Hawman DW, Feldmann H, Khandhar AP, Berglund P, Vogt MR, Erasmus JH.Sci Transl Med. 2024 Aug 7;16(759):eadi1625. doi: 10.1126/scitranslmed.adi1625. Epub 2024 Aug 7.PMID: 39110777

Shedding of measles vaccine RNA in children after receiving measles, mumps and rubella vaccination.

Washam MC, Leber AL, Oyeniran SJ, Everhart K, Wang H.J Clin Virol. 2024 Aug;173:105696. doi: 10.1016/j.jcv.2024.105696. Epub 2024 May 24.PMID: 38823291

Dendritic cell vaccination combined with irreversible electroporation for treating pancreatic cancer-a narrative review.

Zhang Z, Yu G, Eresen A, Chen Z, Yu Z, Yaghmai V, Zhang Z.Ann Transl Med. 2024 Aug 1;12(4):77. doi: 10.21037/atm-23-1882. Epub 2024 May 28.PMID: 39118942

Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy.

Wang F, Cai G, Wang Y, Zhuang Q, Cai Z, Li Y, Gao S, Li F, Zhang C, Zhao B, Liu X.MedComm (2020). 2024 Jul 29;5(8):e667. doi: 10.1002/mco2.667. eCollection 2024 Aug.PMID: 39081513

An Unexpected Post-Egg-Free Influenza Vaccine Granulomatous Reaction.

Engel CE, Fagan KK, Dorsey SB, Grider DJ.Am J Dermatopathol. 2024 Aug 1;46(8):e63-e65. doi: 10.1097/DAD.0000000000002751. Epub 2024 Jun 6.PMID: 38842398

Design and characterization of a multi-epitope vaccine targeting Chlamydia abortus using immunoinformatics approach.

Moqbel Hassan Alzubaydi N, Oun Ali Z, Al-Asadi S, Al-Kahachi R.J Biomol Struct Dyn. 2024 Aug;42(13):6660-6677. doi: 10.1080/07391102.2023.2240891. Epub 2023 Sep 29.PMID: 37774751

Recent progress in engineered extracellular vesicles and their biomedical applications.

Mazahir F, Yadav AK.Life Sci. 2024 Aug 1;350:122747. doi: 10.1016/j.lfs.2024.122747. Epub 2024 May 24.PMID: 38797364

Comparative immunogenic and immunoprotective activities of PCV2d Cap and Rep antigens delivered by an efficient eukaryotic expression system engineered into a Salmonella vaccine vector.

Lloren KKS, Sivasankar C, Lee JH.Vet Microbiol. 2024 Aug;295:110151. doi: 10.1016/j.vetmic.2024.110151. Epub 2024 Jun 10.PMID: 38870752

Advances in the design and delivery of RNA vaccines for infectious diseases.

Lokras AG, Bobak TR, Baghel SS, Sebastiani F, Foged C.Adv Drug Deliv Rev. 2024 Aug 5:115419. doi: 10.1016/j.addr.2024.115419. Online ahead of print.PMID: 39111358

Vaccine a promising immunotherapy option for head and neck cancer patients.

Mohsin SF.Pak J Med Sci. 2024 Aug;40(7):1578-1583. doi: 10.12669/pjms.40.7.8791.PMID: 39092051

Impact of COVID-19 on vaccine confidence and uptake: A systematic literature review.

Vojtek I, van Wouw M, Thomson A.Hum Vaccin Immunother. 2024 Dec 31;20(1):2384180. doi: 10.1080/21645515.2024.2384180. Epub 2024 Aug 6.PMID: 39106971

Digitizing tools for post introduction evaluation of rotavirus vaccine introduction in India.

Kumar P, Kaur A, Ray A, Singh K, Verma S, Hora R, Koshal SS, Kumari A, Mehra R, Quadri SF, Roy AD.Vaccine X. 2024 May 23;19:100502. doi: 10.1016/j.jvacx.2024.100502. eCollection 2024 Aug.PMID: 38827494

The immune status of migrant populations in Europe and implications for vaccine-preventable disease control: a systematic review and meta-analysis.

Cherri Z, Lau K, Nellums LB, Himmels J, Deal A, McGuire E, Mounier-Jack S, Norredam M, Crawshaw A, Carter J, Seedat F, Clemente NS, Bouaddi O, Friedland JS, Edelstein M, Hargreaves S.J Travel Med. 2024 Aug 3;31(6):taae033. doi: 10.1093/jtm/taae033.PMID: 38423523

A novel multi-epitope peptide vaccine candidate targeting hepatitis E virus: An in silico approach.

Kumar A, Sahu U, Agnihotri G, Dixit A, Khare P.J Viral Hepat. 2024 Aug;31(8):446-456. doi: 10.1111/jvh.13949. Epub 2024 May 10.PMID: 38727597

Bacterial glycoengineering: Cell-based and cell-free routes for producing biopharmaceuticals with customized glycosylation.

Palma JA, Bunyatov MI, Hulbert SW, Jewett MC, DeLisa MP.Curr Opin Chem Biol. 2024 Aug;81:102500. doi: 10.1016/j.cbpa.2024.102500. Epub 2024 Jul 10.PMID: 38991462

Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.

Mahendran TR, Cynthia B, Thevendran R, Maheswaran S.Mol Biotechnol. 2024 Aug 1. doi: 10.1007/s12033-024-01240-4. Online ahead of print.PMID: 39085563

Effects of non-tuberculous mycobacteria on BCG vaccine efficacy: A narrative review.

Ghasemi F, Kardan-Yamchi J, Heidary M, Karami-Zarandi M, Akrami S, Maleki A, Khoshnood S, Kazemian H.J Clin Tuberc Other Mycobact Dis. 2024 May 4;36:100451. doi: 10.1016/j.jctube.2024.100451. eCollection 2024 Aug.PMID: 38764556

Differential structure and immunomodulatory functions of lipophosphoglycan between Leishmania spp.

Teufel LU, Joosten LAB, Dos Santos JC.Immunol Lett. 2024 Aug;268:106885. doi: 10.1016/j.imlet.2024.106885. Epub 2024 Jun 18.PMID: 38901739

Immunogenicity and vaccine potential of clinical isolate Mycobacterium kansasii strain against Mycobacterium tuberculosis infection.

Kim H, Shin SJ.Microbiol Spectr. 2024 Aug 6;12(8):e0081924. doi: 10.1128/spectrum.00819-24. Epub 2024 Jul 9.PMID: 38980025

Circulating rotavirus strains in children with acute gastroenteritis in Iran, 1986 to 2023 and their genetic/antigenic divergence compared to approved vaccines strains (Rotarix, RotaTeq, ROTAVAC, ROTASIIL) before mass vaccination: Clues for vaccination policy makers.

Jalilvand S, Latifi T, Kachooei A, Mirhoseinian M, Hoseini-Fakhr SS, Behnezhad F, Roohvand F, Shoja Z.Virus Res. 2024 Aug;346:199411. doi: 10.1016/j.virusres.2024.199411. Epub 2024 Jun 3.PMID: 38823689

Who is (not) vaccinated? A proposal for a comprehensive immunization information system.

Vigezzi GP, Maggioni E, Bert F, de Vito C, Siliquini R, Odone A.Hum Vaccin Immunother. 2024 Dec 31;20(1):2386739. doi: 10.1080/21645515.2024.2386739. Epub 2024 Aug 5.PMID: 39103249

Changing the Conversation: Empowering Community Pharmacists to Address Pneumococcal Vaccine Hesitancy.

Ramrattan D, Nagy D, Eurich D, Hughes C, Lau D, Simpson S.J Am Pharm Assoc (2003). 2024 Aug 3:102202. doi: 10.1016/j.japh.2024.102202. Online ahead of print.PMID: 39103000

Development and application of a cycleave dual-probe fluorescence quantitative PCR method for simultaneous detection of Mycoplasma gallisepticum ts-11 vaccine strain and non-ts-11 strains.

Wang X, Sun N, Wang M, Wang H, Liu Y, Shi H, Zhu H, Li P, Zhang F, Yang T, Li Z, Liu C.Poult Sci. 2024 Aug;103(8):103907. doi: 10.1016/j.psj.2024.103907. Epub 2024 May 28.PMID: 38878745

The bright side of chemistry: Exploring synthetic peptide-based anticancer vaccines.

D'Aniello A, Del Bene A, Mottola S, Mazzarella V, Cutolo R, Campagna E, Di Maro S, Messere A.J Pept Sci. 2024 Aug;30(8):e3596. doi: 10.1002/psc.3596. Epub 2024 Apr 3.PMID: 38571326

Gamma Irradiated Pasteurella multocida Vaccine induces strong humoral immunity and protects rabbits from disease.

Ahmed S, Nemr WA, El-Shershaby A, Fouad EAM, Mahmoud MAE, Liaqat F, Wijewardana V, Unger H.Vet Res Commun. 2024 Aug;48(4):2227-2242. doi: 10.1007/s11259-024-10388-y. Epub 2024 May 6.PMID: 38709372

Young Adult and Parent Willingness to Pay for Meningococcal Serogroup B Vaccination.

Huang L, Srivastava A, Fairchild A, Whittington D, Johnson R.MDM Policy Pract. 2024 Aug 12;9(2):23814683241264280. doi: 10.1177/23814683241264280. eCollection 2024 Jul-Dec.PMID: 39139368

Multisystem inflammatory syndrome in children: an evolving understanding of a syndrome amid the inflammatory continuum.

Areti S, Parrillo M, Baker L, Meszaros A, Dram A, Remy KE.Minerva Pediatr (Torino). 2024 Aug;76(4):545-555. doi: 10.23736/S2724-5276.23.07279-8. Epub 2023 Jun 16.PMID: 37335186

Arbovirology and Cold War Collaborations: A Transnational History of the Tick-borne Encephalitis Vaccine, 1930-1980.

Mazanik A.J Hist Med Allied Sci. 2024 Aug 6;79(3):254-273. doi: 10.1093/jhmas/jrad054.PMID: 37681759

Immunoinformatics design and synthesis of a multi-epitope vaccine against Helicobacter pylori based on lipid nanoparticles.

Jebali A, Esmaeilzadeh A, Esmaeilzadeh MK, Shabani S.Sci Rep. 2024 Aug 2;14(1):17910. doi: 10.1038/s41598-024-68947-x.PMID: 39095538

The Influence of Racism in Healthcare: COVID-19 Vaccine Hesitancy Among Black Mothers in Chicago.

Harris M, Sherrod D, Walsh JL, Hunt BR, Jacobs J, Valencia J, Baumer-Mouradian S, Quinn KG.J Racial Ethn Health Disparities. 2024 Aug;11(4):2425-2434. doi: 10.1007/s40615-023-01708-0. Epub 2023 Aug 2.PMID: 37531019

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.

Clark R, Davies S, Labrador J, Loubet P, Natalini Martínez S, Moríñigo HM, Nicolas JF, Vera MP, Rämet M, Rebollo-Rodrigo MH, Sanz-Muñoz I, Dezutter N, Germain S, David MP, Jayadev A, Hailemariam HA, Kotb S, Meyer N.Clin Infect Dis. 2024 Aug 5:ciae365. doi: 10.1093/cid/ciae365. Online ahead of print.PMID: 39099085

COVID-19 vaccine effectiveness among South Asians in Canada.

Chanchlani R, Shah BR, Bangdiwala SI, de Souza RJ, Luo J, Bolotin S, Bowdish DME, Desai D, Everett K, Lear SA, Loeb M, Punthakee Z, Sherifali D, Wahi G, Anand SS.PLOS Glob Public Health. 2024 Aug 1;4(8):e0003490. doi: 10.1371/journal.pgph.0003490. eCollection 2024.PMID: 39088444

PEGylated liposomes for diagnosis of polyethylene glycol allergy.

Perkins GB, Tunbridge MJ, Hurtado PR, Zuiani J, Mhatre S, Yip KH, Le TA, Yuson C, Kette F, Hissaria P.J Allergy Clin Immunol. 2024 Aug;154(2):503-507.e1. doi: 10.1016/j.jaci.2024.03.030. Epub 2024 May 6.PMID: 38718949

Effectiveness and duration of additional immune defense provided by SARS-CoV-2 infection before and after receiving the mRNA COVID-19 vaccine BNT162b2.

Shimada N, Sugawa S, Murakami S, Shinoda M, Ota S, Morikawa M, Takei H, Serizawa Y, Takahashi H, Toyama-Kousaka M, Matsuse H, Shinkai M.Vaccine X. 2024 Jun 26;19:100518. doi: 10.1016/j.jvacx.2024.100518. eCollection 2024 Aug.PMID: 39040888

VacSol-ML(ESKAPE)(:) Machine learning empowering vaccine antigen prediction for ESKAPE pathogens.

Nasir S, Anwer F, Ishaq Z, Saeed MT, Ali A.Vaccine. 2024 Aug 9;42(22):126204. doi: 10.1016/j.vaccine.2024.126204. Online ahead of print.PMID: 39126830

The tricky second album: Licensure of an mRNA vaccine for respiratory syncytial virus.

Tregoning JS.Mol Ther. 2024 Aug 7;32(8):2428. doi: 10.1016/j.ymthe.2024.06.031. Epub 2024 Jul 3.PMID: 38964331

Social Stigma and COVID-19 Vaccine Refusal in France.

Peretti-Watel P, Fressard L, Giry B, Verger P, Ward JK.J Health Polit Policy Law. 2024 Aug 1;49(4):567-598. doi: 10.1215/03616878-11186095.PMID: 38324348

The prevalence of menstrual changes in COVID-19 vaccinated women: A cross-sectional study.

Homam Safiah M, Kalalib Al Ashabi K, Khalayli N, Hodaifa Y, Kudsi M.Prev Med Rep. 2024 Jun 24;44:102804. doi: 10.1016/j.pmedr.2024.102804. eCollection 2024 Aug.PMID: 39040951

An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.

de La Vega MA, Xiii A, Massey CS, Spengler JR, Kobinger GP, Woolsey CB.Expert Opin Drug Discov. 2024 Aug 1. doi: 10.1080/17460441.2024.2386100. Online ahead of print.PMID: 39090822

Post COVID-19 vaccination medium vessel vasculitis: a systematic review of case reports.

Sanker V, Mylavarapu M, Gupta P, Syed N, Shah M, Dondapati VVK.Infection. 2024 Aug;52(4):1207-1213. doi: 10.1007/s15010-024-02217-w. Epub 2024 Mar 14.PMID: 38483787

Reverse vaccinology-based multi-epitope vaccine design against Indian group A rotavirus targeting VP7, VP4, and VP6 proteins.

Kuri PR, Goswami P.Microb Pathog. 2024 Aug;193:106775. doi: 10.1016/j.micpath.2024.106775. Epub 2024 Jul 1.PMID: 38960216

Enhancing immunogenicity and antiviral protection of inactivated porcine reproductive and respiratory syndrome virus vaccine in piglets.

Wang BL, Zhang S, Liu Y, Zhao YH, Wang CW, Li Y, Zuo YZ, Fan JH.Am J Vet Res. 2024 Jun 17;85(8):ajvr.24.02.0025. doi: 10.2460/ajvr.24.02.0025. Print 2024 Aug 1.PMID: 38889741

Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-deltaG-ZEBOV-GP in a sub-Saharan African paediatric population: a randomised controlled, open-label trial in children aged 1-12 years living in Lambarene, Gabon.

Alabi A, Kokou K, Mahmoudou S, Kavishna R, Nakka SS, Rothenberger S, Musangomunei FP, Olubiyi BF, Bie-Ondo JC, Kabwende AL, Velavan TP; VSV-EBOPLUS Consortium; Medaglini D, Nakaya HI, Engler O, Harandi AM, Siegrist CA, Kremsner PG, Agnandji ST.J Infect. 2024 Aug 7:106237. doi: 10.1016/j.jinf.2024.106237. Online ahead of print.PMID: 39121969

Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers.

Suwarti S, Lazarus G, Zanjabila S, Sinto R, Fransiska F, Deborah T, Oktavia D, Junaidah J, Santayana S, Surendra H, Yuliana J, Pardosi H, Nuraeni N, Soebianto S, Susilowati ND, Subekti D, Pradipta A, Baird JK, Tan LV, Dunachie S, Shankar AH, Nelwan EJ, Hamers RL; SEACOVARIANTS Consortium.BMC Infect Dis. 2024 Aug 1;24(1):768. doi: 10.1186/s12879-024-09644-y.PMID: 39090537

Outer membrane proteins and vesicles as promising vaccine candidates against Vibrio spp. infections.

Singh B, Jaiswal S, Kodgire P.Crit Rev Microbiol. 2024 Aug;50(4):417-433. doi: 10.1080/1040841X.2023.2212072. Epub 2023 Jun 5.PMID: 37272649

mRNA Vaccine Hesitancy: Spreading Misinformation Through Online Narratives.

Sisco HKF, Brummette J.J Health Commun. 2024 Aug 2;29(8):538-547. doi: 10.1080/10810730.2024.2379954. Epub 2024 Jul 17.PMID: 39018340

Anti-PF4 positivity and platelet activation after Ad26.COV2·S vaccination in Brazil.

Bokel J, Martins-Gonçalves R, Grinsztejn E, Mendes-de-Almeida DP, Hoagland B, Cardoso SW, Geraldo KM, Coutinho SN, Georg I, Oliveira MH, Dos Santos Souza F, Sacramento CQ, Rozini SV, Vizzoni AG, Veloso V, Bozza PT, Grinsztejn B.Vaccine. 2024 Aug 5:126175. doi: 10.1016/j.vaccine.2024.126175. Online ahead of print.PMID: 39107160

Safety and effectiveness of a recombinant hepatitis E vaccine in women of childbearing age in rural Bangladesh: a phase 4, double-blind, cluster-randomised, controlled trial.

Zaman K, Julin CH, Aziz AB, Stene-Johansen K, Yunus M, Qadri F, Gurley ES, Sandbu S, Øverbø J, Dembinski JL, Laake I, Bhuiyan TR, Rahman M, Haque W, Khanam M, Clemens JD, Dudman S.Lancet Glob Health. 2024 Aug;12(8):e1288-e1299. doi: 10.1016/S2214-109X(24)00192-X.PMID: 39030060

Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia.

von Mollendorf C, Mungun T, Ulziibayar M, Skoko P, Boelsen L, Nguyen C, Batsaikhan P, Suuri B, Luvsantseren D, Narangerel D, Tsolmon B, Demberelsuren S, Ortika BD, Pell CL, Wee-Hee A, Nation ML, Hinds J, Dunne EM, Mulholland EK, Satzke C.Nat Commun. 2024 Aug 3;15(1):6577. doi: 10.1038/s41467-024-50944-3.PMID: 39097620

A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine.

Kim Y, Bae S, Yu KS, Lee S, Lee C, Kim J, Her H, Oh J.NPJ Vaccines. 2024 Aug 7;9(1):140. doi: 10.1038/s41541-024-00935-8.PMID: 39112515

Selection of vaccine candidates against Pseudomonas koreensis using reverse vaccinology and a preliminary efficacy trial in Empurau (Tor tambroides).

Kho CJY, Lau MML, Chung HH, Fukui K.Fish Shellfish Immunol. 2024 Aug;151:109688. doi: 10.1016/j.fsi.2024.109688. Epub 2024 Jun 8.PMID: 38857817

COVID-19 vaccination and menstrual disturbances: A prospective study from Pakistan.

Parveen N.Pak J Med Sci. 2024 Aug;40(7):1345-1348. doi: 10.12669/pjms.40.7.8709.PMID: 39092064

Pediococcus pentosaceus MIANGUAN Enhances the Immune Response to Vaccination in Mice.

Chen Y, Cao Z, Lu S, Wang Z, Ma C, Zhang G, Chen M, Yang J, Ren Z, Xu J.Probiotics Antimicrob Proteins. 2024 Aug;16(4):1117-1129. doi: 10.1007/s12602-023-10205-z. Epub 2024 Jan 2.PMID: 38169032

A broad-spectrum multiepitope vaccine against seasonal influenza A and B viruses in mice.

Yuan L, Zhang S, Bi R, Liu X, Han Z, Li M, Liao X, Xie T, Bai S, Xie Q, Luo C, Jiang Y, Yuan J, Luo H, Yan H, Sun C, Shu Y.EBioMedicine. 2024 Aug 6;106:105269. doi: 10.1016/j.ebiom.2024.105269. Online ahead of print.PMID: 39111250

Timely Prenatal and Infant Pertussis Vaccine Uptake in an Integrated Health System.

Becerra-Culqui T, Ackerson B, Tseng HF.J Racial Ethn Health Disparities. 2024 Aug;11(4):2459-2466. doi: 10.1007/s40615-023-01711-5. Epub 2023 Jul 25.PMID: 37490209

Lack of knowledge about the human papillomavirus vaccine among Brazilian adolescents: A cross-sectional study.

Silva TMRD, Sá ACMGN, Carrato BA, Siqueira Costa Schreck R, Prates EJS, Oliveira SR, Malta DC.Public Health Nurs. 2024 Aug 1. doi: 10.1111/phn.13375. Online ahead of print.PMID: 39087950

Preferences and Willingness to Pay for Herpes Zoster Vaccination Among Chinese Adults: Discrete Choice Experiment.

Xia Y, Wang M, Hu M, Wang Y, Yuan B, Zhu D, He P.JMIR Public Health Surveill. 2024 Aug 9;10:e51242. doi: 10.2196/51242.PMID: 39121469

A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety.

Bae SH, Yoo S, Lee J, Park HJ, Kwon SP, Jin H, Park SI, Lee YS, Bang YJ, Roh G, Lee S, Youn SB, Kim IW, Oh HR, El-Damasy AK, Keum G, Kim H, Youn H, Nam JH, Bang EK.Bioact Mater. 2024 May 14;38:486-498. doi: 10.1016/j.bioactmat.2024.05.012. eCollection 2024 Aug.PMID: 38779592

Focusing HIV-1 Gag T-cell Responses to Highly Conserved Regions by DNA Vaccination in HVTN 119.

Kalams SA, Felber BK, Mullins JI, Scott HM, Allen MA, De Rosa SC, Heptinstall J, Tomaras GD, Hu J, deCamp AC, Rosati M, Bear J, Pensiero MN, Eldridge J, Egan MA, Hannaman D, McElrath MJ, Pavlakis GN.JCI Insight. 2024 Aug 1:e180819. doi: 10.1172/jci.insight.180819. Online ahead of print.PMID: 39088271

Second malaria vaccine reaches Central African Republic.

Bagcchi S.Lancet Infect Dis. 2024 Aug;24(8):e488. doi: 10.1016/S1473-3099(24)00445-6.PMID: 39067472

CDC guidance on new pentavalent meningococcal vaccine.

Pereira MR.Am J Transplant. 2024 Aug;24(8):1334-1335. doi: 10.1016/j.ajt.2024.07.020.PMID: 39111984

Gavi, the Vaccine Alliance supports rabies vaccination.

Burki T.Lancet Infect Dis. 2024 Aug;24(8):e491-e492. doi: 10.1016/S1473-3099(24)00447-X.PMID: 39067475

Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters.

Darling TL, Harastani HH, Joshi A, Bricker TL, Soudani N, Seehra K, Hassan AO, Diamond MS, Boon ACM.Sci Adv. 2024 Aug 2;10(31):eadp1290. doi: 10.1126/sciadv.adp1290. Epub 2024 Jul 31.PMID: 39083604

Deciphering immune responses: a comparative analysis of influenza vaccination platforms.

Jones CH, Hauguel T, Beitelshees M, Davitt M, Welch V, Lindert K, Allen P, True JM, Dolsten M.Drug Discov Today. 2024 Aug 2;29(9):104125. doi: 10.1016/j.drudis.2024.104125. Online ahead of print.PMID: 39097221

Insights into Theileria transmission-blocking vaccines for East Coast fever control: A disease with an "outdated vaccination approach".

Ndawula C Jr, Emudong P, Muwereza N, Currà C.Ticks Tick Borne Dis. 2024 Aug 10;15(6):102386. doi: 10.1016/j.ttbdis.2024.102386. Online ahead of print.PMID: 39128161

Coding Therapeutic Nucleic Acids from Recombinant Proteins to Next-Generation Vaccines: Current Uses, Limitations, and Future Horizons.

Harisa GI, Faris TM, Sherif AY, Alzhrani RF, Alanazi SA, Kohaf NA, Alanazi FK.Mol Biotechnol. 2024 Aug;66(8):1853-1871. doi: 10.1007/s12033-023-00821-z. Epub 2023 Aug 14.PMID: 37578574

JYNNEOS Vaccine Safety Surveillance During the 2022 Mpox Outbreak Using the Vaccine Adverse Event Reporting System and V-safe, United States, 2022 to 2023.

Duffy J, Myers TR, Marquez P, Rouse D, Brown H, Zhang B, Shay DK, Moro PL.Sex Transm Dis. 2024 Aug 1;51(8):509-515. doi: 10.1097/OLQ.0000000000001978. Epub 2024 Apr 17.PMID: 38647241

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials.

Whitworth HS, Mounier-Jack S, Choi EM, Gallagher KE, Howard N, Kelly H, Mbwanji G, Kreimer AR, Basu P, Barnabas R, Drolet M, Brisson M, Watson-Jones D.Vaccine X. 2024 Apr 16;19:100486. doi: 10.1016/j.jvacx.2024.100486. eCollection 2024 Aug.PMID: 38873638

Orally Dissolving Film as a Potential Vaccine Delivery Carrier to Prevent Influenza Virus Infection.

Yoon KW, Chu KB, Eom GD, Mao J, Kim SS, Quan FS.Antiviral Res. 2024 Aug 5:105979. doi: 10.1016/j.antiviral.2024.105979. Online ahead of print.PMID: 39111639

COVID-19 vaccination in low and middle-income countries: Creating a sustainable roadmap for promoting public health intervention.

Oladapo RK, Obidiro OP, Oyetola AB, Olajide A, Oladapo MO, Lawrence US, Hasan MM, Islam Z, Mustapha AA, Osuagwu-Nwogu E, Ghazanfar S, Olaleye MA, Monisola I, Ibraheem B, Afolayan AA, Barakat A, Adewole MO.Int J Health Plann Manage. 2024 Aug 1. doi: 10.1002/hpm.3834. Online ahead of print.PMID: 39090524

Optic neuritis following COVID-19 vaccination: Case series and review of the literature.

Etemadifar M, Nouri H, Abtahi SH, Bathaei R, Mardi R, Salari M, Dehghani A, Panahi Seifabad M, Jannesari A.J Fr Ophtalmol. 2024 Aug 6;47(8):104264. doi: 10.1016/j.jfo.2024.104264. Online ahead of print.PMID: 39111095

CodonBERT large language model for mRNA vaccines.

Li S, Moayedpour S, Li R, Bailey M, Riahi S, Kogler-Anele L, Miladi M, Miner J, Pertuy F, Zheng D, Wang J, Balsubramani A, Tran K, Zacharia M, Wu M, Gu X, Clinton R, Asquith C, Skaleski J, Boeglin L, Chivukula S, Dias A, Strugnell T, Montoya FU, Agarwal V, Bar-Joseph Z, Jager S.Genome Res. 2024 Aug 7. doi: 10.1101/gr.278870.123. Online ahead of print.PMID: 38951026

A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications.

Schön J, Barut GT, Trüeb BS, Halwe NJ, Berenguer Veiga I, Kratzel A, Ulrich L, Kelly JN, Brügger M, Wylezich C, Taddeo A, Aguiar Moreira E, Túrós D, Grau-Roma L, Ahrens AK, Schlottau K, Britzke T, Breithaupt A, Corleis B, Kochmann J, Oliveira Esteves BI, Almeida L, Thomann L, Devisme C, Stalder H, Steiner S, Ochsenbein S, Schmied K, Labroussaa F, Jores J, V'kovski P, Cmiljanovic V, Alves MP, Benarafa C, Ebert N, Hoffmann D, Beer M, Thiel V.Nat Microbiol. 2024 Aug;9(8):2099-2112. doi: 10.1038/s41564-024-01755-1. Epub 2024 Jul 12.PMID: 38997518

COVID-19 Vaccination in the First Trimester and Major Structural Birth Defects Among Live Births.

Kharbanda EO, DeSilva MB, Lipkind HS, Romitti PA, Zhu J, Vesco KK, Boyce TG, Daley MF, Fuller CC, Getahun D, Jackson LA, Williams JTB, Zerbo O, Weintraub ES, Vazquez-Benitez G.JAMA Pediatr. 2024 Aug 1;178(8):823-829. doi: 10.1001/jamapediatrics.2024.1917.PMID: 38949821

Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis.

Parkash V, Ashwin H, Dey S, Sadlova J, Vojtkova B, Van Bocxlaer K, Wiggins R, Thompson D, Dey NS, Jaffe CL, Schwartz E, Volf P, Lacey CJN, Layton AM, Kaye PM.Nat Med. 2024 Aug 2. doi: 10.1038/s41591-024-03146-9. Online ahead of print.PMID: 39095597

ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study.

Fontana RJ, Li YJ, Vuppalanchi R, Kleiner DE, Gu J, Shroff H, Van Wagner LB, Watkins PB; US DILIN study group.Am J Gastroenterol. 2024 Aug 1;119(8):1496-1505. doi: 10.14309/ajg.0000000000002702. Epub 2024 Feb 5.PMID: 38314748

The geography of COVID-19 vaccine completion by age in North Carolina, U.S.

Sandborn H, Delamater P, Brewer NT, Gilkey MB, Emch M.PLoS One. 2024 Aug 9;19(8):e0304812. doi: 10.1371/journal.pone.0304812. eCollection 2024.PMID: 39121103

The life cycle of vaccines evaluated by the European Medicines Agency.

Gräf DD, Westphal L, Hallgreen CE.Vaccine. 2024 Aug 8;42(21):126186. doi: 10.1016/j.vaccine.2024.126186. Online ahead of print.PMID: 39121512

Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam.

Nguyen HT, Falzarano D, Gerdts V, Liu Q.Microbiol Spectr. 2024 Aug 6;12(8):e0095924. doi: 10.1128/spectrum.00959-24. Epub 2024 Jun 25.PMID: 38916311

Knowledge, attitudes, and practices towards human papillomavirus (HPV) and HPV vaccination among male nurses.

Sağtaş F, Gürsoy MY.Int J Nurs Pract. 2024 Aug;30(4):e13228. doi: 10.1111/ijn.13228. Epub 2023 Dec 19.PMID: 38113644

Achilles' heel: elderly COVID-19 vaccination policy in China.

Deng Z, Grépin KA.Health Res Policy Syst. 2024 Aug 5;22(1):90. doi: 10.1186/s12961-024-01155-1.PMID: 39103903

Multisystemic inflammatory syndrome in children and the BNT162b2 vaccine: a nationwide cohort study.

Schwartz N, Ratzon R, Hazan I, Zimmerman DR, Singer SR, Wasser J, Dweck T, Alroy-Preis S.Eur J Pediatr. 2024 Aug;183(8):3319-3326. doi: 10.1007/s00431-024-05586-4. Epub 2024 May 9.PMID: 38724677

Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil.

Nogueira ML, Cintra MAT, Moreira JA, Patiño EG, Braga PE, Tenório JCV, de Oliveira Alves LB, Infante V, Silveira DHR, de Lacerda MVG, Pereira DB, da Fonseca AJ, Gurgel RQ, Coelho IC, Fontes CJF, Marques ETA, Romero GAS, Teixeira MM, Siqueira AM, Boaventura VS, Ramos F, Júnior EE, de Moraes JC, Whitehead SS, Esteves-Jaramillo A, Shekar T, Lee JJ, Macey J, Kelner SG, Coller BG, Boulos FC, Kallás EG; Phase 3 Butantan-DV Working Group.Lancet Infect Dis. 2024 Aug 5:S1473-3099(24)00376-1. doi: 10.1016/S1473-3099(24)00376-1. Online ahead of print.PMID: 39116904

Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia.

Alessandra R, Sara C, Claudia P, Natasha G, Federica C, Chiara B, Tobia F, Stefano T, Eleonora R, Andrea M, Martin MN, Caterina UF, Nigel T, Stefania DSM, Lucia L, Chiara P.J Transl Med. 2024 Aug 12;22(1):755.

Behavioral nudges in social media ads show limited ability to encourage COVID-19 vaccination across countries.

Çat O, Chang J, Hlatky R, Li H, Nielson DL.PNAS Nexus. 2024 Aug 6;3(8):pgae189. doi: 10.1093/pnasnexus/pgae189. eCollection 2024 Aug.PMID: 39108305

Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques.

Abhyankar MM, Xu F, Chavez D, Goodroe A, Mendoza E, Chen C, Singh DK, Varnador F Jr, Sivananthan SJ, Kinsey R, Lykins WR, Murphy BM, Martin AR, Tomai MA, Ghosal S, Casper C, Pedersen K, Petri WA Jr, Fox CB.Hum Vaccin Immunother. 2024 Dec 31;20(1):2374147. doi: 10.1080/21645515.2024.2374147. Epub 2024 Aug 1.PMID: 39090779

A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge.

Tian Y, Deng Z, Chuai Z, Li C, Chang L, Sun F, Cao R, Yu H, Xiao R, Lu S, Xu Y, Yang P.Virology. 2024 Aug;596:110125. doi: 10.1016/j.virol.2024.110125. Epub 2024 May 23.PMID: 38805804

The relationship between HPV testing attitudes and beliefs, knowledge, and vaccination attitudes: A cross-sectional study.

Küçükkaya B, Cangöl Sögüt S, Cangöl E.Public Health Nurs. 2024 Aug 1. doi: 10.1111/phn.13390. Online ahead of print.PMID: 39087632

Effectiveness of a community-centered Newcastle disease vaccine delivery model under paid and free vaccination frameworks in southeastern Kenya.

Ogolla KO, Anyona DN, Chemuliti JK, Kimani WW, King'oo FM, Waweru KM, Omia DO, Nyamongo IK, Bukachi SA.PLoS One. 2024 Aug 1;19(8):e0308088. doi: 10.1371/journal.pone.0308088. eCollection 2024.PMID: 39088513

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material.

Jastorff A, Bastian AR, Ligtenberg N, Klyashtornyy V, Callendret B, Heijnen E.Hum Vaccin Immunother. 2024 Dec 31;20(1):2383504. doi: 10.1080/21645515.2024.2383504. Epub 2024 Aug 8.PMID: 39118413

An intranasal attenuated Coxsackievirus B3 vaccine induces strong systemic and mucosal immunity against CVB3 lethal challenge.

Deng H, Li Y, He X, Wang H, Wang S, Zhang H, Zhu J, Gu L, Li R, Wang G.J Med Virol. 2024 Aug;96(8):e29831. doi: 10.1002/jmv.29831.PMID: 39072815

Safety profile assessment of HPV4 and HPV9 vaccines through the passive surveillance system of the Veneto Region (Italy) between 2008 and 2022: A 15-year retrospective observational study.

Dalla Valle D, Benoni R, Soriolo N, Battistella C, Moretti F, Gonella LA, Tardivo S, Colpo S, Montresor S, Russo F, Tonon M, Da Re F, Moretti U, Zanoni G.Vaccine X. 2024 Jun 21;19:100511. doi: 10.1016/j.jvacx.2024.100511. eCollection 2024 Aug.PMID: 39040889

Covishield(TM) Vaccine-Induced Autoimmune Urticaria.

Choudhary S, Srivastava A.Skinmed. 2024 Aug 2;22(2):158-159. eCollection 2024.PMID: 39090006

Recombinant proteins production in Escherichia coli BL21 for vaccine applications: a cost estimation of potential industrial-scale production scenarios.

Akmayan I, Ozturk AB, Ozbek T.Prep Biochem Biotechnol. 2024 Aug;54(7):932-945. doi: 10.1080/10826068.2023.2299495. Epub 2024 Jan 10.PMID: 38198230

Cooperating Graph Neural Networks With Deep Reinforcement Learning for Vaccine Prioritization.

Ling L, Mondal WU, Ukkusuri SV.IEEE J Biomed Health Inform. 2024 Aug;28(8):4891-4902. doi: 10.1109/JBHI.2024.3392436. Epub 2024 Aug 6.PMID: 38691436

Sustained release system from PLGA particles co-encapsulated with inactivated influenza virus with natural killer T cell agonist α-galactosylceramide.

Wen Y, Sparks Z, Hawkins I, Lednicky J, Abboud G, Nelson C, Chauhan A, Driver J.Eur J Pharm Biopharm. 2024 Aug;201:114365. doi: 10.1016/j.ejpb.2024.114365. Epub 2024 Jun 12.PMID: 38876362

Safety and durability of mRNA-1273-induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial.

Figueroa AL, Ali K, Berman G, Zhou H, Deng W, Xu W, Lussier S, Girard B, Dutko FJ, Slobod K, Yeakey A, Priddy F, Miller JM, Das R.EClinicalMedicine. 2024 Jul 18;74:102720. doi: 10.1016/j.eclinm.2024.102720. eCollection 2024 Aug.PMID: 39091673

National trends in patterns of under-vaccination in early childhood: national immunization survey-child, United States, 2011-2021.

Daley MF, Clarke CL, Glanz JM, Albers AN, Michels SY, Freeman RE, Newcomer SR.Expert Rev Vaccines. 2024 Aug 7. doi: 10.1080/14760584.2024.2389922. Online ahead of print.PMID: 39109453

Characterizing timeliness of recommended vaccinations among privately-insured children in the United States, 2009-2019.

Butler AM, Newland JG, Sahrmann JM, O'Neil CA, McGrath LJ.Vaccine. 2024 Aug 7;42(21):126179. doi: 10.1016/j.vaccine.2024.126179. Online ahead of print.PMID: 39116485

Coronavirus Disease 2019 Vaccination by Gender and Age in a Sample of Black Adults in Chicago.

Hirschtick JL, DiFranceisco W, Hunt B, Jacobs J, Valencia J, Walsh JL, Quinn K.Health Educ Behav. 2024 Aug;51(4):497-501. doi: 10.1177/10901981241245060. Epub 2024 Apr 12.PMID: 38606988

A novel strategy to elicit enduring anti-morphine immunity and relief from addiction by targeting Acr1 protein nano vaccine through TLR-2 to dendritic cells.

Nanda S, Zafar MA, Lamba T, Malik JA, Khan MA, Bhardwaj P, Bisht B, Ghadi R, Kaur G, Bhalla V, Owais M, Jain S, Sehrawat S, Agrewala JN.Int J Biol Macromol. 2024 Aug;274(Pt 1):133188. doi: 10.1016/j.ijbiomac.2024.133188. Epub 2024 Jun 14.PMID: 38880456

Molecular surveillance of influenza A virus in Saudi Arabia: whole-genome sequencing and metagenomic approaches.

Dandachi I, Alrezaihi A, Amin D, AlRagi N, Alhatlani B, Binjomah A, Aleisa K, Dong X, Hiscox JA, Aljabr W.Microbiol Spectr. 2024 Aug 6;12(8):e0066524. doi: 10.1128/spectrum.00665-24. Epub 2024 Jun 21.PMID: 38904365

The immune response behind peptide vaccination in diffuse midline glioma.

Vincent CA, Remeseiro S.Mol Oncol. 2024 Aug;18(8):1849-1852. doi: 10.1002/1878-0261.13686. Epub 2024 Jun 16.PMID: 38880657

Vaccination with O-linked Mannans Protects against Systemic Candidiasis through Innate Lymphocyte Populations.

Taira CL, Dos Santos Dias L, Lichtenberger S, Whitehead AJ, Kischkel B, Netea MG, Klein BS, Wüthrich M.J Immunol. 2024 Aug 7:ji2400065. doi: 10.4049/jimmunol.2400065. Online ahead of print.PMID: 39109925

Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial.

Aziz AB, Dudman S, Julin CH, Ahmmed F, Stene-Johansen K, Sandbu S, Øverbø J, Dembinski JL, Wisløff T, Rana S, Basunia AH, Haque W, Qadri F, Zaman K, Clemens JD.Lancet Glob Health. 2024 Aug;12(8):e1300-e1311. doi: 10.1016/S2214-109X(24)00193-1.PMID: 39030061

Lipodystrophy following Covid-19 Vaccination: A case report.

Shakarami M, Sinaei F, Ghaderi Yazdi B, Ziaadini B.Vaccine X. 2024 Jun 22;19:100513. doi: 10.1016/j.jvacx.2024.100513. eCollection 2024 Aug.PMID: 39091362

Human papillomavirus-driven head and neck cancers in Japan during 2008-2009 and 2018-2019: The BROADEN study.

Nibu KI, Oridate N, Saito Y, Roset M, Forés Maresma M, Cuadras D, Morais E, Roberts C, Chen YT, Spitzer J, Sato K, Saito I, Tazaki I, Clavero O, Schroeder L, Alemany L, Mehanna H, Mirghani H, Giuliano AR, Pavón MA, Waterboer T.Cancer Sci. 2024 Aug;115(8):2808-2818. doi: 10.1111/cas.16230. Epub 2024 Jun 7.PMID: 38847353

Medical and molecular biophysical techniques as substantial tools in the era of mRNA-based vaccine technology.

Hussain A, Wang M, Yu D, Zhang J, Naseer QA, Ullah A, Milon Essola J, Zhang X.Biomater Sci. 2024 Aug 6;12(16):4117-4135. doi: 10.1039/d4bm00561a.PMID: 39016519

Immune-based Therapies for Penile Cancer.

Al Assaad M, Safa H, Mercinelli C, Spiess PE, Necchi A, Chahoud J.Urol Clin North Am. 2024 Aug;51(3):355-365. doi: 10.1016/j.ucl.2024.03.014. Epub 2024 Apr 16.PMID: 38925738

Generation of a virus-like particles based vaccine against IgE.

Gharailoo Z, Plattner K, Augusto G, Engeroff P, Vogel M, Bachmann MF.Allergy. 2024 Aug;79(8):2207-2221. doi: 10.1111/all.16090. Epub 2024 Mar 6.PMID: 38445568

Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma.

Gross NE, Zhang Z, Mitchell JT, Charmsaz S, Hernandez AG, Coyne EM, Shin SM, Vargas Carvajal DC, Sidiropoulos DN, Cho Y, Mo G, Yuan X, Cannon C, Suresh Babu J, Lyman MR, Armstrong T, Kagohara LT, Bever KM, Le DT, Jaffee EM, Fertig EJ, Ho WJ.JCI Insight. 2024 Aug 6:e179292. doi: 10.1172/jci.insight.179292. Online ahead of print.PMID: 39106104

The Roles of Social Media Use and Medical Mistrust in Black Americans' COVID-19 Vaccine Hesitancy: The RISP Model Perspective.

Nah S, Williamson LD, Kahlor LA, Atkinson L, Upshaw SJ, Ntang-Beb JL.Health Commun. 2024 Aug;39(9):1833-1846. doi: 10.1080/10410236.2023.2244169. Epub 2023 Aug 8.PMID: 37551159

Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination.

Song Y, Choi W, Shim E.Am J Prev Med. 2024 Aug;67(2):231-240. doi: 10.1016/j.amepre.2024.03.008. Epub 2024 Mar 18.PMID: 38508425

Effect of Automated and Personalized Outreach Messages on Well-Child Visit Catch Up: A Randomized Clinical Trial.

Berset AE, Burkhardt MC, Xu Y, Mescher A, Brinkman WB.Acad Pediatr. 2024 Aug;24(6):914-921. doi: 10.1016/j.acap.2023.11.017. Epub 2023 Nov 23.PMID: 38007156 Clinical Trial.

A complex fuzzy decision model for analysing the post-pandemic immuno-sustainability.

Pragathi S, Narayanamoorthy S, Dhivya S, Saraswathy R, Pamucar D, Simic V, Kang D.Acta Trop. 2024 Aug;256:107261. doi: 10.1016/j.actatropica.2024.107261. Epub 2024 May 19.PMID: 38772435

Contriving a novel of CHB therapeutic vaccine based on IgV CTLA-4 and L protein via immunoinformatics approach.

Zhu Y, Yu M, Aisikaer M, Zhang C, He Y, Chen Z, Yang Y, Han R, Li Z, Zhang F, Ding J, Lu X.J Biomol Struct Dyn. 2024 Aug;42(12):6323-6341. doi: 10.1080/07391102.2023.2234043. Epub 2023 Jul 9.PMID: 37424209

Racial, Ethnic, and Gender Differences in the Timing of Initiating the HPV Vaccine in the United States: the Case of Southeast Asian Americans.

Truong-Vu KP.J Racial Ethn Health Disparities. 2024 Aug;11(4):2210-2223. doi: 10.1007/s40615-023-01689-0. Epub 2023 Aug 2.PMID: 37531020

Characterizing the splice map of Turkey Hemorrhagic Enteritis Virus.

Quaye A, Pickett BE, Griffitts JS, Berges BK, Poole BD.Virol J. 2024 Aug 6;21(1):175. doi: 10.1186/s12985-024-02449-0.PMID: 39107824

Determination of DTaP vaccine potency by multiplex immunogenicity testing using electrochemiluminescence.

Friedrichs B, Rehg S, Hanschmann KM, Öppling V, Bekeredjian-Ding I.NPJ Vaccines. 2024 Aug 7;9(1):142. doi: 10.1038/s41541-024-00915-y.PMID: 39112508

Pickering emulsion-guided monomeric delivery of monophosphoryl lipid A for enhanced vaccination.

Du Y, Lv J, Hao Z, Li Z, Song T, Ge H, Wang H, Yu Z, Xie Z, Li D, Liu Y.J Control Release. 2024 Aug 8;374:39-49. doi: 10.1016/j.jconrel.2024.08.005. Online ahead of print.PMID: 39111597

Emerging therapeutic avenues against Cryptosporidium: A comprehensive review.

Ali M, Xu C, Wang J, Kulyar MF, Li K.Vet Parasitol. 2024 Aug 2;331:110279. doi: 10.1016/j.vetpar.2024.110279. Online ahead of print.PMID: 39116547

Gay and Bisexual Men's Perceptions about a Potential HIV Vaccine within a Post-COVID-19 Era: A Qualitative Study.

D'Angelo AB, Dearolf MH, MacMartin J, Elder M, Nash D, Golub SA, Grov C.AIDS Behav. 2024 Aug 10. doi: 10.1007/s10461-024-04450-8. Online ahead of print.PMID: 39122906

Prevention of nodules and enhancement of antibody response to genetically engineered recombinant vaccine against Human Chorionic Gonadotropin (hCG) for contraception.

Tiwari P, Srivastava M, Sehgal R, Kumar S, Selvapandiyan A, Kumari A, Gupta JC, Talwar GP.Eur J Contracept Reprod Health Care. 2024 Aug;29(4):182-187. doi: 10.1080/13625187.2024.2359127. Epub 2024

Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines.

Borrajo ML, Lou G, Anthiya S, Lapuhs P, Álvarez DM, Tobío A, Loza MI, Vidal A, Alonso MJ.Drug Deliv Transl Res. 2024 Aug;14(8):2046-2061. doi: 10.1007/s13346-024-01635-5. Epub 2024 May 29.PMID: 38811465

Immunological responses in a Chlamydia trachomatis vaccine trial.

Huston W.Lancet Infect Dis. 2024 Aug;24(8):795-796. doi: 10.1016/S1473-3099(24)00174-9. Epub 2024 Apr 11.PMID: 38615674

A new tool for accelerating tuberculosis vaccine development.

Jeyanathan M, Xing Z.Lancet Infect Dis. 2024 Aug;24(8):803-804. doi: 10.1016/S1473-3099(24)00178-6. Epub 2024 Apr 12.PMID: 38621406

BNT162b2 mRNA vaccine in transfusion dependent thalassemia patients.

Daungsupawong H, Wiwanitkit V.Transfus Med. 2024 Aug;34(4):329. doi: 10.1111/tme.13054. Epub 2024 May 25.PMID: 38794864

Impact of Glycan Depletion, Glycan Debranching and Increased Glycan Charge on HIV-1 Neutralization Sensitivity and Immunogenicity.

D'Addabbo A, Tong T, Crooks ET, Osawa K, Xu J, Thomas A, Allen JD, Crispin M, Binley JM.Glycobiology. 2024 Aug 8:cwae063. doi: 10.1093/glycob/cwae063. Online ahead of print.PMID: 39115361

Social Processes and COVID-19 Vaccination of Children of Hesitant Mothers.

Willis DE, Purvis RS, Moore R, Li J, Selig JP, Imran T, Zimmerman S, McElfish PA.J Community Health. 2024 Aug;49(4):700-707. doi: 10.1007/s10900-024-01340-x. Epub 2024 Feb 25.PMID: 38402520

Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy.

Saad-Roy CM, Morris SE, Boots M, Baker RE, Lewis BL, Farrar J, Marathe MV, Graham AL, Levin SA, Wagner CE, Metcalf CJE, Grenfell BT.PLoS Comput Biol. 2024 Aug 5;20(8):e1012211. doi: 10.1371/journal.pcbi.1012211. eCollection 2024 Aug.PMID: 39102402

Vaccine Hesitancy in Taiwan: Temporal, Multilayer Network Study of Echo Chambers Shaped by Influential Users.

Yin JD.Online J Public Health Inform. 2024 Aug 9;16:e55104. doi: 10.2196/55104.PMID: 39121466

Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019.

Clopper BR, Zhou Y, Tannis A, Staat MA, Rice M, Boom JA, Sahni LC, Selvarangan R, Harrison CJ, Halasa NB, Stewart LS, Weinberg GA, Szilagyi PG, Klein EJ, Englund JA, Rha B, Lively JY, Ortega-Sanchez IR, McMorrow ML, Moline HL.J Pediatr. 2024 Aug;271:114045. doi: 10.1016/j.jpeds.2024.114045. Epub 2024 Mar 30.PMID: 38561048

Attitudes of pregnant women in the Dominican Republic towards a future maternal Group B Streptococcus vaccine.

Job MJ, Kim D, Acosta F, Valera S, Fernandez A, Laycock KM, Ratner AJ, Steenhoff AP, Feemster K, Geoghegan S.Vaccine. 2024 Aug 9;42(22):126169. doi: 10.1016/j.vaccine.2024.126169. Online ahead of print.PMID: 39126829

Francisella tularensis Live Vaccine Strain training of murine alveolar and bone marrow-derived macrophages.

Khan H, Bhargava V, Elkins KL.Microbiol Spectr. 2024 Aug 6;12(8):e0002824. doi: 10.1128/spectrum.00028-24. Epub 2024 Jun 28.PMID: 38940590

Genotyping of infectious bronchitis virus in Canada.

Ojkic D, Susta L, Martin E.J Vet Diagn Invest. 2024 Aug 6:10406387241265955. doi: 10.1177/10406387241265955. Online ahead of print.PMID: 39108146

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.

Díez-Domingo J, Simkó R, Icardi G, Chong CP, Zocchetti C, Syrkina O, Bchir S, Bertrand-Gerentes I.Infect Dis Ther. 2024 Aug;13(8):1835-1859. doi: 10.1007/s40121-024-01009-x. Epub 2024 Jul 2.PMID: 38955966

The latest news in France before distribution of third-generation pneumococcal conjugate vaccines.

Cohen R, Levy C, Varon E.Infect Dis Now. 2024 Aug;54(5):104937. doi: 10.1016/j.idnow.2024.104937. Epub 2024 Jun 13.PMID: 38876363

Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness.

Mageau A, Simard JF, Svenungsson E, Arkema EV.Lupus. 2024 Aug 12:9612033241273052. doi: 10.1177/09612033241273052. Online ahead of print.PMID: 39133903

Mass vaccination with reassortment-impaired live H9N2 avian influenza vaccine.

Cargnin Faccin F, Cáceres CJ, Gay LC, Seibert B, van Bentem N, Rodriguez LA, Soares Fraiha AL, Cardenas M, Geiger G, Ortiz L, Carnaccini S, Kapczynski DR, Rajao DS, Perez DR.NPJ Vaccines. 2024 Aug 3;9(1):136. doi: 10.1038/s41541-024-00923-y.PMID: 39097573

Epidemiological characteristics and serological survey of mumps 15 years after MMR vaccine was included in the immunization program.

Gong X, Fang Q, Zheng W, Lai S, Xu W, Yin Z.J Med Virol. 2024 Aug;96(8):e29856. doi: 10.1002/jmv.29856.PMID: 39135476

Immunoprotective efficacy evaluation of OmpTS subunit vaccine against Aeromonas hydrophila infection in Megalobrama amblycephala.

Xu Z, Zhang M, Zhang T, Cui H, Li H, Wang X, Zhao X, Chen X, Cheng H, Xu J, Ding Z.Fish Shellfish Immunol. 2024 Aug;151:109665. doi: 10.1016/j.fsi.2024.109665. Epub 2024 Jun 1.PMID: 38830521

Evaluation of the immune responses of biological adjuvant bivalent vaccine with three different insertion modes for ND and IBD.

Sun W, Li S, Niu D, Qin R, Li H, Xue Z, Guo Y, Liu J, Liu Y, Jiang X, Yin J, Guo X, Ren G.Virulence. 2024 Dec;15(1):2387181. doi: 10.1080/21505594.2024.2387181. Epub 2024 Aug 5.PMID: 39101682

Status and future developments for downstream processing of biological products: Perspectives from the Recovery XIX yield roundtable discussions.

Jungbauer A, Ferreira G, Butler M, D'Costa S, Brower K, Rayat A, Willson R.Biotechnol Bioeng. 2024 Aug;121(8):2524-2541. doi: 10.1002/bit.28738. Epub 2024 May 25.PMID: 38795025

Moral persuasion for value-laden objections to human papillomavirus vaccination.

Owusu-Boaitey N, Aulisio M.Patient Educ Couns. 2024 Aug;125:108296. doi: 10.1016/j.pec.2024.108296. Epub 2024 Apr 21.PMID: 38688093

Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population.

Stejskal L, Thistlethwaite A, Ramirez-Bencomo F, Rashmi S, Harrison O, Feavers IM, Maiden MCJ, Jerse A, Barnes G, Chirro O, Chemweno J, Nduati E, Cehovin A, Tang C, Sanders EJ, Derrick JP.Nat Commun. 2024 Aug 7;15(1):6712. doi: 10.1038/s41467-024-51053-x.PMID: 39112489

Description of BCG and Tuberculosis Disease in a Cohort of 79 Patients with Chronic Granulomatous Disease.

León-Lara X, Pérez-Blanco U, Yamazaki-Nakashimada MA, Bustamante-Ogando JC, Aguilar-Gómez N, Cristerna-Tarrasa H, Staines-Boone AT, Saucedo-Ramírez OJ, Fregoso-Zuñiga E, Macías-Robles AP, Canseco-Raymundo MR, Venancio-Hernández M, Moctezuma-Trejo C, Gámez-González B, Zarate-Hernández C, Ramírez-Rivera R, Scheffler-Mendoza S, Jiménez-Polvo N, Hernández-Nieto L, Carmona-Vargas J, García-Cruz ML, Zavaleta-Martínez Ó, Román-Montes CM, Cervantes-Parra V, González-Reynoso A, Guzmán-Cotaya R, Espinosa-Rosales F, Saltigeral-Simental P, Espinosa-Padilla S, Blancas Galicia L.J Clin Immunol. 2024 Aug 5;44(8):171. doi: 10.1007/s10875-024-01778-7.PMID: 39102004

Is there a need for an alternative varicella vaccine?

Dagnew AF.Lancet Infect Dis. 2024 Aug;24(8):804-806. doi: 10.1016/S1473-3099(24)00218-4. Epub 2024 Apr 10.PMID: 38614118

Modelling on COVID-19 control with double and booster-dose vaccination.

Kalra P, Ali S, Ocen S.Gene. 2024 Aug 6;928:148795. doi: 10.1016/j.gene.2024.148795. Online ahead of print.PMID: 39097207

Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia.

Ben Jemaa A, Bouabsa R, Ben Othmen M, Oueslati R, Dhaouadi H.Tunis Med. 2024 Aug 5;102(8):457-464. doi: 10.62438/tunismed.v102i8.4944.PMID: 39129572

Statistical Experimental Designs for cLTB-Syn Vaccine Production Using Daucus carota Cell Suspension Cultures.

Carreño-Campos C, Villegas E, Villarreal ML, Morales-Aguilar M, Govea-Alonso D, Romero-Maldonado A, Jimenez-Capdeville ME, Rosales-Mendoza S, Ortiz-Caltempa A.Planta Med. 2024 Aug;90(10):744-756. doi: 10.1055/a-2307-0400. Epub 2024 May 2.PMID: 38698590

Does HPV vaccination during periconceptional or gestational period increase the risk of adverse pregnancy outcomes?-An updated systematic review and meta-analysis based on timing of vaccination.

Zhang J, Lian Z, Xue X, Li J, Zhu Y, Huang N, Xie W.Acta Obstet Gynecol Scand. 2024 Aug 6. doi: 10.1111/aogs.14881. Online ahead of print.PMID: 39106178

Esoteric beliefs and CAM impact SARS-CoV-2 immunization drivers, uptake and pediatric immunization views in Germany.

Jäckle S, Timmis JK.NPJ Vaccines. 2024 Aug 3;9(1):137. doi: 10.1038/s41541-024-00928-7.PMID: 39097580

Why did I participate in an HIV vaccine study? Experiences of participation in the first phase II HIV vaccine trial in Mozambique: An ancillary study using a mixed-method approach.

Ubisse Capitine IP, Manhiça ÁM, Tembe Júnior P, Ramgi PM, Chicumbe S, Kroidl A, Fischer MR, De Schacht C.Vaccine X. 2024 Jun 6;19:100510. doi: 10.1016/j.jvacx.2024.100510. eCollection 2024 Aug.PMID: 39021617

Design of Cryptococcus neoformans multiepitope vaccine based on immunoinformatics method.

Zhou Z, Zhu F, Ma S, Tan C, Yang H, Zhang P, Xu Y, Qin R, Luo Y, Chen J, Pan P.Med Mycol. 2024 Aug 9:myae080. doi: 10.1093/mmy/myae080. Online ahead of print.PMID: 39122658

Uniform Polymeric Nanovaccine Platform for Improving the Availability and Efficacy of Neoantigen Peptides.

Chen H, Zhu Z, Lv K, Qi Y, Si X, Ma S, Song W, Chen X.Nano Lett. 2024 Aug 7. doi: 10.1021/acs.nanolett.4c02196. Online ahead of print.PMID: 39109634

Postmenopausal Bleeding After Coronavirus Disease 2019 (COVID-19) Vaccination: Vaccine Adverse Event Reporting System.

Strid P, Abara WE, Clark E, Moro PL, Olson CK, Gee J.Obstet Gynecol. 2024 Aug 1;144(2):283-287. doi: 10.1097/AOG.0000000000005615. Epub 2024 May 23.PMID: 38781590

Protective efficacy and immune responses of largemouth bass (Micropterus salmoides) immunized with an inactivated vaccine against the viral hemorrhagic septicemia virus genotype IVa.

Huang H, Lu X, Guo J, Chen Y, Yi M, Jia K.Fish Shellfish Immunol. 2024 Aug;151:109691. doi: 10.1016/j.fsi.2024.109691. Epub 2024 Jun 11.PMID: 38871138

Structure-Activity Relationship Studies in Benzothiadiazoles as Novel Vaccine Adjuvants.

Belsuzarri MM, Sako Y, Brown TD, Chan M, Cozza R, Jin J, Sato-Kaneko F, Yao S, Pu M, Messer K, Hayashi T, Cottam HB, Corr M, Carson DA, Shukla NM.J Med Chem. 2024 Aug 8. doi:

Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.

Marcos-Villar L, Perdiguero B, López-Bravo M, Zamora C, Sin L, Álvarez E, Sorzano CÓS, Sánchez-Cordón PJ, Casasnovas JM, Astorgano D, García-Arriaza J, Anthiya S, Borrajo ML, Lou G, Cuesta B, Franceschini L, Gelpí JL, Thielemans K, Sisteré-Oró M, Meyerhans A, García F, Esteban I, López-Bigas N, Plana M, Alonso MJ, Esteban M, Gómez CE.Emerg Microbes Infect. 2024 Dec;13(1):2387906. doi: 10.1080/22221751.2024.2387906. Epub 2024 Aug 8.PMID: 39087555

Creating a Culturally Safe Online Data Collection Instrument to Measure Vaccine Confidence Among Indigenous Youth: Indigenous Consensus Method.

Maar M, Bourdon C, Berti J, Bisaillon E, Boesch L, Boston A, Chapdelaine J, Humphrey A, Kumar S, Maar-Jackson B, Martell R, Naokwegijig B, Preet Kaur D, Rice S, Rickaby B, Sutherland M, Reade M.JMIR Form Res. 2024 Aug 12;8:e52884. doi: 10.2196/52884.PMID: 39133917

Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients.

Capone M, Vanni A, Salvati L, Lamacchia G, Mazzoni A, Maggi L, Cosmi L, Liotta F, Romagnani P, Cirillo L, Buti E, Terlizzi V, Azzari C, Citera F, Barbati F, Rossolini GM, Bresci S, Borchi B, Cavallo A, Mencarini J, Francalanci E, Kiros ST, Bartoloni A, Annunziato F.Immunol Lett. 2024 Aug;268:106886. doi: 10.1016/j.imlet.2024.106886. Epub 2024 Jun 19.PMID: 38906482

Evaluation of female university students' knowledge, attitudes, and practices toward human papillomavirus infection and vaccination. Multicenter cross-sectional study.

Mekonnen BA, Anagaw YK, Kassahun BA, Worku MC.BMC Womens Health. 2024 Aug 1;24(1):437. doi: 10.1186/s12905-024-03279-6.PMID: 39090723

Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response.

Wen Y, Deng S, Wang T, Gao M, Nan W, Tang F, Xue Q, Ju Y, Dai J, Wei Y, Xue F.Antiviral Res. 2024 Aug;228:105943. doi: 10.1016/j.antiviral.2024.105943. Epub 2024 Jun 21.PMID: 38909959

Multiplex Assay to Determine Acute Phase Proteins in Modified Live PRRSV Vaccinated Pigs.

Tor M, Fraile L, Vilaró F, Pena RN.J Proteome Res. 2024 Aug 2;23(8):3515-3523. doi: 10.1021/acs.jproteome.4c00154. Epub 2024 Jul 15.PMID: 39007742

Cost-effectiveness analysis of NVX-CoV2373 COVID-19 vaccination for elderly people in Japan.

Kato M, Ono T, Deguchi H, Ohmagari N, Igarashi A.Vaccine X. 2024 Jun 20;19:100514. doi: 10.1016/j.jvacx.2024.100514. eCollection 2024 Aug.PMID: 39108420

A bacterial ghost vaccine against Aeromonas salmonicida infection in turbot (Scophthalmus maximus).

Zhou J, Yu R, Ma Y, Wang Q, Liu Q, Zhang Y, Liu X.Fish Shellfish Immunol. 2024 Aug;151:109711. doi: 10.1016/j.fsi.2024.109711. Epub 2024 Jun 18.PMID: 38901685

A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice.

Liu J, Sun J, Ding X, Liu W, Wang Y, Wang Z, Peng H, Zhang Y, Su W, Jiang C.Emerg Microbes Infect. 2024 Aug 12:2389115. doi: 10.1080/22221751.2024.2389115. Online ahead of print.PMID: 39129566

HCMV IE1/IE1mut Therapeutic Vaccine Induces Tumor Regression via Intratumoral Tertiary Lymphoid Structure Formation and Peripheral Immunity Activation in Glioblastoma Multiforme.

Yang X, Jiang S, Liu F, Li Z, Liu W, Zhang X, Nan F, Li J, Yu M, Wang Y, Wang B.Mol Neurobiol. 2024 Aug;61(8):5935-5949. doi: 10.1007/s12035-024-03937-8. Epub 2024 Jan 23.PMID: 38261253

Characterization of a novel functional porcine $CD3^{+}CD4^{low}CD8\alpha^{+}CD8\beta^{+}$ T-helper/memory lymphocyte subset in the respiratory tract lymphoid tissues of swine influenza A virus vaccinated pigs.

Patil V, Yadagiri G, Bugybayeva D, Schrock J, Suresh R, Hernandez-Franco JF, HogenEsch H, Renukaradhya GJ.Vet Immunol Immunopathol. 2024 Aug;274:110785. doi: 10.1016/j.vetimm.2024.110785. Epub 2024 Jun 4.PMID: 38861830

Multiplexed real-time PCR for the detection and differentiation of *Klebsiella pneumoniae* O-antigen serotypes.

Slater D, Hutt Vater K, Sridhar S, Hwang W, Bielawski D, Turbett SE, LaRocque RC, Harris JB.Microbiol Spectr. 2024 Aug 8:e0037524. doi: 10.1128/spectrum.00375-24. Online ahead of print.PMID: 39115309

Immunisation of koalas against Chlamydia pecorum results in significant protection against chlamydial disease and mortality.

Phillips S, Hanger J, Grosmaire J, Mehdi A, Jelocnik M, Wong J, Timms P.NPJ Vaccines. 2024 Aug 6;9(1):139. doi: 10.1038/s41541-024-00938-5.PMID: 39107329

Uptake of human papilloma virus vaccination among adolescent girls living with HIV in Uganda: A mixed methods study.

Nakibuuka V, Muddu M, Kraehenbuhl JP, Birungi C, Semitala FC, Tusubira AK.PLoS One. 2024 Aug 8;19(8):e0300155. doi: 10.1371/journal.pone.0300155. eCollection 2024.PMID: 39116172

Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment.

Augello M, Wagenhäuser I, Krone M, Dauby N, Ferrara P, Sabbatucci M, Ruta S, Rezahosseini O, Velikov P, Gkrania-Klotsas E, Montes J, Franco-Paredes C, Goodman AL, Küçükkaya S, Tuells J, Harboe ZB, Epaulard O.Vaccine. 2024 Aug 2:126184. doi: 10.1016/j.vaccine.2024.126184. Online ahead of print.PMID: 39097440

User Experiences With a Moderated Facebook Group to Promote Vaccination.

Wysota CN, Abroms LC, DeVarona H, Koban D, Napolitano M, Broniatowski DA.Am J Health Promot. 2024 Aug 7:8901171241272061. doi: 10.1177/08901171241272061. Online ahead of print.PMID: 39110567

A Randomized Study to Determine the Effect of a Culturally Focused Video Intervention on Improving HPV Vaccine Intentions in a Christian Population in the United States.

Redd DS, Altman JD, Jensen JL, Sloan-Aagard CD, Crook TB, Asay AE, Nielson BU, Larson RJ, Miner DS, Poole BD.J Community Health. 2024 Aug;49(4):661-673. doi: 10.1007/s10900-024-01327-8. Epub 2024 Feb 23.PMID: 38393654

Surface-Engineered Polygonatum Sibiricum Polysaccharide CaCO(3) Microparticles as Novel Vaccine Adjuvants to Enhance Immune Response.

He J, Zhu T, Jiao L, Yu L, Peng S, Wang Z, Wang D, Liu H, Zhang S, Hu Y, Sun Y, Gao G, Cai T, Liu Z.Mol Pharm. 2024 Aug 5;21(8):3936-3950. doi: 10.1021/acs.molpharmaceut.4c00295. Epub 2024 Jul 17.PMID: 39017595

Controlling the speed of antigens transport in dendritic cells improves humoral and cellular immunity for vaccine.

Song Z, Jiao L, Wang D, Qiu Y, Miao J, Zhu T, Yu R, Wang Z, Zhou Y, Cai T, Zhang S, Liu H, Sun H, Sun Y, Liu Z.Biomed Pharmacother. 2024 Aug;177:117036. doi: 10.1016/j.biopha.2024.117036. Epub 2024 Jun 27.PMID: 38941888

Should We Vaccinate Healthcare Workers Against Respiratory Syncytial Virus?

Faico-Filho KS, Sita Perosa AH, Bellei N.Influenza Other Respir Viruses. 2024 Aug;18(8):e13363. doi: 10.1111/irv.13363.PMID: 39135433

Impact of COVID-19 Vaccine Rollout on Mental Health, Social Determinants of Health, and Attitudes Among Individuals With COPD.

Fawzy A, Wang JG, Krings JG, He J, Offor O, Eakin MN, Holbrook JT, Wise RA.Chronic Obstr Pulm Dis. 2024 Aug 12. doi: 10.15326/jcopdf.2024.0537. Online ahead of print.PMID: 39137254

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1.

Muik A, Quandt J, Lui BG, Bacher M, Lutz S, Grünenthal M, Toker A, Grosser J, Ozhelvaci O, Blokhina O, Shpyro S, Vogler I, Salisch N, Türeci Ö, Sahin U.Cell Rep. 2024 Aug 2;43(8):114567. doi: 10.1016/j.celrep.2024.114567. Online ahead of print.PMID: 39097927

Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65.

Buynak R, Cannon K, DeAtkine D, Kirby J, Usdan L, Bhavsar A, Gérard C, Kuznetsova A, Jayadev A, Amare H, Valenciano S, Meyer N.Infect Dis Ther. 2024 Aug;13(8):1789-1805. doi: 10.1007/s40121-024-00985-4. Epub 2024 Jun 26.PMID: 38981954

Blocking HXA_3-mediated neutrophil elastase release during *S. pneumoniae* lung infection limits pulmonary epithelial barrier disruption and bacteremia.

Xu S, Tan S, Romanos P, Reedy JL, Zhang Y, Mansour MK, Vyas JM, Mecsas J, Mou H, Leong JM.mBio. 2024 Aug 9:e0185624. doi: 10.1128/mbio.01856-24. Online ahead of print.PMID: 39120139

Purification processes of live virus vaccine candidates expressed in adherent Vero cell lines via multimodal chromatography in flowthrough mode.

Konstantinidis S, Poplyk MR, Ma WJ, Reilly D, Zhang Y, Wang J, Thompson R, Stiving A, Winters MA, Wang SC, Kristopeit A.Biotechnol Bioeng. 2024 Aug;121(8):2482-2499. doi: 10.1002/bit.28430. Epub 2023 May 20.PMID: 37209394

Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.

Fryer HA, Geers D, Gommers L, Zaeck LM, Tan NH, Jones-Freeman B, Goorhuis A, Postma DF, Visser LG, Hogarth PM, Koopmans MPG, GeurtsvanKessel CH, O'Hehir RE, van der Kuy PHM, de Vries RD, van Zelm MC.J Infect. 2024 Aug 8:106246. doi: 10.1016/j.jinf.2024.106246. Online ahead of print.PMID: 39127451

Hybrid immunity protection against SARS-CoV-2 and severe COVID-19 in kidney transplantation: a retrospective, comparative cohort study.

Favà A, Couceiro C, Calatayud L, Hernandez-Hermida Y, Melilli E, Montero N, Manonelles A, Coloma A, Codina S, Lloberas N, Oliveras L, Lino LA, Galofré C, Sabé N, Gomez-Preciado F, Sandoval D, Pizarro D, Domínguez MA, Cruzado JM.Am J Transplant. 2024 Aug 1:S1600-6135(24)00455-6. doi: 10.1016/j.ajt.2024.07.028. Online ahead of print.PMID: 39097095

The association of COVID-19 vaccination and menstrual health: A period-tracking app-based cohort study.

Ramaiyer M, El Sabeh M, Zhu J, Shea A, Segev D, Yenokyan G, Borahay MA.Vaccine X. 2024 May 18;19:100501. doi: 10.1016/j.jvacx.2024.100501. eCollection 2024 Aug.PMID: 38832342

Immune protection of grass carp by oral vaccination with recombinant Bacillus methylotrophicus expressing the heterologous tolC gene.

Mei J, Yang Q, Jiang L, Wang T, Li Y, Yu X, Wu Z.Fish Shellfish Immunol. 2024 Aug;151:109701. doi: 10.1016/j.fsi.2024.109701. Epub 2024 Jun 13.PMID: 38878911

Construction and immune effect evaluation of the S protein heptad repeat-based nanoparticle vaccine against porcine epidemic diarrhea virus.

Yang D, Wang X, Yang X, Qi S, Zhao F, Guo D, Li C, Zhu Q, Xing X, Cao Y, Sun D.Virology. 2024 Aug;596:110113. doi: 10.1016/j.virol.2024.110113. Epub 2024 May 20.PMID: 38801794

Time to optimize vaccination strategies in blood cancer patients.

Muhsen IN, Heslop HE.Br J Haematol. 2024 Aug;205(2):406-408. doi: 10.1111/bjh.19598. Epub 2024 Jun 19.PMID: 38895787

Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.

Bajpai D, Bose S, Saxena N, Kulkarni B, Kumar K, Rao N, Thakare S, Torane V, Nataraj G, Jamale T.Vaccine. 2024 Aug 8:126206. doi: 10.1016/j.vaccine.2024.126206. Online ahead of print.PMID: 39122634

Enterovirus A71 2A-S125A acts as an attenuated vaccine candidate, indicating a universal approach in developing enterovirus vaccines.

Zhang P, Zou W, Xiong R, Wu Y, Fan C, Peng Y.J Med Virol. 2024 Aug;96(8):e29838. doi: 10.1002/jmv.29838.PMID: 39081166

Motivators and Barriers to COVID-19 Vaccination Intentions Across U.S. County-Level Barriers in the COVID-19 Vaccine Coverage Index.

Fernandez JR, Richmond J, Strassle PD, Cunningham-Erves J, Forde AT.J Racial Ethn Health Disparities. 2024 Aug 2. doi: 10.1007/s40615-024-02096-9. Online ahead of print.PMID: 39093376

Attitudes and beliefs of nurses who choose to not vaccinate for COVID 19 in West Virginia: A qualitative study.

Carpenter R, Carter-Templeton H, Phillips B, Vance B, Charnik A.Appl Nurs Res. 2024 Aug;78:151825. doi: 10.1016/j.apnr.2024.151825. Epub 2024 Jul 14.PMID: 39053994

Comirnaty-induced cardiopulmonary distress and other symptoms of complement-mediated pseudo-anaphylaxis in a hyperimmune pig model: Causal role of anti-PEG antibodies.

Barta BA, Radovits T, Dobos AB, Tibor Kozma G, Mészáros T, Berényi P, Facskó R, Fülöp T, Merkely B, Szebeni J.Vaccine X. 2024 May 23;19:100497. doi: 10.1016/j.jvacx.2024.100497. eCollection 2024 Aug.PMID: 38933697

The recombinant vaccine of Lactobacillus plantarum elicits immune protection against H1N1 and H9N2 influenza virus infection.

Zhou Y, Lin Z, Fang J, Wang Z, Guo J, Li G, Xu Q, Jin M, Chen H, Zou J, Zhou H.Int J Biol Macromol. 2024 Aug;275(Pt 1):133453. doi: 10.1016/j.ijbiomac.2024.133453. Epub 2024 Jun 26.PMID: 38942402

Generalized cutaneous talaromycosis (Penicilliosis) in an immunocompetent individual.

Aryanian Z, Afshar ZM, Khasti T, Azhari V, Heidari S, Ghandi N.JAAD Case Rep. 2024 Jun 5;50:97-101. doi: 10.1016/j.jdcr.2024.05.029. eCollection 2024 Aug.PMID: 39077752

Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial.

Kurtovic L, Feng G, Hysa A, Haghiri A, O'Flaherty K, Wines BD, Santano R, D'Andrea L, Drummer HE, Hogarth PM, Sacarlal J, Fowkes FJI, Simpson JA, Dobaño C, Beeson JG.Lancet Microbe. 2024 Aug 7:100898. doi: 10.1016/S2666-5247(24)00130-7. Online ahead of print.PMID: 39127054

Acceptability of HPV vaccination for cervical cancer prevention amongst emerging adult women in rural Mysore, India: a mixed-methods study.

Coursey K, Muralidhar K, Srinivas V, Jaykrishna P, Begum F, Ningaiah N, Lee SJ, Madhivanan P.BMC Public Health. 2024 Aug 7;24(1):2139. doi: 10.1186/s12889-024-19485-8.PMID: 39112938

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial.

Pollock KM, Borges ÁH, Cheeseman HM, Rosenkrands I, Schmidt KL, Søndergaard RE, Day S, Evans A, McFarlane LR, Joypooranachandran J, Amini F, Skallerup P, Dohn RB, Jensen CG, Olsen AW, Bang P, Cole T, Schronce J, Lemm NM, Kristiansen MP, Andersen PL, Dietrich J, Shattock RJ, Follmann F.Lancet Infect Dis. 2024 Aug;24(8):829-844. doi: 10.1016/S1473-3099(24)00147-6. Epub 2024 Apr 11.PMID: 38615673 Clinical Trial.

Global antigenic landscape and vaccine recommendation strategy for low pathogenic avian influenza A (H9N2) viruses.

Zhai K, Dong J, Zeng J, Cheng P, Wu X, Han W, Chen Y, Qiu Z, Zhou Y, Pu J, Jiang T, Du X.J Infect. 2024 Aug;89(2):106199. doi: 10.1016/j.jinf.2024.106199. Epub 2024 Jun 18.PMID: 38901571

Generation of novel respiratory syncytial virus vaccine candidate antigens that can induce high levels of prefusion-specific antibodies.

Matsuyama-Ito R, Hogiri T, Kishida H, Takedomi K, Okada O, Nishizawa A, Higashi-Nakatani S, Omasa T.J Biosci Bioeng. 2024 Aug;138(2):127-136. doi: 10.1016/j.jbiosc.2024.05.008. Epub 2024 Jun 8.PMID: 38851988

A systematic review and meta-analysis of strategies to promote vaccination uptake.

Liu S, Durantini MR, Calabrese C, Sanchez F, Albarracin D.Nat Hum Behav. 2024 Aug 1. doi: 10.1038/s41562-024-01940-6. Online ahead of print.PMID: 39090405

Duck CD40L as an adjuvant enhances systemic immune responses of avian flavivirus DNA vaccine.

Huang J, Luo G, Wang W, Lu Y, Wang M, Liu M, Zhu D, Chen S, Zhao X, Yang Q, Wu Y, Zhang S, Ou X, Tian B, Sun D, He Y, Wu Z, Cheng A, Jia R.NPJ Vaccines. 2024 Aug 1;9(1):135. doi: 10.1038/s41541-024-00926-9.PMID: 39085226

Structural basis for the broad antigenicity of the computationally optimized influenza hemagglutinin X6.

Nagashima KA, Dzimianski JV, Yang M, Abendroth J, Sautto GA, Ross TM, DuBois RM, Edwards TE, Mousa JJ.Structure. 2024 Aug 8;32(8):1079-1089.e6. doi: 10.1016/j.str.2024.05.001. Epub 2024 May 28.PMID: 38810648

Follow-up of immune response in patients with common variable immunodeficiency following SARS-CoV-2 vaccination.

Gutiérrez-Bautista JF, Díaz-Alberola I, Tarriño M, Aguilera M, Cobo F, Reguera JA, Rodríguez-Granger J, Mendoza J, López-Nevot MÁ, Sampedro A.Clin Exp Immunol. 2024 Aug 9;217(3):253-262. doi: 10.1093/cei/uxae039.PMID: 38693777

Assessment of safety and adverse events following COVID-19 vaccination and their predictors in first 30 days among healthcare workers of a tertiary care teaching hospital in North India.

Bashar MA, Kamble B, Kumar S, Nandekar SV, Mathur SK.Vaccine X. 2024 Jul 5;19:100522. doi: 10.1016/j.jvacx.2024.100522. eCollection 2024 Aug.PMID: 39077369

Therapeutic Response to Treatment of a Papillomatous Ocular Surface Squamous Neoplasia With Intramuscular Human Papillomavirus Vaccine.

Zein M, De Arrigunaga S, Amer MM, Galor A, Nichols AJ, Ioannides T, Dubovy SR, Karp CL.Cornea. 2024 Aug 1;43(8):1049-1052. doi: 10.1097/ICO.0000000000003525. Epub 2024 Mar 7.PMID: 38456662

Iron regulatory protein from the hard tick Haemaphysalis longicornis: characterization, function and assessment as a protective antigen.

Wang D, Zhang X, Li H, Wang T, Ma X, Yu Z, Wang F, Zhang Y, Liu J.Pest Manag Sci. 2024 Aug;80(8):3922-3934. doi: 10.1002/ps.8095. Epub 2024 Apr 9.PMID: 38520319

Prevalence and genotype distribution of human papillomavirus infection among 66000 women from 2014 to 2023 in the plateau region of Southwest China.

Hu JP, Wang JL, Li Y, Feng Y, Tian CQ, Zhang GH, Chen XQ, Liu HX, Yang JS, Fang ZW, Li YX, Wu ZS, Zhu R, Li XP, Xiong Q, Gao LH, Ji T, Zhang JD, Song JM, Chen Q, Li SM, He F, Yang CJ, Li HW.Virol J. 2024 Aug 6;21(1):176. doi: 10.1186/s12985-024-02447-2.PMID: 39107796

Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins.

Aregay A, Slunečko J, Korva M, Bogovic P, Resman Rus K, Knap N, Beicht J, Kubinski M, Saletti G, Avšič-Županc T, Steffen I, Strle F, Osterhaus ADME, Rimmelzwaan GF.NPJ Vaccines. 2024 Aug 7;9(1):141. doi: 10.1038/s41541-024-00936-7.PMID: 39112523

Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenza.

Cui X, Vervaeke P, Gao Y, Opsomer L, Sun Q, Snoeck J, Devriendt B, Zhong Z, Sanders NN.NPJ Vaccines. 2024 Aug 3;9(1):138. doi: 10.1038/s41541-024-00932-x.PMID: 39097672

Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice.

Huang L, Tang W, He L, Li M, Lin X, Hu A, Huang X, Wu Z, Wu Z, Chen S, Hu Y.Nat Commun. 2024 Aug 9;15(1):6802. doi: 10.1038/s41467-024-51182-3.PMID: 39122688

Nonantibiotic prophylaxis for urinary tract infections: a network meta-analysis of randomized controlled trials.

Han Z, Yi X, Li J, Liao D, Ai J.Infection. 2024 Aug 2. doi: 10.1007/s15010-024-02357-z. Online ahead of print.PMID: 39095666

Impact of COVID-19 vaccination on seminal and systemic inflammation in men.

Schaler L, Ghanim M, Guardiola J, Kaulsay J, Ibrahim A, Brady G, McCormack W, Conlon N, Kelly VP, Wingfield M, Glover L.J Reprod Immunol. 2024 Aug;164:104287. doi: 10.1016/j.jri.2024.104287. Epub 2024 Jun 25.PMID: 38964132

#VacinaMare campaign: addressing vaccine inequity in socially vulnerabilised communities.

Batista-da-Silva AA, Bastos LSL, Arouca LE, Gonzaga-da-Silva TW, Hamacher S, Bozza FA, Ranzani OT.Lancet Reg Health Am. 2024 Jun 24;36:100827. doi: 10.1016/j.lana.2024.100827. eCollection 2024 Aug.PMID: 39015817

Coupling enterotoxigenic Escherichia coli heat-stable peptide toxin with 8-arm PEG enhances immunogenicity.

Zegeye ED, Chaukimath P, Diaz Y, Visweswariah SS, Puntervoll P.J Pept Sci. 2024 Aug 1:e3647. doi: 10.1002/psc.3647. Online ahead of print.PMID: 39091086

Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.

Xin Q, Wang K, Toh TH, Yuan Y, Meng X, Jiang Z, Zhang H, Yang J, Yang H, Zeng G.Nat Commun. 2024 Aug 6;15(1):6660. doi: 10.1038/s41467-024-50802-2.PMID: 39107270

A New Validated Approach for Identifying Childhood Immunizations in Electronic Health Records in the United Kingdom.

Suffel AM, Walker JL, Campbell C, Carreira H, Warren-Gash C, McDonald HI.Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5848. doi: 10.1002/pds.5848.PMID: 39092455

Disulfide-stabilized Trimeric Hemagglutinin Ectodomains Provide Enhanced Heterologous Influenza Protection.

Liu DJ, Zhong XQ, Ru YX, Zhao SL, Liu CC, Tang YB, Wu X, Zhang YS, Zhang HH, She JY, Wan MY, Li YW, Zheng HP, Deng L.Emerg Microbes Infect. 2024 Aug 5:2389095. doi: 10.1080/22221751.2024.2389095. Online ahead of print.PMID: 39101691

The influence of circadian rhythms on $CD8^+$ T cell activation upon vaccination: A mathematical modeling perspective.

Balit N, Cermakian N, Khadra A.J Theor Biol. 2024 Aug 7;590:111852. doi: 10.1016/j.jtbi.2024.111852. Epub 2024 May 23.PMID: 38796098

Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar.

Chemaitelly H, Akhtar N, Jerdi SA, Kamran S, Joseph S, Morgan D, Uy R, Abid FB, Al-Khal A, Bertollini R, Abou-Samra AB, Butt AA, Abu-Raddad LJ.Int J Infect Dis. 2024 Aug;145:107095. doi: 10.1016/j.ijid.2024.107095. Epub 2024 May 20.PMID: 38777080

Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease.

Paulet E, Contreras V, Galhaut M, Rosenkrands I, Holland M, Burton M, Dietrich J, Gallouet AS, Bosquet N, Relouzat F, Langlois S, Follmann F, Le Grand R, Labetoulle M, Rousseau A.PLoS Negl Trop Dis. 2024 Aug 2;18(8):e0012388. doi: 10.1371/journal.pntd.0012388. Online ahead of print.PMID: 39093884

Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.

Nkinda L, Barabona G, Ngare I, Nkuwi E, Kamori D, Msafiri F, Kunambi PP, Osati E, Kidenya BR, Chuwa H, Kinasa G, Hassan FE, Judicate GP, Gasper J, Kisuse J, Mfinanga S, Senkoro M, Ueno T, Lyamuya E, Balandya E.J Med Virol. 2024 Aug;96(8):e29822. doi: 10.1002/jmv.29822.PMID: 39056238

Engineered ClearColi-derived outer membrane vesicles as functional carriers for development of HIV-1 therapeutic vaccine candidate.

Sadeghi L, Bolhassani A, Mohit E, Baesi K, Aghasadeghi MR, Milani A, Agi E.Microb Pathog. 2024 Aug;193:106749. doi: 10.1016/j.micpath.2024.106749. Epub 2024 Jun 13.PMID: 38879140

HPV specificity and multiple infections and association with cervical cytology in Chongqing, China: a cross-sectional study.

Luo Q, Zhang H, Zeng X, Han N, Ma Z, Luo H.BMC Infect Dis. 2024 Aug 9;24(1):804. doi: 10.1186/s12879-024-09693-3.PMID: 39123121

Models for predicting the risk of illness in leprosy contacts in Brazil: Leprosy prediction models in Brazilian contacts.

de Alecrin ES, Martins MAP, de Oliveira ALG, Lyon S, Lages ATC, Reis IA, Pereira FH, Oliveira D, Goulart IMB, da Costa Rocha MO.Trop Med Int Health. 2024 Aug;29(8):680-696. doi: 10.1111/tmi.14020. Epub 2024 Jul 4.PMID: 38961761

The full genome characterization of avian encephalomyelitis virus, Iran: a vertical transmission case.

Ghalyanchilangeroudi A, Madani SA, Najafi H, Ziafati Kafi Z, Sadri N, Sarmadi S, Eghbali O, Jamiri F, Bakhshi A, Hosseini H.Virus Genes. 2024 Aug;60(4):393-401. doi: 10.1007/s11262-024-02076-5. Epub 2024 May 29.PMID: 38811493

Influence of adjuvant type and route of administration on the immunogenicity of Leishmania-derived tick-borne encephalitis virus-like particles - A recombinant vaccine candidate.

Zimna M, Brzuska G, Salát J, Růžek D, Krol E.Antiviral Res. 2024 Aug;228:105941. doi: 10.1016/j.antiviral.2024.105941. Epub 2024 Jun 19.PMID: 38901737

Vaccine manufacturers should produce a pertussis only vaccine for use in pregnancy.

Selley P.BMJ. 2024 Aug 7;386:q1669. doi: 10.1136/bmj.q1669.PMID: 39111817

2024 Public Health Actions to Reduce the Burden of Asthma: Influenza and COVID-19 Vaccination Uptake Among People with Asthma.

Jaffee H, Eftekhari S, Carver M.Prev Chronic Dis. 2024 Aug 8;21:E59. doi: 10.5888/pcd21.240058.PMID: 39117351

A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany).

Kowalzik F, Teschner D, Mesquita M, Jensen C, Schreiner D, Kronfeld K, Tubic-Grozdanis M, Cheatham-Seitz D, Hettich F, Quintini G, Schoenborn-Kellenberger O, Codó P, von Eisenhart-Rothe P, Mann P, Oostvogels L, Gehring S.Vaccine X. 2024 Jun 20;19:100512. doi: 10.1016/j.jvacx.2024.100512. eCollection 2024 Aug.PMID: 39040887

Cationic pH-sensitive liposome-based subunit tuberculosis vaccine induces protection in mice challenged with Mycobacterium tuberculosis.

Szachniewicz MM, van den Eeden SJF, van Meijgaarden KE, Franken KLMC, van Veen S, Geluk A, Bouwstra JA, Ottenhoff THM.Eur J Pharm Biopharm. 2024 Aug 7:114437. doi: 10.1016/j.ejpb.2024.114437. Online ahead of print.PMID: 39122053

Reprint of: A retrospective review of the impact of immunization eCare plans in community-based pharmacy setting.

Snapp A, Gatewood SS, Kaefer TN, Nadpara P, Goode JR.J Am Pharm Assoc (2003). 2024 Aug 10:102178. doi: 10.1016/j.japh.2024.102178. Online ahead of print.PMID: 39127945

Informing an investment case for Japanese encephalitis vaccine introduction in Bangladesh.

Duque MP, Naser AM, Dos Santos GR, O'Driscoll M, Paul KK, Rahman M, Alam MS, Al-Amin HM, Rahman MZ, Hossain ME, Paul RC, Luby SP, Cauchemez S, Vanhomwegen J, Gurley ES, Salje H.Sci Adv. 2024 Aug 9;10(32):eadp1657. doi: 10.1126/sciadv.adp1657. Epub 2024 Aug 9.PMID: 39121225

Evaluating patient immunocompetence through antibody response to pneumococcal polysaccharide vaccine using a newly developed 23 serotype multiplexed assay.

Martins TB, Hill HR, Peterson LK.Clin Immunol. 2024 Aug;265:110295. doi: 10.1016/j.clim.2024.110295. Epub 2024 Jun 22.PMID: 38914359

Total synthesis of the hexasaccharide arabinan domain of mycobacterial arabinogalactan.

Fang S, Huang C, Ao J, Xiao Q, Zhou S, Deng W, Cai H, Ding F.Carbohydr Res. 2024 Aug;542:109204. doi: 10.1016/j.carres.2024.109204. Epub 2024 Jul 4.PMID: 38981322

Feasibility of an innovative medical dental integration program to provide overdue adolescent vaccinations in a federally qualified health center.

Jack JL, Buban A, Krentz C, Durniak M, Hamilton S, Williams JTB.J Public Health Dent. 2024 Aug 4. doi: 10.1111/jphd.12638. Online ahead of print.PMID: 39099159

Exploring Health Information Seeking Among Participants from a Black Ethnic Group in the UK: a Qualitative Study.

Ndungu A, Nellums L, Bramley L.J Racial Ethn Health Disparities. 2024 Aug;11(4):2475-2487. doi: 10.1007/s40615-023-01713-3. Epub 2023 Jul 14.PMID: 37450252

Personalized cancer T-cell therapy takes the stage, mirroring vaccine success.

Chiffelle J, Harari A.J Exp Med. 2024 Aug 5;221(8):e20240854. doi: 10.1084/jem.20240854. Epub 2024 Jun 11.PMID: 38861029

Application of nervous necrosis virus capsid protein-based antigen-presenting particles for vaccine development.

Wayha S, Koiwai K, Sano M, Hirono I, Kondo H.Fish Shellfish Immunol. 2024 Sep;152:109803. doi: 10.1016/j.fsi.2024.109803. Epub 2024 Aug 2.PMID: 39096980

Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk.

Roels S, Bruckner M, Sadoff J, Cárdenas V, Tang C, Hagedoorn S, Heerwegh D, Stieh DJ, Le Gars M.Vaccine. 2024 Aug 8;42(22):126159. doi: 10.1016/j.vaccine.2024.126159. Online ahead of print.PMID: 39121698

Lessons for Future Vaccination Policies: COVID-19 Vaccination Intention in People with and without Chronic Diseases.

Ju J, Han K, Kim J, Kwon Y.Asian Nurs Res (Korean Soc Nurs Sci). 2024 Aug 2:S1976-1317(24)00075-6. doi: 10.1016/j.anr.2024.07.008. Online ahead of print.PMID: 39098485

From Hesitancy to Acceptance: An Interpretative Approach to Unravel the Vaccination Motivation Among the Rural Population.

Krithika V, Sunder MV.Health Commun. 2024 Aug 5:1-13. doi: 10.1080/10410236.2024.2384811. Online ahead of print.PMID: 39101223

Evaluation of the immune responses in buffaloes vaccinated with a live-attenuated lumpy skin disease vaccine (Lumpi-ProVac(Ind)).

Dhanda S, Sharma DK, Kamboj H, Kumar G, Mittal P, Kumar R, Verma A, Rathore K, Gaur M, Barua S, Tripathi BN, Sharma S, Kumar N.Trop Anim Health Prod. 2024 Aug 2;56(7):226. doi: 10.1007/s11250-024-04089-6.PMID: 39093442

How stressful was the COVID-19 vaccination procedure? Comparison between mass vaccination centers and general practices.

Schrimpf A, Jentzsch A, Bleckwenn M, Geier AK.Vaccine X. 2024 Jul 9;19:100524. doi: 10.1016/j.jvacx.2024.100524. eCollection 2024 Aug.PMID: 39105134

Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries.

Prem K, Cernuschi T, Malvolti S, Brisson M, Jit M.EClinicalMedicine. 2024 Jul 18;74:102735. doi: 10.1016/j.eclinm.2024.102735. eCollection 2024 Aug.PMID: 39091671

Absenteeism and Health Behavior Trends Associated With Acute Respiratory Illness Before and During the COVID-19 Pandemic in a Community Household Cohort, King County, Washington.

Chung E, Wang Y, Chow EJ, Emanuels A, Heimonen J, Ogokeh CE, Rolfes MA, Hughes JP, Uyeki TM, Starita LM, Hoag S, Boeckh M, Englund JA, Chu HY; Seattle Flu Study Investigators.AJPM Focus. 2024 Jun 6;3(4):100248. doi: 10.1016/j.focus.2024.100248. eCollection 2024 Aug.PMID: 39045125

The battle between host antiviral innate immunity and immune evasion by cytomegalovirus.

Li S, Xie Y, Yu C, Zheng C, Xu Z.Cell Mol Life Sci. 2024 Aug 9;81(1):341. doi: 10.1007/s00018-024-05369-y.PMID: 39120730

Trust in health workers and patient-centeredness of care were strongest factors associated with vaccination for Kenyan children born between 2017-2022.

Moucheraud C, Ochieng E, Ogutu V, Sudhinaraset M, Szilagyi PG, Hoffman RM, Glenn B, Golub G, Njomo D.Vaccine X. 2024 Jul 4;19:100523. doi: 10.1016/j.jvacx.2024.100523. eCollection 2024 Aug.PMID: 39070930

Using the Health Belief Model to understand intention to vaccinate for Lyme disease in the United States.

Gould LH, Stark JH, McFadden B, Patel N, Kelly PH, Riis J.Zoonoses Public Health. 2024 Aug;71(5):526-537. doi: 10.1111/zph.13142. Epub 2024 May 10.PMID: 38730082

A Mycobacterium ulcerans vaccine pilot trial using an accurate low-dose challenge.

Muhi S, Porter JL, Stinear TP.Microbiol Spectr. 2024 Aug 6;12(8):e0055524. doi: 10.1128/spectrum.00555-24. Epub 2024 Jun 25.PMID: 38916323

COVID-19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy.

du Preez HN, Lin J, Maguire GEM, Aldous C, Kruger HG.Eur J Clin Invest. 2024 Aug 8:e14296. doi: 10.1111/eci.14296. Online ahead of print.PMID: 39118373

Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a cellular receptor for delta inulin adjuvant.

Stewart EL, Counoupas C, Steain M, Ashley C, Alca S, Hartley-Tassell L, von Itzstein M, Britton WJ, Petrovsky N, Triccas JA.Immunol Cell Biol. 2024 Aug;102(7):593-604. doi: 10.1111/imcb.12774. Epub 2024 May 17.PMID: 38757764

Induced Pluripotent Stem Cells Facilitate the Development and Evaluation of Cancer Vaccines.

Zhai Y, Xu X, Fang J, He F, Li S.Cancer Res. 2024 Aug 6. doi: 10.1158/0008-5472.CAN-24-0642. Online ahead of print.PMID: 39106469

Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model.

Kempster S, Hassall M, Graham V, Kennedy E, Findlay-Wilson S, Salguero FJ, Bagci B, Elaldi N, Oz M, Tasseten T, Charlton FW, Barr JN, Fontana J, Duru C, Ezeajughi E, Matejtschuk P, Arnold U, Adedeji Y, Mirazimi A, Hewson R, Dowall S, Almond N.Virus Res. 2024 Aug;346:199409. doi: 10.1016/j.virusres.2024.199409. Epub 2024 Jun 1.PMID: 38815869

Examining the Effects of Social Media Warning Labels on Perceived Credibility and Intent to Engage with Health Misinformation: The Moderating Role of Vaccine Hesitancy.

Zhang B, Chen L, Moe A.J Health Commun. 2024 Aug 7:1-10. doi: 10.1080/10810730.2024.2385638. Online ahead of print.PMID: 39110871

Identifying Rab2 Protein as a Key Interactor of Centrin1 Essential for *Leishmania donovani* Growth.

Roshanara, Tandon R, Baig MS, Das S, Srivastava R, Puri N, Nakhasi HL, Selvapandiyan A.ACS Infect Dis. 2024 Aug 7. doi: 10.1021/acsinfecdis.4c00351. Online ahead of print.PMID: 39110117

Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study.

López-Lacort M, Corberán-Vallet A, Santonja FJ, Muñoz-Quiles C, Díez-Domingo J, Orrico-Sánchez A.J Infect Public Health. 2024 Aug;17(8):102492. doi: 10.1016/j.jiph.2024.102492. Epub 2024 Jul 8.PMID: 39002465

Impact of vaccination with the Anaplasma phagocytophilum MSP4 chimeric antigen on gene expression in the rabbit host.

Moraga-Fernández A, de Sousa-Blanco M, Marques JP, Queirós J, Fernández-Melgar R, García-Álvarez O, Alves PC, Contreras M.Res Vet Sci. 2024 Aug 5;178:105370. doi: 10.1016/j.rvsc.2024.105370. Online ahead of print.PMID: 39116823

COVID-19 vaccination uptake in remote areas-Evidence from a panel survey in Bangladesh.

Rudolph L, Koubi V, Freihardt J.PLoS One. 2024 Aug 9;19(8):e0305659. doi: 10.1371/journal.pone.0305659. eCollection 2024.PMID: 39121025

Development of a multi-epitope vaccine candidate against Pseudomonas aeruginosa causing urinary tract infection and evaluation of its immunoreactivity in a rabbit model.

Kalantari H, Habibi M, Ferdousi A, Asadi Karam MR, Mohammadian T.J Biomol Struct Dyn. 2024 Aug;42(12):6212-6227. doi: 10.1080/07391102.2023.2239915. Epub 2023 Jul 24.PMID: 37489041

The Effectiveness and Impact of the Enterovirus 71 Vaccine on the Onset of Hand, Foot, and Mouth Disease in Children Aged 5 Years: A 7-Year Study.

Fan C, Yang Y, Zhan S, Sun X, Fu C.J Infect. 2024 Aug 7:106244. doi: 10.1016/j.jinf.2024.106244. Online ahead of print.PMID: 39121970

APEX-pHLA: A novel method for accurate prediction of the binding between exogenous short peptides and HLA class I molecules.

Su Z, Wu Y, Cao K, Du J, Cao L, Wu Z, Wu X, Wang X, Song Y, Wang X, Duan H.Methods. 2024 Aug;228:38-47. doi: 10.1016/j.ymeth.2024.05.013. Epub 2024 May 19.PMID: 38772499

Prenatal RSV Vaccine Not Tied to Higher Risk of Preterm Births.

Harris E.JAMA. 2024 Aug 2. doi: 10.1001/jama.2024.13773. Online ahead of print.PMID: 39093559

Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.

Gong X, Peng L, Wang F, Liu J, Tang Y, Peng Y, Niu S, Yin J, Guo L, Lu H, Liu Y, Yang Y.J Infect. 2024 Aug;89(2):106208. doi: 10.1016/j.jinf.2024.106208. Epub 2024 Jun 20.PMID: 38908522

Genetic Diversity and Natural Selection of Plasmodium vivax Merozoite Surface Protein 8 in Global Populations.

Zhang M, Wang Y, Shen HM, Chen SB, Wang TY, Kassegne K, Chen JH.Infect Genet Evol. 2024 Aug;122:105605. doi: 10.1016/j.meegid.2024.105605. Epub 2024 May 15.PMID: 38759940

Letter to the editor regarding 'Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis'.

Van Wyk H, Zhu MQ, Stone DR, Singh AK, Bassiouni S.ESC Heart Fail. 2024 Aug;11(4):2467-2468. doi: 10.1002/ehf2.14819. Epub 2024 Apr 25.PMID: 38661239

Evaluating the dynamics and efficacy of a live, attenuated Mycoplasma anserisalpingitidis vaccine candidate under farm conditions.

Grózner D, Kreizinger Z, Mitter A, Bekő K, Buni D, Kovács ÁB, Wehmann E, Nagy EZ, Dobos Á, Dán Á, Belecz N, Költő K, Hrivnák V, Udvari L, Földi D, Czifra G, Kiss M, Spitzmüller L, Molnár B, Gyuranecz M.Avian Pathol. 2024 Aug;53(4):257-263. doi: 10.1080/03079457.2024.2318006. Epub 2024 Feb 26.PMID: 38353105

Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model.

Avanthay R, Garcia-Nicolas O, Ruggli N, Grau-Roma L, Párraga-Ros E, Summerfield A, Zimmer G.PLoS Pathog. 2024 Aug 8;20(8):e1012393. doi: 10.1371/journal.ppat.1012393. eCollection 2024 Aug.PMID: 39116029

Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.

Weaver AN, Iams WT, Park JC, Mita M, Holtick U, Gordon MS, Rodabaugh KJ, Dhani N, Neupane P, Taylor M, Amanda Duvall E, Jennings J, Miselis NR, Loughhead S, Warren MS, Bernstein H, Klussmann JP,

Baranda J, Jimeno A.Mol Carcinog. 2024 Aug;63(8):1421-1428. doi: 10.1002/mc.23738. Epub 2024 May 2.PMID: 38695604 Clinical Trial.

Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.

Sieghart D, Hana CA, Dürrschmid C, Heinz LX, Haslacher H, Zlesak M, Piccini G, Manenti A, Montomoli E, Jorda A, Fedrizzi C, Hasenoehrl T, Zdravkovic A, Anderle K, Wiedermann U, Drapalik S, Steinbrecher H, Bergmann F, Firbas C, Jordakieva G, Wagner B, Leonardi M, Pierleoni G, Ballini M, Benincasa L, Marchi S, Trombetta C, Perkmann T, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H.J Clin Virol. 2024 Aug;173:105661. doi: 10.1016/j.jcv.2024.105661. Epub 2024 Feb 28.PMID: 38503118 Clinical Trial.

Development of highly adaptable RT-PCR methods for identifying Delta and BA.1 variants in inactivated COVID-19 vaccines.

Wang Z, He Y, He Z, Guo Y, Zhao Y, Zhang Y.Mol Biol Rep. 2024 Aug 7;51(1):892. doi: 10.1007/s11033-024-09799-6.PMID: 39110319

Knock down of transforming growth factor beta improves expressions of co-stimulatory molecules, type I interferon-regulated genes, and pro-inflammatory cytokine in PRRSV-inoculated monocyte-derived macrophages.

Fabros D, Charerntantanakul W.BMC Vet Res. 2024 Aug 3;20(1):344. doi: 10.1186/s12917-023-03760-8.PMID: 39097704

A study of antigen selection by extracellular vesicles as vaccine candidates against Mycobacterium tuberculosis infection.

Ji L, Ruan H, Fu Y, Xiong S.J Med Microbiol. 2024 Aug;73(8). doi: 10.1099/jmm.0.001865.PMID: 39133547

Advocating for inclusive respiratory syncytial virus vaccine trials to address health disparities.

Harboe ZB, Rezahosseini O, Fischer TK.Lancet Infect Dis. 2024 Aug;24(8):e479. doi: 10.1016/S1473-3099(24)00401-8. Epub 2024 Jun 20.PMID: 38909616

Assessing vaccine efficacy for infectious diseases with variable immunity using a mathematical model.

Al-Arydah M.Sci Rep. 2024 Aug 10;14(1):18572. doi: 10.1038/s41598-024-69651-6.PMID: 39127773

The World Needs a Staph Vaccine-New Research Could Bring It a Step Closer.

Coffey D.JAMA. 2024 Aug 2. doi: 10.1001/jama.2024.1015. Online ahead of print.PMID: 39093572

"There's a little bit of mistrust": Red River Métis experiences of the H1N1 and COVID-19 pandemics.

Driedger SM, Maier R, Capurro G, Jardine C, Tustin J, Chartrand F, Sanguins J, Kloss O.Risk Anal. 2024 Aug;44(8):1770-1787. doi: 10.1111/risa.14274. Epub 2024 Jan 29.PMID: 38286593

Tailoring biomaterials for vaccine delivery.

Zhuo Y, Zeng H, Su C, Lv Q, Cheng T, Lei L.J Nanobiotechnology. 2024 Aug 12;22(1):480. doi: 10.1186/s12951-024-02758-0.PMID: 39135073

R21/Matrix-M malaria vaccine: A realm of hope for combating malaria in developing countries?

Farhan K, Tariq B, Sohail F, Saeed N, Akilimali A.New Microbes New Infect. 2024 Jun 11;60-61:101443. doi: 10.1016/j.nmni.2024.101443. eCollection 2024 Aug-Oct.PMID: 39040126

Public health audit of vaccine cold chain management in general practice and community pharmacy in Western Australia.

Hillan A, Pung L, Ridderhof S, Ramsay J, Vinogradov R, Westphal D, Foong M, Leeb A, Scalley B, Phillips A.Aust N Z J Public Health. 2024 Aug;48(4):100168. doi: 10.1016/j.anzjph.2024.100168. Epub 2024 Jul 13.PMID: 39003884

Differential polyvalent passive immune protection of egg yolk antibodies (IgY) against live and inactivated Vibrio fluvialis in fish.

Liu X, Xiao H, Cui P, Chen J, Chao J, Wu X, Lu J, Zhang X, Xu G, Liu Y.Fish Shellfish Immunol. 2024 Aug;151:109751. doi: 10.1016/j.fsi.2024.109751. Epub 2024 Jul 4.PMID: 38971349

Vision Crisis-Bilateral Outer Retinitis Due to Mumps Virus.

Sriram R, Sethu S, Ghosh A, Shetty R, Rizvi S, Dave N, Fernandes RS, Bagchi A, Kawali A, Mishra SB, Mahendradas P.Ocul Immunol Inflamm. 2024 Aug 8:1-8. doi: 10.1080/09273948.2024.2382925. Online ahead of print.PMID: 39116409

Adverse events of COVID-19 vaccination during 2021-2022 suppressed by breakfast consumption and favorable sleeping habit among Japanese university students.

Tetsuka N, Suzuki K, Suzuki K, Ishihara T, Miwa T, Tajirika S, Adachi M, Horita R, Fukao T, Yamamoto M.Vaccine X. 2024 Jun 22;19:100516. doi: 10.1016/j.jvacx.2024.100516. eCollection 2024 Aug.PMID: 39040886

Antigenic epitope analysis of Pakistani G3 and G9 rotavirus strains compared to vaccine strains revealed multiple amino acid differences.

Sadiq A, Khan T, Bostan N, Yinda CK, Matthijnssens J.Diagn Microbiol Infect Dis. 2024 Aug;109(4):116346. doi: 10.1016/j.diagmicrobio.2024.116346. Epub 2024 May 9.PMID: 38759540

The effect of education based on planned behavior theory on women's knowledge and attitudes about human papillomavirus.

Rafeie L, Vizeshfar F, Nick N.Sci Rep. 2024 Aug 10;14(1):18581. doi: 10.1038/s41598-024-69340-4.PMID: 39127722

Investigating the Immune-Stimulating Potential of β-Glucan from *Aureobasidium pullulans* in Cancer Immunotherapy.

Jeong JH, Kim DJ, Hong SJ, Ahn JH, Lee DJ, Jang AR, Kim S, Cho HJ, Lee JY, Park JH, Kim YM, Ko HJ.Biomol Ther (Seoul). 2024 Aug 2. doi: 10.4062/biomolther.2024.047. Online ahead of print.PMID: 39091181

Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS-CoV-2 Through Mutant Bacteriophage Qβ-Receptor Binding Domain Conjugate.

Tan Z, Yang C, Lin PH, Ramadan S, Yang W, Rashidi Z, Lang S, Shafieichaharberoud F, Gao J, Pan X, Soloff N, Wu X, Bolin S, Pyeon D, Huang X.Adv Healthc Mater. 2024 Aug;13(20):e2302755. doi: 10.1002/adhm.202302755. Epub 2024 May 17.PMID: 38733291

Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.

O'Donnell KL, Henderson CW, Anhalt H, Fusco J, Erasmus JH, Lambe T, Marzi A.Int J Mol Sci. 2024 Aug 5;25(15):8516. doi: 10.3390/ijms25158516.PMID: 39126087

Assessment of Knowledge, Attitudes, and Vaccination Practices Regarding the New RSV Vaccine among Health Professionals in Greece.

Papagiannis D, Tiganis N, Kotsiou OS, Lampropoulos IC, Fradelos EC, Malli F, Gourgoulianis KI.Healthcare (Basel). 2024 Aug 2;12(15):1536. doi: 10.3390/healthcare12151536.PMID: 39120239

Impacts of COVID-19 vaccine boosters on clinical outcomes associated with the Omicron variant in China: A cross-sectional survey.

Feng H, Chen J, Sun J, Jiang Y.Vaccine X. 2024 Jun 6;19:100508. doi: 10.1016/j.jvacx.2024.100508. eCollection 2024 Aug.PMID: 38903607

Spillover of Newcastle disease virus to Himalayan Griffon vulture: a possible food-based transmission.

Bhattacharya S, Deka P, Das S, Ali S, Choudhury B, Kakati P, Kumar S.Virus Genes. 2024 Aug;60(4):385-392. doi: 10.1007/s11262-024-02072-9. Epub 2024 May 13.PMID: 38739246

Challenges in assessing the immunization status of adults in Germany-lessons from a population-based VACCELERATE survey on polio vaccination.

Nacov JA, Stemler J, Salmanton-García J, Cremer LM, Zeitlinger M, Mallon PWG, Pana ZD, Schmitt HJ, Cornely OA; VACCELERATE Consortium.Infection. 2024 Aug;52(4):1563-1574. doi: 10.1007/s15010-024-02296-9. Epub 2024 May 28.PMID: 38806974

Association of pneumococcal conjugate vaccination with SARS-CoV-2 infection among older adult recipients of COVID-19 vaccines: a longitudinal cohort study.

Lewnard JA, Hong V, Grant LR, Ackerson BK, Bruxvoort KJ, Pomichowski M, Arguedas A, Cané A, Jodar L, Gessner BD, Tartof SY.J Infect Dis. 2024 Aug 5:jiae387. doi: 10.1093/infdis/jiae387. Online ahead of print.PMID: 39101606

RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.

Dickey TH, Salinas ND, Patel P, Orr-Gonzalez S, Ouahes T, McAleese H, Richardson BL, Singleton M, Murphy M, Eaton B, Kwan JL, Holbrook MR, Lambert LE, Tolia NH.Antiviral Res. 2024 Aug;228:105937. doi: 10.1016/j.antiviral.2024.105937. Epub 2024 Jun 18.PMID: 38901738

Genome wide screening to discover novel toxin-antitoxin modules in Mycobacterium indicus pranii; perspective on gene acquisition during mycobacterial evolution.

Bahl A, Rakshit R, Pandey S, Tripathi D.Biotechnol Appl Biochem. 2024 Aug 7. doi: 10.1002/bab.2651. Online ahead of print.PMID: 39113212

Changes in antibody titer after four and five doses of the SARS-CoV-2 vaccine in Japanese post-kidney transplant patients.

Fujieda K, Tanaka A, Kikuchi R, Takai N, Saito S, Yasuda Y, Sano Y, Kato M, Furuhashi K, Maruyama S.Ther Apher Dial. 2024 Aug;28(4):489-498. doi: 10.1111/1744-9987.14114. Epub 2024 Feb 22.PMID: 38385762

Adapting celiac immunity for the future: Addressing the immunization gap in children with celiac disease.

Du N, Silvester JA.J Pediatr Gastroenterol Nutr. 2024 Aug;79(2):195-197. doi: 10.1002/jpn3.12237. Epub 2024 May 8.PMID: 38720560

A novel highly virulent nephropathogenic QX-like infectious bronchitis virus originating from recombination of GI-13 and GI-19 genotype strains in China.

Chen H, Shi W, Feng S, Yuan L, Jin M, Liang S, Wang X, Si H, Li G, Ou C.Poult Sci. 2024 Aug;103(8):103881. doi: 10.1016/j.psj.2024.103881. Epub 2024 May 23.PMID: 38865766

Covid-19: NHS staff will be offered vaccine this autumn, but JCVI recommends more limited rollout.

Wise J.BMJ. 2024 Aug 5;386:q1728. doi: 10.1136/bmj.q1728.PMID: 39103173

A novel multi-epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico.

Mahmoodi S, Amirzakaria JZ, Ghasemian A.Biotechnol Appl Biochem. 2024 Aug 11. doi: 10.1002/bab.2646. Online ahead of print.PMID: 39128888

Grappling Covishield fear in India: the urgent need for strong countermeasures to build vaccine confidence.

Poddar A, Rao SR.Lancet Reg Health Southeast Asia. 2024 Jul 11;27:100447. doi: 10.1016/j.lansea.2024.100447. eCollection 2024 Aug.PMID: 39071894

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to 60 Years of Age.

Ferguson M, Schwarz TF, Núñez SA, Rodríguez-García J, Mital M, Zala C, Schmitt B, Toursarkissian N, Mazarro DO, Großkopf J, Voors-Pette C, Mehta H, Hailemariam HA, de Heusch M, Salaun B, Damaso S, David MP, Descamps D, Hill J, Vandermeulen C, Hulstrøm V; RSV OA=ADJ-018 Study Group.Clin Infect Dis. 2024 Aug 5:ciae364. doi: 10.1093/cid/ciae364. Online ahead of print.PMID: 39099093

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease.

Scher G, Yankowski C, Kurup D, Josleyn NM, Wilkinson ER, Wells J, Steffens J, Lynn G, Vantongeren S, Zeng X, Twenhafel N, Cashman KA, Schnell MJ.NPJ Vaccines. 2024 Aug 9;9(1):143. doi: 10.1038/s41541-024-00930-z.PMID: 39122759

PruΔcdpk2 Protects Pigs against Acute Toxoplasmosis Depending on T-Lymphocyte Subsets and Natural Killer Cell Responses.

Fan YM, Shi WQ, Jin QW, Pan M, Hou ZF, Fu L, Tao JP, Huang SY.Foodborne Pathog Dis. 2024 Aug 12. doi: 10.1089/fpd.2024.0060. Online ahead of print.PMID: 39133119

Chitosan-alginate/R8 ternary polyelectrolyte complex as an oral protein-based vaccine candidate induce effective mucosal immune responses.

Liu Y, Long M, Wang Y, Liang Z, Dong Y, Qu M, Ge X, Nan Y, Chen Y, Zhou X.Int J Biol Macromol. 2024 Aug;275(Pt 2):133671. doi: 10.1016/j.ijbiomac.2024.133671. Epub 2024 Jul 5.PMID: 38971274

Wastewater Surveillance to Confirm Differences in Influenza A Infection between Michigan, USA, and Ontario, Canada, September 2022-March 2023.

Corchis-Scott R, Beach M, Geng Q, Podadera A, Corchis-Scott O, Norton J, Busch A, Faust RA, McFarlane S, Withington S, Irwin B, Aloosh M, Ng KKS, McKay RM.Emerg Infect Dis. 2024 Aug;30(8):1580-1588. doi: 10.3201/eid3008.240225.PMID: 39043398

Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database.

Wang B, Bao EH, Jiang BL, Yang L, Liu Y, Xia L, Wang JH, Wang L, Zhu PY.Expert Opin Drug Saf. 2024 Aug 8:1-8. doi: 10.1080/14740338.2024.2388212. Online ahead of print.PMID: 39096111

Political Partisanship, Confucian Collectivism, and Public Attitudes toward the Vaccination Policy in Taiwan.

Yeh MJ, Hsieh YC.J Health Polit Policy Law. 2024 Aug 9:11513094. doi: 10.1215/03616878-11513094. Online ahead of print.PMID: 39118278

Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.

Audran R, Karoui O, Donnet L, Soumas V, Fares F, Lovis A, Noirez L, Cavassini M, Fayet-Mello A, Satti I, McShane H, Spertini F.J Infect. 2024 Aug;89(2):106205. doi: 10.1016/j.jinf.2024.106205. Epub 2024 Jun 17.PMID: 38897242

Structure-based design of a Plasmodium vivax Duffy-binding protein immunogen focuses the antibody response to functional epitopes.

Dickey TH, McAleese H, Salinas ND, Lambert LE, Tolia NH.Protein Sci. 2024 Aug;33(8):e5095. doi: 10.1002/pro.5095.PMID: 38988315

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.

Latzer P, Zelba H, Battke F, Reinhardt A, Shao B, Bartsch O, Rabsteyn A, Harter J, Schulze M, Okech T, Golf A, Kyzirakos-Feger C, Kayser S, Pieper N, Feldhahn M, Wünsche J, Seitz C, Hadaschik D, Garbe C,

Hauser TK, la Fougère C, Biskup D, Brooke D, Parker D, Martens UM, Illerhaus G, Blumenthal DT, Merrell R, Lorenzo LS, Hidvégi M, de Robles P, Kebir S, Li WW, Li VW, Williams M, Miller AM, Kesari S, Castro M, Desjardins A, Ashley DM, Friedman HS, Wen PY, Neil EC, Iwamoto FM, Sipos B, Geletneky K, Zender L, Glas M, Reardon DA, Biskup S.Nat Commun. 2024 Aug 11;15(1):6870. doi: 10.1038/s41467-024-51315-8.PMID: 39127809

Acute abducens nerve palsy following coronavirus disease 2019 vaccination: a case report.

Wang CT, Li JY.J Med Case Rep. 2024 Aug 6;18(1):364. doi: 10.1186/s13256-024-04681-2.PMID: 39103960

Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.

Durier C, Ninove L, van der Werf S, Lefebvre M, Desaint C, Bauer R, Attia M, Lecompte AS, Lachatre M, Maakaroun-Vermesse Z, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Corbin V, Ansart S, Melica G, Resch M, Netzer E, Kherabi Y, Tardieu R, Lelièvre JD, Tartour E, Meyer L, de Lamballerie X, Launay O; ANRS002S CoviCompareP group.Infect Dis Now. 2024 Aug;54(5):104886. doi: 10.1016/j.idnow.2024.104886. Epub 2024 Mar 16.PMID: 38494117

A (RP)UHPLC/UV analytical method to quantify dsRNA during the mRNA vaccine manufacturing process.

Rosa SS, Zhang S, Sari Y, Marques MPC.Anal Methods. 2024 Aug 1;16(30):5146-5153. doi: 10.1039/d4ay00560k.PMID: 39011770

Pulmonary MicroRNA expression after heterologous challenge with swine influenza A virus (H1N2) in immunized and non-immunized pigs.

Brogaard L, Heegaard PMH, Larsen LE, Skovgaard K.Virology. 2024 Aug;596:110117. doi: 10.1016/j.virol.2024.110117. Epub 2024 May 23.PMID: 38797064

Mosaic neuraminidase-based vaccine induces antigen-specific T cell responses against homologous and heterologous influenza viruses.

Han Z, Mai Q, Zhao Y, Liu X, Cui M, Li M, Chen Y, Shu Y, Gan J, Pan W, Sun C.Antiviral Res. 2024 Aug 6;230:105978. doi: 10.1016/j.antiviral.2024.105978. Online ahead of print.PMID: 39117282

Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer.

Cruz VA, Guimarães C, Rêgo J, Machado KLLL, Miyamoto ST, Burian APN, Dias LH, Pretti FZ, Batista DCFA, Mill JG, de Oliveira YGP, Gadelha CSE, da Penha Gomes Gouveia M, Moulin ACS, Souza BO, Aguiar LGR, Vieira GSS, Grillo LL, de Lima MD, Pasti LP, Surlo HF, Faé F, Moulaz IR, Macabú MO, Ribeiro PDC, Magalhães VO, de Aguiar MF, Biegelmeyer E, Peixoto FMMMC, Kayser C, de Souza AWS, de Moura Castro CH, Ribeiro SLE, Telles CMPF, Bühring J, de Lima RL, Dos Santos SHO, Dias SEB, de Melo NS, da Silva Sanches RH, Boechat AL, Sartori NS, Hax V, Dória LD, de Rezende RPV, Baptista KL, Fortes NRQ, de Melo AKG, Melo TS, de Abreu Vieira RMR, Vieira ASR, Kakehasi AM, Tavares ACFMG, de Landa AT, da Costa PVT, Azevedo VF, Martins-Filho OA, Peruhype-Magalhães V, de Medeiros Pinheiro M, Monticielo OA, Dos Reis-Neto ET, Ferreira GA, de Souza VA, Teixeira-Carvalho A, Xavier RM, Sato EI, Valim V, Pileggi GS,

da Silva NA.Adv Rheumatol. 2024 Aug 12;64(1):58. doi: 10.1186/s42358-024-00397-5.PMID: 39135131 Clinical Trial.

Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study).

Casas Deza D, Julián Gomara AB, Caudevilla Biota E, Beltrán B, Domènech E, Gutiérrez Casbas A, Mañosa M, Zabana Y, Roc Alfaro L, Valverde Romero E, García González E, Sicilia B, Laredo V, Alcalá Escriche MJ, Madero Velázquez L, Ferreiro-Iglesias R, Palmero Pérez A, Calafat M, Rubio Iturria S, Moraleja Yudego I, Ber Nieto Y, García Mateo S, Gisbert JP, Vicente Lidón R, Arias L, Alfambra E, Doñate Borao AB, Peña González E, Corsino Roche P, Vicuña Arregui M, Elorza A, Domínguez Cajal M, Chaparro M, Barreiro-de Acosta M, García-López S.Gastroenterol Hepatol. 2024 Aug-Sep;47(7):750-758. doi: 10.1016/j.gastrohep.2023.12.012. Epub 2024 Jan 12.PMID: 38219960 English, Spanish.

Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek's disease vaccine with an insertion of the long terminal repeat of reticuloendotheliosis virus in the CVI988 strain genome (CVI-LTR).

Faiz NM, Cortes AL, Phang YF, Gimeno IM.Avian Pathol. 2024 Aug;53(4):303-311. doi: 10.1080/03079457.2024.2324930. Epub 2024 Mar 20.PMID: 38411905

Haemorrhagic intracranial complications associated with vaccine-induced thrombocytopenia or central venous thrombosis after COVID-19 vaccination: postulated underlying mechanisms with literature and case review.

Cheda M, Kuczyńska M, Dąbrowska I, Sobstyl J, Szmygin H, Zarajczyk A, Materek M, Rejdak K, Drelich-Zbroja A.Neurol Neurochir Pol. 2024 Aug 5. doi: 10.5603/pjnns.97675. Online ahead of print.PMID: 39101645

The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia.

Vayne C, Rollin J, Clare R, Daka M, Atsouawe M, Guéry EA, Cauchie P, Cordonnier C, Cuisenier P, De Maistre E, Donnard M, Drillaud N, Faille D, Galinat H, Gouin-Thibault I, Lemoine S, Mourey G, Mullier F, Siguret V, Susen S, Godon A, Nazy I, Gruel Y, Pouplard C.J Thromb Haemost. 2024 Aug;22(8):2306-2315. doi: 10.1016/j.jtha.2024.05.005. Epub 2024 May 16.PMID: 38762021

Edging towards a third dengue vaccine.

Wilder-Smith AB, Freedman DO, Wilder-Smith A.Lancet Infect Dis. 2024 Aug 5:S1473-3099(24)00434-1. doi: 10.1016/S1473-3099(24)00434-1. Online ahead of print.PMID: 39116905

Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers - An updated European Academy of Neurology consensus statement.

Filipović SR, Özturk S, Bereczki D, Bodini B, Cavallieri F, Fanciulli A, Guekht A, Helbok R, Hochmeister S, Martinelli Boneschi F, Priori A, Rakusa M, Romoli M, Willekens B, Zedde M, Sellner J, Moro E; Neuro COVID-19 Task Force of the European Academy of Neurology.Eur J Neurol. 2024 Aug 1:e16408. doi: 10.1111/ene.16408. Online ahead of print.PMID: 39088330

p67 gene alleles sequence analysis reveals Theileria parva parasites associated with East Coast fever and Corridor disease in buffalo from Zambia.

Choopa CN, Muleya W, Fandamu P, Mukolwe LD, Sibeko-Matjila KP.Vet Parasitol. 2024 Aug;330:110240. doi: 10.1016/j.vetpar.2024.110240. Epub 2024 Jun 24.PMID: 38959671

Efficacy and prognostic factors of COVID-19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study.

Zhao H, Li Y, Tian P, Sun W, Luo Y, Zhang X, Li J, Gong T, Yang Z, Song P, Li X.Cancer Med. 2024 Aug;13(15):e70068. doi: 10.1002/cam4.70068.PMID: 39119737

Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors.

Grebe E, Stone M, Spencer BR, Akinseye A, Wright D, Di Germanio C, Bruhn R, Zurita KG, Contestable P, Green V, Lanteri MC, Saa P, Biggerstaff BJ, Coughlin MM, Kleinman S, Custer B, Jones JM, Busch MP.Emerg Infect Dis. 2024 Aug;30(8):1621-1630. doi: 10.3201/eid3008.240659. Epub 2024 Jul 9.PMID: 38981189

An Experimental Study on how Messaging from CDC Affects Attitudes toward Mandatory MMR Vaccination for Schoolchildren.

Viskupič F, Wiltse DL.J Community Health. 2024 Aug;49(4):763-769. doi: 10.1007/s10900-024-01334-9. Epub 2024 Feb 27.PMID: 38413407

Response to: Szuster-Ciesielska, letter to the editor regarding 'Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis'.

Hulscher N, Hodkinson R, Makis W, McCullough PA.ESC Heart Fail. 2024 Aug;11(4):2479-2480. doi: 10.1002/ehf2.14862. Epub 2024 May 22.PMID: 38773951

Varicella-Zoster Virus Pretransplant Vaccination and Posttransplant Infections Among Pediatric Solid Organ Recipients in the Two-Dose Varicella Era: A Single-Center, Multi-Organ Retrospective Study.

Espinoza-Candelaria GJ, Albert J, Sojati J, Martin JM, Michaels MG, Green M.Pediatr Transplant. 2024 Aug;28(5):e14822. doi: 10.1111/petr.14822.PMID: 39054880

Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis.

Kanakura M, Kihara K, Kinoshita M, Sugimoto T, Murata H, Beppu S, Shiraishi N, Sugiyama Y, Koda T, Takahashi MP, Chinen I, Okuno T, Mochizuki H.Clin Neurol Neurosurg. 2024 Aug;243:108378. doi: 10.1016/j.clineuro.2024.108378. Epub 2024 Jun 15.PMID: 38901377

Access to COVID-19 vaccination by socio-economic status in older Singaporean adults: a population-based cohort study.

Wee LE, Yap AJW, Dickens B, Tan S, Ong B, Lye DC, Tan KB.Public Health. 2024 Aug;233:38-44. doi: 10.1016/j.puhe.2024.05.003. Epub 2024 Jun 7.PMID: 38850601

The impact of targeted local outreach clinics to improve COVID-19 vaccine uptake: controlled interrupted time series in South West England.

Jones T, Adamali H, Redaniel MT, de Vocht F, Tilling K, Kenward C, Ben-Shlomo Y, Creavin S.Arch Public Health. 2024 Aug 7;82(1):118. doi: 10.1186/s13690-024-01341-1.PMID: 39113156

Effects of religious and cultural beliefs on vaccine attitudes in a Hispanic immigrant population in the United States.

Larson RJ, Jensen JL, Alvord SM, Sloan-Aagard C, Skyles T, Davis SC, Obray AM, Pogue K, Poole BD.PLOS Glob Public Health. 2024 Aug 6;4(8):e0003519. doi: 10.1371/journal.pgph.0003519. eCollection 2024.PMID: 39106278

Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine.

Hendy DA, Ma Y, Dixon TA, Murphy CT, Pena ES, Carlock MA, Ross TM, Bachelder EM, Ainslie KM, Fenton OS.J Control Release. 2024 Aug;372:168-175. doi: 10.1016/j.jconrel.2024.06.007. Epub 2024 Jun 19.PMID: 38844178

Target Protein Expression on Tetrahymena thermophila Cell Surface Using the Signal Peptide and GPI Anchor Sequences of the Immobilization Antigen of Cryptocaryon irritans.

Watanabe Y, Asada M, Inokuchi M, Kotake M, Yoshinaga T.Mol Biotechnol. 2024 Aug;66(8):1907-1918. doi: 10.1007/s12033-023-00824-w. Epub 2023 Jul 22.PMID: 37480447

Single nucleotide variation catalog from clinical isolates mapped on tertiary and quaternary structures of ESX-1-related proteins reveals critical regions as putative Mtb therapeutic targets.

Tzfadia O, Gijsbers A, Vujkovic A, Snobre J, Vargas R, Dewaele K, Meehan CJ, Farhat M, Hakke S, Peters PJ, de Jong BC, Siroy A, Ravelli RBG.Microbiol Spectr. 2024 Aug 6;12(8):e0381623. doi: 10.1128/spectrum.03816-23. Epub 2024 Jun 14.PMID: 38874407

Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant subunit vaccine against the Zika virus in BALB/c mice.

Valdes I, Suzarte E, Lazo L, Cobas K, Cabrales A, Pérez Y, Garateix R, Silva JA, Aguilar JC, Guzman CA, Guillén G.Vaccine. 2024 Aug 12:126213. doi: 10.1016/j.vaccine.2024.126213. Online ahead of print.PMID: 39138071

The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report.

Maimon O, Nisman B, Broier S, Ben-David I, Kuznetz A, Gelfand Y, Mizrahi A, Prus E, Fuchs I, Lotem M, Popovtzer A, Khutsurauli S, Meirovitz A, Nechushtan H, Peretz T.Anticancer Res. 2024 Aug;44(8):3543-3550. doi: 10.21873/anticanres.17175.PMID: 39060086

Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5-11 years with underlying diseases: A prospective observational study.

Funaki T, Yamada M, Miyake K, Ueno S, Myojin S, Aiba H, Matsui T, Ogimi C, Kato H, Miyairi I, Shoji K.J Infect Chemother. 2024 Aug;30(8):773-779. doi: 10.1016/j.jiac.2024.02.020. Epub 2024 Feb 20.PMID: 38387787

Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.

Gao Y, Yang X, Li X, Chen H, Li Y, Tan X, Yu D, Feng T, Zhou S, Lei S, Zhao C, Wang J, Guan Q.Vaccine. 2024 Aug 7;42(21):126182. doi: 10.1016/j.vaccine.2024.126182. Online ahead of print.PMID: 39116486

Wells syndrome following vaccination: A pediatric case with positive patch test to gelatin.

Granja BV, Cruz MJ, De Matos PR, Cunha AP, Canão PA, Baudrier T, Mota A.Pediatr Dermatol. 2024 Aug 7. doi: 10.1111/pde.15719. Online ahead of print.PMID: 39112433

Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial.

Szymura SJ, Wang L, Zhang T, Cha SC, Song J, Dong Z, Anderson A, Oh E, Lee V, Wang Z, Parshottam S, Rao S, Olsem JB, Crumpton BN, Lee HC, Manasanch EE, Neelapu S, Kwak LW, Thomas SK.Nat Commun. 2024 Aug 11;15(1):6874. doi: 10.1038/s41467-024-50880-2.PMID: 39128904

Trends in anaphylaxis management during COVID-19.

Hamadi W, Casale TB.J Allergy Clin Immunol Glob. 2024 May 29;3(3):100284. doi: 10.1016/j.jacig.2024.100284. eCollection 2024 Aug.PMID: 38975256

Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities.

Chen M, Zhou Y, Fu Y, Wang Q, Wu C, Pan X, Quan G.Expert Opin Drug Deliv. 2024 Aug 3. doi: 10.1080/17425247.2024.2388832. Online ahead of print.PMID: 39096307

Influences of race, ethnicity, and other social factors on coronavirus disease 2019 vaccination uptake among patients undergoing in vitro fertilization.

Humphries LA, Applebaum J, Polite FG, Kravitz E, Gracia CR, Berger DS.Fertil Steril. 2024 Aug;122(2):376-378. doi: 10.1016/j.fertnstert.2024.04.026. Epub 2024 Apr 19.PMID: 38643852

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine.

Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD.Eur J Nucl Med Mol Imaging. 2024 Aug 12. doi: 10.1007/s00259-024-06853-0. Online ahead of print.PMID: 39133306

How the African vaccine manufacturing accelerator can assist in strengthening Africa's response to global health challenges.

Omojuyigbe JO, Ade-Adekunle OA, Atobatele IR, Adekunle FO.Vaccine X. 2024 May 21;19:100499. doi: 10.1016/j.jvacx.2024.100499. eCollection 2024 Aug.PMID: 38841419

COVID-19 Vaccination-Related Pericarditis: A Korean Nationwide Study.

Lee N, Kim KH, Park JH, Cho JY, Cho SH, Kim DK, Kim SY, Kim EK, Choi EY, Choi JO, Cho S, Choi GH, Park H, Kim HY, Yoon HJ, Ahn Y, Jeong MH.Mayo Clin Proc. 2024 Aug 2:S0025-6196(24)00196-4. doi: 10.1016/j.mayocp.2024.03.026. Online ahead of print.PMID: 39093271

Influenza vaccine uptake among youth with sickle cell disease who are seen in clinic before and after the COVID-19 pandemic.

Walden J, Stanek JR, Young J, Griffith MM, Nahata L, Creary SE.Vaccine. 2024 Aug 9;42(22):126212. doi: 10.1016/j.vaccine.2024.126212. Online ahead of print.PMID: 39126828

Letter to the Editor about "Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers before the booster dose of the vaccine".

Daungsupawong H, Wiwanitkit V.Rev Clin Esp (Barc). 2024 Aug-Sep;224(7):481. doi: 10.1016/j.rceng.2024.06.011. Epub 2024 Jun 27.PMID: 38944200

Retraction notice to "Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models" [Life Sci. 288 (2022) 120166].

Kiani FK, Izadi S, Dezfouli EA, Ebrahimi F, Mohammadi M, Chalajour H, Bulus MM, Esfahani MN, Karpisheh V, Khesht AMS, Abbaszadeh-Goudarzi K, Soleimani A, Navashenaq JG, Ahmadi M, Hassannia H, Hojjat-Farsangi M, Farid SS, Hashemi V, Jadidi-Niaragh F.Life Sci. 2024 Aug 1;350:122775. doi: 10.1016/j.lfs.2024.122775. Epub 2024 Jun 8.PMID: 38851943

Conjugation of TLR7 and TLR7/8 agonists onto weak protein antigen via versatile oxime ligation for enhanced vaccine efficacy.

Zhang RY, Wen Y, He CB, Zhou SH, Wu YH, Wang EY, Feng RR, Ding D, Du JJ, Gao XF, Guo J.Int J Biol Macromol. 2024 Aug 8:134620. doi: 10.1016/j.ijbiomac.2024.134620. Online ahead of print.PMID: 39127274

Mpox in people with HIV: A narrative review.

Nakamura H, Yamamoto K.HIV Med. 2024 Aug;25(8):910-918. doi: 10.1111/hiv.13661. Epub 2024 May 15.PMID: 38745559

Supporting vaccine (co)-administration decisions: Development and validation of a tool for assessing the risk of severe outcomes due to lower respiratory tract infections.

Lapi F, Domnich A, Marconi E, Cricelli I, Rossi A, Icardi G, Cricelli C.Respir Med. 2024 Aug 6;232:107761. doi: 10.1016/j.rmed.2024.107761. Online ahead of print.PMID: 39117010

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody.

Adachi E, Sedohara A, Arizono K, Takahashi K, Otani A, Kanno Y, Saito M, Koga M, Yotsuyanagi H.Emerg Infect Dis. 2024 Aug;30(8):1668-1671. doi: 10.3201/eid3008.240019.PMID: 39043430

Protective Activity and Safety of Experimental Acellular Pertussis Vaccines Based on Antigenic Complexes Isolated from Biofilm and Planktonic Cultures of Bordetella pertussis.

Zaytsev EM, Britsina MV, Ozeretskovskaya MN, Zaitsev AE.Bull Exp Biol Med. 2024 Aug 10. doi: 10.1007/s10517-024-06187-9. Online ahead of print.PMID: 39126548

Polyphenol-Enabled 2D Nanopatch for Enhanced Nasal Mucoadhesion and Immune Activation.

Han JP, Nam YR, Chung HY, Lee H, Yeom SC.Nano Lett. 2024 Aug 9. doi: 10.1021/acs.nanolett.4c03228. Online ahead of print.PMID: 39120059

RLpMIEC: High-Affinity Peptide Generation Targeting Major Histocompatibility Complex-I Guided and Interpreted by Interaction Spectrum-Navigated Reinforcement Learning.

Deng Q, Wang Z, Xiang S, Wang Q, Liu Y, Hou T, Sun H.J Chem Inf Model. 2024 Aug 8. doi: 10.1021/acs.jcim.4c01153. Online ahead of print.PMID: 39118363

Counter reply in reference to "Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine".

Montagud AC, Llenas-García J, Moragues R, Pérez-Bernabeu A, Alcocer Pertegal MJ, García Gómez FJ, Gamayo Serna AM, García Morante H, Caballero P, Tuells J.Rev Clin Esp (Barc). 2024 Aug-Sep;224(7):482-483. doi: 10.1016/j.rceng.2024.06.006. Epub 2024 Jun 7.PMID: 38852738

Vaccine hesitancy among college students and individuals seeking healthcare: A social norms perspective.

Terry DL, Hui PA, Terry CP, Trabold A.J Am Coll Health. 2024 Aug-Sep;72(6):1672-1677. doi: 10.1080/07448481.2022.2086009. Epub 2022 Jun 21.PMID: 35728070

Clinical application of COVID-19 vaccine in liver transplant recipients.

Liu FC, Xie M, Rao W.Hepatobiliary Pancreat Dis Int. 2024 Aug;23(4):339-343. doi: 10.1016/j.hbpd.2023.08.010. Epub 2023 Aug 12.PMID: 37620225

Improved thermal stabilization of VSV-vector with enhanced vacuum drying in pullulan and trehalose-based films.

Iwashkiw JA, Mohamud AO, Kazhdan N, Ameen A, Beecher JE, Filipe CDM, Lichty BD.Sci Rep. 2024 Aug 9;14(1):18522. doi: 10.1038/s41598-024-69003-4.PMID: 39122821

Response to: Van Wyk et al. letter to the editor regarding 'Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis'.

Hulscher N, Hodkinson R, Makis W, McCullough PA.ESC Heart Fail. 2024 Aug;11(4):2476-2478. doi: 10.1002/ehf2.14861. Epub 2024 May 21.PMID: 38772619

COVID-19 related disruption and resilience in immunisation activities in LMICs: a rapid review.

Hartner AM, Li X, Gaythorpe K.BMJ Open. 2024 Aug 6;14(8):e076607. doi: 10.1136/bmjopen-2023-076607.PMID: 39107008

Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.

Liu WD, Lin MS, Sun HY, Shih MC, Chuang YC, Huang YS, Lin KY, Li GC, Wu PY, Chen LY, Liu WC, Su YC, He PC, Chen YT, Lin CY, Cheng YC, Yao Y, Yeh YC, Liu CC, Pan MY, Luo YZ, Chang HY, Wang JT, Sheng WH, Hsieh SM, Chang SY, Hung CC.J Microbiol Immunol Infect. 2024 Aug;57(4):554-563. doi: 10.1016/j.jmii.2024.02.004. Epub 2024 Feb 26.PMID: 38429206

Mental health conditions and COVID-19 vaccine outcomes: A scoping review.

Jia R, Coupland C, Vinogradova Y, Qureshi N, Turner E, Vedhara K.J Psychosom Res. 2024 Aug;183:111826. doi: 10.1016/j.jpsychores.2024.111826. Epub 2024 Jun 8.PMID: 38870550

Prophylactic and therapeutic cancer vaccine with continuous localized immunomodulation.

Kota N, Gonzalez DD, Liu HC, Viswanath D, Vander Pol R, Wood A, Di Trani N, Chua CYX, Grattoni A.Nanomedicine. 2024 Aug 3;62:102776. doi: 10.1016/j.nano.2024.102776. Online ahead of print.PMID: 39102973

Disseminated histoplasmosis mimicking post-vaccination side effects in an immunocompromised person with multiple sclerosis.

Toubasi AA, Allon S, Bagnato F.Mult Scler J Exp Transl Clin. 2024 Aug 7;10(3):20552173241271790. doi: 10.1177/20552173241271790. eCollection 2024 Jul-Sep.PMID: 39119360

Subacute Thyroiditis Following COVID-19 and COVID-19 Vaccination.

Duskin-Bitan H, Robenshtok E, Peretz A, Beckenstein T, Tsur N, Netzer D, Cohen AD, Saliba W, Shimon I, Gorshtein A.Endocr Pract. 2024 Aug;30(8):731-736. doi: 10.1016/j.eprac.2024.05.001. Epub 2024 May 8.PMID: 38729568

Vaccine Hesitancy in the Autism Spectrum Disorder Context: Parental Vaccine Decision-Making and Coping with Stress Strategies.

Gulle BT, Yassibas U, Sarigedik E.J Autism Dev Disord. 2024 Aug 8. doi: 10.1007/s10803-024-06508-x. Online ahead of print.PMID: 39115743

Measuring vaccination coverage and concerns of vaccine holdouts from web search logs.

Chang S, Fourney A, Horvitz E.Nat Commun. 2024 Aug 1;15(1):6496. doi: 10.1038/s41467-024-50614-4.PMID: 39090092

A closer look at Indonesia's circulating vaccine-derived poliovirus type 2 outbreak.

Satapathy P, Kumar P, Sharma A, Rustagi S, Gaidhane S, Zahiruddin QS, Mehta R, Sah S, Harapan H.J Med Virol. 2024 Aug;96(8):e29861. doi: 10.1002/jmv.29861.PMID: 39138645

A Propensity Score Approach and a Partitioned Approach for the Self-Controlled Case Series Design to Evaluate Safety of a 2-dose Vaccine Series: Comment.

Daungsupawong H, Wiwanitkkit V.Am J Epidemiol. 2024 Aug 6:kwae258. doi: 10.1093/aje/kwae258. Online ahead of print.PMID: 39108183

Update on the research on the antigens of anti-sperm antibodies over the last decade.

Chen Y, Hasegawa A, Wakimoto Y, Shibahara H.J Reprod Immunol. 2024 Aug;164:104292. doi: 10.1016/j.jri.2024.104292. Epub 2024 Jul 1.PMID: 38964133

COVID-19 Vaccine Hesitancy in Caregivers of Hospitalized Children From 2020 Through 2023.

Orbea M, Lopez MA, Huang X, Guffey D, Cunningham RM, Healy CM, Boom JA, Bocchini CE.Hosp Pediatr. 2024 Aug 5:e2023007660. doi: 10.1542/hpeds.2023-007660. Online ahead of print.PMID: 39099438

A bivalent Delta/BA.5 mRNA vaccine elicits broad immune responses against various lineages of SARS-CoV-2 including JN.1.

Li K, Liu Q, Wu Y, Wu B, Chen S, Zhang X, Jia X, Gong R, Peng Y, Zhang H, Chiu S.Virol Sin. 2024 Aug 8:S1995-820X(24)00117-2. doi: 10.1016/j.virs.2024.08.003. Online ahead of print.PMID: 39127113

COVID-19 vaccine messaging for young adults: Examining framing, other-referencing, and health beliefs.

Newbold TR, Burak EGD, Leshner G, Connelly S, Wong N, Lee SK, Jang SR.Health Psychol. 2024 Aug;43(8):615-625. doi: 10.1037/hea0001376. Epub 2024 Apr 18.PMID: 38635189

What Influences Parents on Their Decision to Vaccinate Their Daughters Against HPV?

Bogka E, Naoum P, Pavi E, Athanasakis K.J Pediatr Adolesc Gynecol. 2024 Aug;37(4):396-401. doi: 10.1016/j.jpag.2024.02.001. Epub 2024 Feb 15.PMID: 38367952

Impact of the COVID-19 Pandemic on Measles Vaccination Coverage and Estimated Catch-Up Efforts for Serbia.

Burgess C, Lisul B, Pawaskar M, Petigara T, Murtagh J, Kanazir M, Loncarevic G, Carias C.Pediatr Infect Dis J. 2024 Aug 2. doi: 10.1097/INF.0000000000004487. Online ahead of print.PMID: 39105529

Identifying psychological predictors of SARS-CoV-2 vaccination: A machine learning study.

Bronstein MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S.Vaccine. 2024 Aug 5;42(21):126198. doi: 10.1016/j.vaccine.2024.126198. Online ahead of print.PMID: 39106578

COVID-19 vaccination and postmenopausal bleeding: a retrospective cohort study.

Pastor-Goutherot L, Miralpeix E, Fabregó B, Serrano L, Vizoso A, Solé-Sedeño JM, Mancebo G.Climacteric. 2024 Aug 12:1-5. doi: 10.1080/13697137.2024.2385360. Online ahead of print.PMID: 39133082

The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review.

SeyedAlinaghi S, Dashti M, Afzalian A, Siami H, Ghasemzadeh A, Varshochi S, Parikhani SN, Amrollah MF, Nourian A, Mehraeen E, Dadras O.Prev Med Rep. 2024 May 31;44:102778. doi: 10.1016/j.pmedr.2024.102778. eCollection 2024 Aug.PMID: 38979481

Geographic Distribution of Rabies Virus and Genomic Sequence Alignment of Wild and Vaccine Strains, Kenya.

Wambugu EN, Kimita G, Kituyi SN, Washington MA, Masakhwe C, Mutunga LM, Jaswant G, Thumbi SM, Schaefer BC, Waitumbi JN.Emerg Infect Dis. 2024 Aug;30(8):1642-1650. doi: 10.3201/eid3008.230876.PMID: 39043404

Hesitant or Confident: A Qualitative Study Examining Latinos' Perceptions of COVID-19 Vaccines in Arizona.

Mercado M, Lopez G, Ignacio M, Ayers S, Carver A, Hamm K, Wolfersteig W, Oesterle S.Health Educ Behav. 2024 Aug;51(4):512-520. doi: 10.1177/10901981241255619. Epub 2024 May 28.PMID: 38804533

Live Vaccine and Varicella Postexposure Prophylaxis in Pediatric Liver Transplant Recipients: A Survey of Practice in Australia and New Zealand.

Bonett E, Doyle R, Roberts A, Wen SCH.Pediatr Transplant. 2024 Aug;28(5):e14833. doi: 10.1111/petr.14833.PMID: 39039719

Accelerated Development of Pharmaceuticals Past, Present, and Future.

Byrn SR.Pharm Res. 2024 Aug 6. doi: 10.1007/s11095-024-03737-8. Online ahead of print.PMID: 39107515

Vaccine Equity: Lessons Learned Exploring Facilitators and Barriers to COVID-19 Vaccination in Urban Black Communities.

Parameswaran L, Jaysing A, Ding H, Wilkenfeld M, Dean R, Wilson KK, Frank O, Duerr R, Mulligan MJ.J Racial Ethn Health Disparities. 2024 Aug;11(4):2109-2119. doi: 10.1007/s40615-023-01680-9. Epub 2023 Jun 30.PMID: 37391605

Investigating the Relation of Political Orientation and Vaccination Outcomes: Identifying the Roles of Political Ideology, Party Affiliation, and Vaccine Hesitancy.

Howard MC.Psychol Rep. 2024 Aug;127(4):1796-1817. doi: 10.1177/00332941221144604. Epub 2022 Dec 7.PMID: 36476182

Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink.

Denoble AE, Vazquez-Benitez G, Sheth SS, Ackerman-Banks CM, DeSilva MB, Zhu J, Daley MF, Getahun D, Klein NP, Vesco KK, Irving SA, Nelson J, Williams JTB, Hambidge SJ, Donahue JG, Weintraub ES, Kharbanda EO, Lipkind HS.Obstet Gynecol. 2024 Aug 1;144(2):215-222. doi: 10.1097/AOG.0000000000005632. Epub 2024 Jun 6.PMID: 38843526

Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.

Lyke KE, Chua JV, Koren M, Friberg H, Gromowski GD, Rapaka RR, Waickman AT, Joshi S, Strauss K, McCracken MK, Gutierrez-Barbosa H, Shrestha B, Culbertson C, Bernal P, De La Barrera RA, Currier JR,

Jarman RG, Edelman R.Lancet Infect Dis. 2024 Aug;24(8):896-908. doi: 10.1016/S1473-3099(24)00100-2. Epub 2024 Apr 25.PMID: 38679035 Clinical Trial.

Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial.

van der Heiden M, Shetty S, Bijvank E, Beckers L, Cevirgel A, van Sleen Y, Tcherniaeva I, Ollinger T, Burny W, van Binnendijk RS, van Houten MA, Buisman AM, Rots NY, van Beek J, van Baarle D.Nat Commun. 2024 Aug 4;15(1):6603. doi: 10.1038/s41467-024-50760-9.PMID: 39097574

Yeast β-glucan promotes antiviral type I interferon response via dectin-1.

Wang J, Jin X, Yan S, Zhao H, Pang D, Ouyang H, Tang X.Vet Microbiol. 2024 Aug;295:110107. doi: 10.1016/j.vetmic.2024.110107. Epub 2024 May 9.PMID: 38838382

Sociodemographic determinants of HPV vaccine awareness, uptake, and intention among parents of adolescents in France 2021-22.

Rivera AF, Dussault JM, Oudin Doglioni D, Chyderiotis S, Sicsic J, Barret AS, Raude J, Gauchet A, Gagneux-Brunon A, Bruel S, Michel M, Le Duc-Banaszuk AS, Thilly N, Mueller JE.Hum Vaccin Immunother. 2024 Dec 31;20(1):2381300. doi: 10.1080/21645515.2024.2381300. Epub 2024 Aug 6.PMID: 39105306

Influenza virus circulation and vaccine effectiveness during June 2021-May 2023 in Thailand.

Prasert K, Praphasiri P, Nakphook S, Ditsungnoen D, Sapchookul P, Sornwong K, Naosri S, Akkapaiboon Okada P, Suntarattiwong P, Chotpitayasunondh T, Montgomery MP, Davis WW, Pittayawonganon C.Vaccine X. 2024 Jun 28;19:100517. doi: 10.1016/j.jvacx.2024.100517. eCollection 2024 Aug.PMID: 39044732

New vaccination approach using formalin-killed Streptococcus pyogenes vaccine on the liver of Oreochromis niloticus fingerlings.

Nasr-Eldahan S, Attia Shreadah M, Maher AM, El-Sayed Ali T, Nabil-Adam A.Sci Rep. 2024 Aug 7;14(1):18341. doi: 10.1038/s41598-024-67198-0.PMID: 39112606

Health and Economic Benefits of Routine Childhood Immunizations in the Era of the Vaccines for Children Program - United States, 1994-2023.

Zhou F, Jatlaoui TC, Leidner AJ, Carter RJ, Dong X, Santoli JM, Stokley S, Daskalakis DC, Peacock G.MMWR Morb Mortal Wkly Rep. 2024 Aug 8;73(31):682-685. doi: 10.15585/mmwr.mm7331a2.PMID: 39116024

COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study.

Lakin KS, Wu Y, Gordon JK, Kwakkenbos L, Carrier ME, Henry RS, Denton CP, Mouthon L, Spiera RF, Thombs BD; SPIN COVID-19 Vaccination Patient Advisory Team; SPIN Investigators.Semin Arthritis Rheum. 2024 Aug;67:152453. doi: 10.1016/j.semarthrit.2024.152453. Epub 2024 May 9.PMID: 38851172

Nanodisc assembly from bacterial total lipid extracts.

Llewellyn TR, Pimentel ORC, Lenz KD, Montoya MM, Kubicek-Sutherland JZ.Chem Phys Lipids. 2024 Aug 5;264:105425. doi: 10.1016/j.chemphyslip.2024.105425. Online ahead of print.PMID: 39111725

Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice.

Li D, Bian L, Cui L, Zhou J, Li G, Zhao X, Xing L, Cui J, Sun B, Jiang C, Kong W, Zhang Y, Chen Y.Int J Nanomedicine. 2024 Aug 6;19:8029-8042. doi: 10.2147/IJN.S464720. eCollection 2024.PMID: 39130684

Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease.

Cameron RL, Palmer TJ, Cuschieri K, Kavanagh K, Roy K.Vaccine. 2024 Aug 10;42(21):126177. doi: 10.1016/j.vaccine.2024.126177. Online ahead of print.PMID: 39128198

Incidence of Bacteremia and Serious Bacterial Infections in Hyperpyrexic Infants Offered Universal Pneumococcal Conjugate Vaccine 13 and Haemophilus influenzae B Immunization.

Be'er M, Rimon A, Segev O, Huber A, Scolnik D, Glatstein M.Pediatr Emerg Care. 2024 Aug 1;40(8):e143-e146. doi: 10.1097/PEC.0000000000003217. Epub 2024 May 23.PMID: 38776442

UK paediatricians' attitudes towards the chicken pox vaccine: The SPOTTY study.

O'Mahony E, Sherman SM, Marlow R, Bedford H, Fitzgerald F.Vaccine. 2024 Aug 8;42(22):126199. doi: 10.1016/j.vaccine.2024.126199. Online ahead of print.PMID: 39121697

Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.

Wateska AR, Nowalk MP, Altawalbeh SM, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, Smith KJ.J Am Geriatr Soc. 2024 Aug;72(8):2423-2433. doi: 10.1111/jgs.19031. Epub 2024 Jun 1.PMID: 38822745

Vaccine literacy, vaccination intention, and their correlation among adults in Mainland China: a cross-sectional study.

Gao S, Li Y, Wang X, Li S, Chen M, Yue B.J Health Popul Nutr. 2024 Aug 10;43(1):122. doi: 10.1186/s41043-024-00602-7.PMID: 39127762

Determination of Opinions on HPV Infection and HPV Vaccine among Nursing Students by Focus Group Discussion.

Çetin SA, Çinar D.J Adolesc Young Adult Oncol. 2024 Aug;13(4):693-702. doi: 10.1089/jayao.2024.0036. Epub 2024 May 13.PMID: 38738288

Post-introduction evaluation (PIE) of rotavirus vaccine in India.

Kumar P, Ray A, Kumari A, Kaur A, Hora R, Singh K, Mehra R, Koshal SS, Verma S, Quadri SF, Deb Roy A.Vaccine X. 2024 Jul 17;19:100526. doi: 10.1016/j.jvacx.2024.100526. eCollection 2024 Aug.PMID: 39135678

Attitudes, perceptions, and experiences of Western Australians towards vaccine safety surveillance systems following COVID-19 vaccines: A qualitative descriptive study.

Liu Shiu Cheong D, Tran J, Chong W, May S, Carlson SJ, Salter SM, Attwell K.Aust N Z J Public Health. 2024 Aug;48(4):100177. doi: 10.1016/j.anzjph.2024.100177. Epub 2024 Jul 18.PMID: 39029385

Minimal purification method enables developability assessment of recombinant proteins.

Rodriguez-Aponte SA, Naranjo CA, Johnston RS, Dalvie NC, Crowell LE, Bajoria S, Kumru OS, Joshi SB, Volkin DB, Love JC.Biotechnol Bioeng. 2024 Aug;121(8):2423-2434. doi: 10.1002/bit.28385. Epub 2023 Apr 3.PMID: 36929469

Mapping vaccine names in clinical trials to vaccine ontology using cascaded fine-tuned domain-specific language models.

Li J, Li Y, Pan Y, Guo J, Sun Z, Li F, He Y, Tao C.J Biomed Semantics. 2024 Aug 10;15(1):14. doi: 10.1186/s13326-024-00318-x.PMID: 39123237

The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies.

Lu Y, Ao D, He X, Wei X.MedComm (2020). 2024 Jul 29;5(8):e675. doi: 10.1002/mco2.675. eCollection 2024 Aug.PMID: 39081516

Credibility Perceptions of Information and Vaccine Intention: The Role of Collective Vs. Individual Framing Messages.

Borah P.Health Commun. 2024 Aug 2:1-10. doi: 10.1080/10410236.2024.2386718. Online ahead of print.PMID: 39092464

The Association Between the We Can Do This Campaign and Vaccination Beliefs in the United States, January 2021-March 2022.

Kim JC, Kranzler EC, Yu K, Denison B, Dahlen HM, Luchman JN, Ihongbe TO, Marshall MC, Hoffman B, Moffett K, Dupervil D, Margolis KA, Hoffman L.J Health Commun. 2024 Aug 2;29(8):502-513. doi: 10.1080/10810730.2024.2373159. Epub 2024 Jul 3.PMID: 38958603

Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo.

Hick TAH, Geertsema C, Nguyen W, Bishop CR, van Oosten L, Abbo SR, Dumenil T, van Kuppeveld FJM, Langereis MA, Rawle DJ, Tang B, Yan K, van Oers MM, Suhrbier A, Pijlman GP.Mol Ther. 2024 Aug 7;32(8):2519-2534. doi: 10.1016/j.ymthe.2024.06.019. Epub 2024 Jun 17.PMID: 38894543

Beyond the needle: a qualitative exploration of Sierra Leonean healthcare workers' post COVID-19 vaccination experiences.

David I, Tefera GM, Majee W.Health Promot Int. 2024 Aug 1;39(4):daae092. doi: 10.1093/heapro/daae092.PMID: 39136158

Optimization data for an ARTIC-/Illumina-based whole-genome sequencing protocol and pipeline for SARS-CoV-2 analysis.

Bundschuh C, Weidner N, Klein J, Rausch T, Azevedo N, Telzerow A, Jost KL, Schnitzler P, Kräusslich HG, Benes V.Data Brief. 2024 Jun 12;55:110607. doi: 10.1016/j.dib.2024.110607. eCollection 2024 Aug.PMID: 39006345

Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses.

Ou BS, Baillet J, Filsinger Interrante MV, Adamska JZ, Zhou X, Saouaf OM, Yan J, Klich JH, Jons CK, Meany EL, Valdez AS, Carter L, Pulendran B, King NP, Appel EA.Sci Adv. 2024 Aug 9;10(32):eadn7187. doi: 10.1126/sciadv.adn7187. Epub 2024 Aug 7.PMID: 39110802

Real-world effectiveness of the CoronaVac vaccine in a retrospective population-based cohort in four Colombian Cities 2021-2022.

Alberto RC, Patricia AM, Hugo B, Delia O, Catalina TA, Liliana LC, Doracelly HP, Maritza AA, Germán AR, Andrea AP, Liliana MI, David AL, Geraldine QM, Melanie SO, Daniela EL, Pablo R, Carlos AJ, Anthony GH, Sebastián R, Alberto CE.Int J Infect Dis. 2024 Aug 2:107156. doi: 10.1016/j.ijid.2024.107156. Online ahead of print.PMID: 39098742

Integrating youth participatory action research and health communication to inform youth and young adult covid-19 vaccine communication research.

Kikut-Stein A, Givan K, Fishman J, Blanco-Liz A, Alvarez-Sanchez D, Fletcher J, Gambrell R, Hernandez A, Richardson C, Shaw A, von Oiste JJ.Health Educ Res. 2024 Aug 8:cyae026. doi: 10.1093/her/cyae026. Online ahead of print.PMID: 39113324

Avian Influenza Virus A(H5Nx) and Prepandemic Candidate Vaccines: State of the Art.

Focosi D, Maggi F.Int J Mol Sci. 2024 Aug 5;25(15):8550. doi: 10.3390/ijms25158550.PMID: 39126117

HPV vaccine behaviors and intentions among a diverse sample of women aged 27-45 years: implications for shared clinical decision-making.

Allen JD, Abuelezam NN, Rose R, Isakoff K, Zimet G, Fontenot HB.BMC Public Health. 2024 Aug 8;24(1):2154. doi: 10.1186/s12889-024-18740-2.PMID: 39118089

COVID-19 Vaccine Hesitancy and Misinformation Endorsement among a Sample of Native Spanish-Speakers in the US: A Cross-Sectional Study.

Carosella EA, Su M, Testa MA, Arzilli G, Conni A, Savoia E.Healthcare (Basel). 2024 Aug 5;12(15):1545. doi: 10.3390/healthcare12151545.PMID: 39120248

Examining dental providers counseling on human papillomavirus vaccine: Insights from parents and dental professionals.

Barrientos L, Shortall S, Williams J, Hamilton S, Jack J.J Public Health Dent. 2024 Aug 8. doi: 10.1111/jphd.12637. Online ahead of print.PMID: 39117566

Susceptibility testing of the live attenuated tuberculosis vaccine BCG and the vaccine candidate MTBVAC to currently WHO-recommended anti-tuberculosis drugs by the European committee on antimicrobial susceptibility testing (EUCAST) method.

Rabodoarivelo MS, Gómez AB, Picó Marco A, Martín C, Ramón-García S.Clin Microbiol Infect. 2024 Aug;30(8):1080-1082. doi: 10.1016/j.cmi.2024.04.017. Epub 2024 May 7.PMID: 38723747

Risk compensation after COVID-19 vaccination: Evidence from vaccine rollout by exact birth date in South Korea.

Hwang J, Hwang SS, Kim HB, Lee J, Lee J.Health Econ. 2024 Aug;33(8):1811-1830. doi: 10.1002/hec.4837. Epub 2024 May 10.PMID: 38728372

Respecting Conversational Norms Improves Reception of Expert Messages Among Unvaccinated Individuals.

McCrea SM, Thürmer JL, Helm MR, Erion CJ, Krueger K.Health Commun. 2024 Aug;39(9):1795-1806. doi: 10.1080/10410236.2023.2243047. Epub 2023 Aug 2.PMID: 37528775

Skin exposure to soil microbiota elicits changes in cell-mediated immunity to pneumococcal vaccine.

Roslund MI, Nurminen N, Oikarinen S, Puhakka R, Grönroos M, Puustinen L, Kummola L, Parajuli A, Cinek O, Laitinen OH, Hyöty H, Sinkkonen A.Sci Rep. 2024 Aug 10;14(1):18573. doi: 10.1038/s41598-024-68235-8.PMID: 39127736

Influence and presumption of the vaccine against Covid-19 in South American families.

Cotrina Cabello GG, Livia Cristóbal LS, Pariona Cervantes DJ, Blanco Salcedo GA, Zevallos ML, Navarro LA, Cotrina NC, Guadalupe LE, Faustino CDB, Rojas Galluffi JC, Delgado MM, Huapaya Zavala FO, Buendia Quispe BF, Zenteno Ruiz FA, Alania Ricaldi PF, Areche FO, Alejos Patiño IW, Campos Félix U.Braz J Biol. 2024 Aug 5;84:e281199. doi: 10.1590/1519-6984.281199. eCollection 2024.PMID: 39109716

When evidence changes: Communicating uncertainty protects against a loss of trust.

Dries C, McDowell M, Rebitschek FG, Leuker C.Public Underst Sci. 2024 Aug;33(6):777-794. doi: 10.1177/09636625241228449. Epub 2024 Feb 27.PMID: 38414113

Understanding the influence of social media on COVID-19 vaccine acceptance in a war-torn Syria: A cross-sectional study.

Kahwaji A, Alaryan T, Alhelwani H, Salem M, Alsuliman T.Medicine (Baltimore). 2024 Aug 9;103(32):e38956. doi: 10.1097/MD.0000000000038956.PMID: 39121327

A novel high sensitive, specificity duplex enzyme-activated differentiating probes PCR method for the SNP detection and differentiation of MS-H vaccine strains from wild-type Mycoplasma synoviae strains.

Liu R, Lin Q, Cai Q, Liang Y, Xu X, Chen Q, Xu C, Liu H, Liao M, Zhang J.Poult Sci. 2024 Aug;103(8):103874. doi: 10.1016/j.psj.2024.103874. Epub 2024 May 16.PMID: 38833744

An unnatural amino acid dependent, conditional Pseudomonas vaccine prevents bacterial infection.

Pigula M, Lai YC, Koh M, Diercks CS, Rogers TF, Dik DA, Schultz PG.Nat Commun. 2024 Aug 8;15(1):6766. doi: 10.1038/s41467-024-50843-7.PMID: 39117651

The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.

Maytum A, Porter D, de Whalley P, Thompson A, Plested E, Kerridge S, Liu X, Smits G, van der Klis F, Snape MD, Clutterbuck E, Pollard AJ.Pediatr Infect Dis J. 2024 Aug 1;43(8):809-812. doi: 10.1097/INF.0000000000004373. Epub 2024 May 8.PMID: 38717982 Clinical Trial.

Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer.

Kono M, Wakisaka R, Komatsuda H, Hayashi R, Kumai T, Yamaki H, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Kobayashi H, Hayashi T, Takahara M.Head Neck. 2024 Aug;46(8):2056-2067. doi: 10.1002/hed.27703. Epub 2024 Feb 23.PMID: 38390628

Pec 1 of *Pseudomonas aeruginosa* Inhibits Bacterial Clearance of Host by Blocking Autophagy in Macrophages.

Jin X, Zhang C, Lin S, Gao T, Qian H, Qu L, Yao J, Du X, Feng G.ACS Infect Dis. 2024 Aug 9;10(8):2741-2754. doi: 10.1021/acsinfecdis.4c00096. Epub 2024 Jul 24.PMID: 39047963

Impact of the COVID-19 pandemic on self-paid vaccination intentions for children: a cross-sectional study in China.

Wang S, Xu J, Zhu J.BMJ Open. 2024 Aug 9;14(8):e083056. doi: 10.1136/bmjopen-2023-083056.PMID: 39122407

Influenza vaccine effectiveness in older adults: study methods, transparency and impacts on public health.

Nealon J, Biering-Sørensen T, Crépey P, Harris R, Schaberg T, Chit A.Int J Infect Dis. 2024 Aug;145:107103. doi: 10.1016/j.ijid.2024.107103. Epub 2024 Jun 5.PMID: 38871602

Re: Influenza vaccine effectiveness in older adults: Study methods, transparency and impacts on public health.

Domnich A; IT-BIVE-HOSP Network Study Group.Int J Infect Dis. 2024 Aug;145:107104. doi: 10.1016/j.ijid.2024.107104. Epub 2024 Jun 4.PMID: 38866690

Prioritising older individuals for COVID-19 booster vaccination leads to optimal public health outcomes in a range of socio-economic settings.

Bouros I, Hill EM, Keeling MJ, Moore S, Thompson RN.PLoS Comput Biol. 2024 Aug 8;20(8):e1012309. doi: 10.1371/journal.pcbi.1012309. eCollection 2024 Aug.PMID: 39116038

The emergent invasive serotype 4 ST10172 strain acquires vanG type vancomycin-resistance element: A case of a 66-year-old with bacteremic pneumococcal pneumonia.

Chochua S, Beall B, Lin W, Tran T, Rivers J, Li Z, Arvay ML, Kobayashi M, Houston J, Arias S, McGee L.J Infect Dis. 2024 Aug 8:jiae393. doi: 10.1093/infdis/jiae393. Online ahead of print.PMID: 39116351

Do national innovation projects shape citizens' public health behaviours?

Ansell B, Bauer MW, Gingrich J, Stilgoe J.Healthc Manage Forum. 2024 Aug 9:8404704241271159. doi: 10.1177/08404704241271159. Online ahead of print.PMID: 39120578

Vaccine effectiveness against anal HPV among men who have sex with men aged 18-45 years attending sexual health clinics in three United States cities, 2018-2023.

DeSisto CL, Winer RL, Querec TD, Dada D, Pathela P, Asbel L, Lin J, Tang J, Iqbal A, Meites E, Unger ER, Markowitz LE.J Infect Dis. 2024 Aug 8:jiae394. doi: 10.1093/infdis/jiae394. Online ahead of print.PMID: 39122662

Resolution of extensive plantar verruca vulgaris but not facial verruca plana following nonavalent human papillomavirus vaccine: A case report and literature review.

Lee KH, Jeong JH, Park CJ, Kim YS.J Dermatol. 2024 Aug;51(8):e279-e281. doi: 10.1111/1346-8138.17190. Epub 2024 Mar 12.PMID: 38469697

Delayed B-cell maturation and attenuated vaccine responses in infants exposed to B-cell depleting therapies in utero.

Soomann M, Prader S, Carlomagno R, Pachlopnik Schmid J, Trück J.J Allergy Clin Immunol Pract. 2024 Aug 8:S2213-2198(24)00823-7. doi: 10.1016/j.jaip.2024.08.007. Online ahead of print.PMID: 39127106

Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs.

Coelho CH, Marquez S, Nguemwo Tentokam BC, Berhe AD, Miura K, Rao VN, Long CA, Doumbo OK, Sagara I, Healy S, Kleinstein SH, Duffy PE.NPJ Vaccines. 2024 Aug 10;9(1):144. doi: 10.1038/s41541-024-00929-6.PMID: 39127706

Factors affecting the outcome of primary rabies vaccination in young cats.

Tasioudi KE, Papatheodorou D, Symeonidis F, Iliadou P, Kostoulas P, Gianniou M, Chondrokouki E, Mangana-Vougiouka O, Mylonakis ME.Comp Immunol Microbiol Infect Dis. 2024 Aug 2;112:102225. doi: 10.1016/j.cimid.2024.102225. Online ahead of print.PMID: 39116543

Homonymous hemianopia following yellow fever vaccination: a case of acute disseminated encephalomyelitis.

Hensel CA, Jackson JD.J Travel Med. 2024 Aug 10:taae108. doi: 10.1093/jtm/taae108. Online ahead of print.PMID: 39126372

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways.

Gagne M, Flynn BJ, Honeycutt CC, Flebbe DR, Andrew SF, Provost SJ, McCormick L, Van Ry A, McCarthy E, Todd JM, Bao S, Teng IT, Marciano S, Rudich Y, Li C, Jain S, Wali B, Pessaint L, Dodson A, Cook A, Lewis MG, Andersen H, Zahradník J, Suthar MS, Nason MC, Foulds KE, Kwong PD, Roederer M, Schreiber G, Seder RA, Douek DC.Nat Commun. 2024 Aug 12;15(1):6894. doi: 10.1038/s41467-024-51046-w.PMID: 39134521

The risk and risk factors of chikungunya virus infection and rheumatological sequelae in a cohort of U.S. Military Health System beneficiaries: Implications for the vaccine era.

Pollett S, Hsieh HC, Lu D, Grance M, Richard S, Nowak G, Lanteri C, Tribble D, Burgess T.PLoS Negl Trop Dis. 2024 Aug 5;18(8):e0011810. doi: 10.1371/journal.pntd.0011810. Online ahead of print.PMID: 39102422

Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases.

Teles MS, Brundage J, Chiang TP, Alejo JL, Henriquez N, Wallwork R, Christopher-Stine L, Massie A, Segev DL, Connolly CM, Paik JJ, Werbel WA.J Rheumatol. 2024 Aug 1:jrheum.2023-1212. doi: 10.3899/jrheum.2023-1212. Online ahead of print.PMID: 38950954

Effect of homophily on coupled behavior-disease dynamics near a tipping point.

He Z, Bauch CT.Math Biosci. 2024 Aug 2;376:109264. doi: 10.1016/j.mbs.2024.109264. Online ahead of print.PMID: 39097225

Experimental vaccination by single dose sporozoite injection of blood-stage attenuated malaria parasites.

Sattler JM, Keiber L, Abdelrahim A, Zheng X, Jäcklin M, Zechel L, Moreau CA, Steinbrück S, Fischer M, Janse CJ, Hoffmann A, Hentzschel F, Frischknecht F.EMBO Mol Med. 2024 Aug 5. doi: 10.1038/s44321-024-00101-6. Online ahead of print.PMID: 39103697

Structural Investigations of Cargo Molecules Inside Icosahedrally Symmetric Encapsulin by VUVCD Spectroscopic Measurements.

Kumamoto S, Yamamoto A, Shiratsuchi Y, Matsuo K, Higashiura A, Hira D.Chirality. 2024 Aug;36(8):e23700. doi: 10.1002/chir.23700.PMID: 39077830

Enhancing in situ cancer vaccines using delivery technologies.

Gong N, Alameh MG, El-Mayta R, Xue L, Weissman D, Mitchell MJ.Nat Rev Drug Discov. 2024 Aug;23(8):607-625. doi: 10.1038/s41573-024-00974-9. Epub 2024 Jul 1.PMID: 38951662

A genetically engineered neuronal membrane-based nanotoxoid elicits protective immunity against neurotoxins.

Guo Z, Zhu AT, Wei X, Jiang Y, Yu Y, Noh I, Gao W, Fang RH, Zhang L.Bioact Mater. 2024 May 9;38:321-330. doi: 10.1016/j.bioactmat.2024.05.006. eCollection 2024 Aug.PMID: 38764446

Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists.

Ami D, Franco AR, Artusa V, Romerio A, Shaik MM, Italia A, Anguita J, Pasco S, Mereghetti P, Peri F, Natalello A.Talanta. 2024 Aug 1;275:126104. doi: 10.1016/j.talanta.2024.126104. Epub 2024 Apr 17.PMID: 38677166

Mechanisms of antibody-dependent enhancement of infectious disease.

Wells TJ, Esposito T, Henderson IR, Labzin LI.Nat Rev Immunol. 2024 Aug 9. doi: 10.1038/s41577-024-01067-9. Online ahead of print.PMID: 39122820

Effect of human H3N2 influenza virus reassortment on influenza incidence and severity during the 2017-18 influenza season in the USA: a retrospective observational genomic analysis.

Liu H, Shaw-Saliba K, Westerbeck J, Jacobs D, Fenstermacher K, Chao CY, Gong YN, Powell H, Ma Z, Mehoke T, Ernlund AW, Dziedzic A, Vyas S, Evans J, Sauer LM, Wu CC, Chen SH, Rothman RE, Thielen P, Chen KF, Pekosz A.Lancet Microbe. 2024 Aug;5(8):100852. doi: 10.1016/S2666-5247(24)00067-3. Epub 2024 May 8.PMID: 38734029

Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study.

Meslé MMI, Brown J, Mook P, Katz MA, Hagan J, Pastore R, Benka B, Redlberger-Fritz M, Bossuyt N, Stouten V, Vernemmen C, Constantinou E, Maly M, Kynčl J, Sanca O, Krause TG, Vestergaard LS, Leino T, Poukka E, Gkolfinopoulou K, Mellou K, Tsintziloni M, Molnár Z, Aspelund G, Thordardottir M, Domegan L, Kelly E, O'Donell J, Urdiales AM, Riccardo F, Sacco C, Bumšteinas V, Liausediene R, Mossong J, Vergison A, Borg ML, Melillo T, Kocinski D, Pollozhani E, Meijerink H, Costa D, Gomes JP, Leite PP, Druc A, Gutu V, Mita V, Lazar M, Popescu R, Popovici O, Musilová M, Mrzel M, Socan M, Učakar V, Limia A, Mazagatos C, Olmedo C, Dabrera G, Kall M, Sinnathamby M, McGowan G, McMenamin J, Morrison K, Nitzan D, Widdowson MA, Smallwood C, Pebody R; WHO European Respiratory Surveillance Network.Lancet Respir Med. 2024 Aug 7:S2213-2600(24)00179-6. doi: 10.1016/S2213-2600(24)00179-6. Online ahead of print.PMID: 39127051

Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults.

Sun T, Li L, Mues KE, Georgieva MV, Kirk B, Mansi JA, Van de Velde N, Beck EC.Infect Dis Ther. 2024 Aug;13(8):1771-1787. doi: 10.1007/s40121-024-01005-1. Epub 2024 Jun 25.PMID: 38916690

Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity.

Amini A, Klenerman P, Provine NM.Curr Opin Virol. 2024 Aug;67:101412. doi: 10.1016/j.coviro.2024.101412. Epub 2024 Jun 4.PMID: 38838550

Fully human single-domain antibody targeting a highly conserved cryptic epitope on the Nipah virus G protein.

Wang Y, Sun Y, Shen Z, Wang C, Qian J, Mao Q, Wang Y, Song W, Kong Y, Zhan C, Chen Z, Dimitrov DS, Yang Z, Jiang S, Wu F, Lu L, Ying T, Sun L, Wu Y.Nat Commun. 2024 Aug 12;15(1):6892. doi: 10.1038/s41467-024-51066-6.PMID: 39134522

Exploring the complexity of the implementation determinants of human papillomavirus vaccination in Africa through a systems thinking lens: A rapid review.

Adamu AA, Jalo RI, Ndwandwe D, Wiysonge CS.Hum Vaccin Immunother. 2024 Dec 31;20(1):2381922. doi: 10.1080/21645515.2024.2381922. Epub 2024 Aug 7.PMID: 39113230

Differential pathogenicity and lethality of bubonic plague (1720-1945) by sex, age and place.

Mongillo J, Zedda N, Rinaldo N, Bellini T, Manfrinato MC, Du Z, Yang R, Stenseth NC, Bramanti B.Proc Biol Sci. 2024 Aug;291(2027):20240724. doi: 10.1098/rspb.2024.0724. Epub 2024 Jul 24.PMID: 39045692

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0.

Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Dehlawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S.Mol Cancer Ther. 2024 Aug 1;23(8):1139-1143. doi: 10.1158/1535-7163.MCT-23-0652.PMID: 38657233

Opportunities and challenges in design and optimization of protein function.

Listov D, Goverde CA, Correia BE, Fleishman SJ.Nat Rev Mol Cell Biol. 2024 Aug;25(8):639-653. doi: 10.1038/s41580-024-00718-y. Epub 2024 Apr 2.PMID: 38565617

Short, stringent lockdowns halted SARS-CoV-2 transmissions in Danish municipalities.

Ege F.Sci Rep. 2024 Aug 12;14(1):18712. doi: 10.1038/s41598-024-68929-z.PMID: 39134618

Pertussis vaccination in adults in France: Overview and suggestions for improvement.

Blanchard E, Chavade D, de Wazières B, Bakhache P, Fumet T, Guiso N.Infect Dis Now. 2024 Aug 2;54(6):104961. doi: 10.1016/j.idnow.2024.104961. Online ahead of print.PMID: 39098758

Engineering CaP-Pickering emulsion for enhanced mRNA cancer vaccines via dual DC and NK activations.

Wu S, Zhou Y, Asakawa N, Wen M, Sun Y, Ming Y, Song T, Chen W, Ma G, Xia Y.J Control Release. 2024 Aug 3;373:837-852. doi: 10.1016/j.jconrel.2024.07.051. Online ahead of print.PMID: 39059499

TSpred: a robust prediction framework for TCR-epitope interactions using paired chain TCR sequence data.

Kim HY, Kim S, Park WY, Kim D.Bioinformatics. 2024 Aug 2;40(8):btae472. doi: 10.1093/bioinformatics/btae472.PMID: 39052940

Development of the Pneumococcal Genome Library, a core genome multilocus sequence typing scheme, and a taxonomic life identification number barcoding system to investigate and define pneumococcal population structure.

Jansen van Rensburg MJ, Berger DJ, Yassine I, Shaw D, Fohrmann A, Bray JE, Jolley KA, Maiden MCJ, Brueggemann AB.Microb Genom. 2024 Aug;10(8). doi: 10.1099/mgen.0.001280.PMID: 39137139

DNA-terminus-dependent transcription by T7 RNA polymerase and its C-helix mutants.

Yu B, Chen Y, Yan Y, Lu X, Zhu B.Nucleic Acids Res. 2024 Aug 12;52(14):8443-8453. doi: 10.1093/nar/gkae593.PMID: 38979568

Use of corticosteroids for adult chronic pain interventions: sympathetic and peripheral nerve blocks, trigger point injections - guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, the American Society of Interventional Pain Physicians, the International Pain and Spine Intervention Society, and the North American Spine Society.

Benzon HT, Elmofty D, Shankar H, Rana M, Chadwick AL, Shah S, Souza D, Nagpal AS, Abdi S, Rafla C, Abd-Elsayed A, Doshi TL, Eckmann MS, Hoang TD, Hunt C, Pino CA, Rivera J, Schneider BJ, Stout A, Stengel A, Mina M, FitzGerald JD, Hirsch JA, Wasan AD, Manchikanti L, Provenzano DA, Narouze S, Cohen SP, Maus TP, Nelson AM, Shanthanna H.Reg Anesth Pain Med. 2024 Aug 7:rapm-2024-105593. doi: 10.1136/rapm-2024-105593. Online ahead of print.PMID: 39019502

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.

Satti I, Marshall JL, Harris SA, Wittenberg R, Tanner R, Lopez Ramon R, Wilkie M, Ramos Lopez F, Riste M, Wright D, Peralta Alvarez MP, Williams N, Morrison H, Stylianou E, Folegatti P, Jenkin D, Vermaak S, Rask L, Cabrera Puig I, Powell Doherty R, Lawrie A, Moss P, Hinks T, Bettinson H, McShane H.Lancet Infect Dis. 2024 Aug;24(8):909-921. doi: 10.1016/S1473-3099(24)00143-9. Epub 2024 Apr 12.PMID: 38621405

First detection of Cupriavidus gilardii in a bovine neonatal diarrhea outbreak.

Papageorgiou K, Stoikou A, Delis G, Giantsis IA, Stamelou E, Sofia M, Papadopoulos D, Panousis N, Palamidas P, Billinis C, Kritas SK, Petridou E.BMC Vet Res. 2024 Aug 6;20(1):345. doi: 10.1186/s12917-024-04197-3.PMID: 39103839

Evaluation of the protective efficacy of three novel identified membrane associated proteins of Streptococcus suis serotype 2.

Fan Q, Wang H, Wang Y, Yi L, Wang Y.Microb Pathog. 2024 Aug;193:106759. doi: 10.1016/j.micpath.2024.106759. Epub 2024 Jun 19.PMID: 38906494

Cell-wall-anchored proteins affect invasive host colonization and biofilm formation in Staphylococcus aureus.

Xu Z, Li Y, Xu A, Soteyome T, Yuan L, Ma Q, Seneviratne G, Li X, Liu J.Microbiol Res. 2024 Aug;285:127782. doi: 10.1016/j.micres.2024.127782. Epub 2024 May 27.PMID: 38833832

Whole-genome demography of COVID-19 virus during its pandemic period and on "panvalent" vaccine design.

Kim BJ, Choi J, Kim SH.Sci Rep. 2024 Aug 1;14(1):17752. doi: 10.1038/s41598-024-68432-5.PMID: 39085292

Altered epidemiological patterns of Respiratory Syncytial Virus and influenza detections in a tropical Australian setting 2020 to 2023.

Nixon JC, Freeman K, Baird RW.Aust N Z J Public Health. 2024 Aug;48(4):100172. doi: 10.1016/j.anzjph.2024.100172. Epub 2024 Jul 25.PMID: 39059095

Deciphering the Thermal Stability of Bacteriophage MS2-Derived Virus-like Particle and Its Engineered Variant.

Vishwakarma P, Puri S, Banerjee M, Chang CY, Chang CC, Chaudhuri TK.ACS Biomater Sci Eng. 2024 Aug 12;10(8):4812-4822. doi: 10.1021/acsbiomaterials.4c00770. Epub 2024 Jul 8.PMID: 38976823

Discovery of the rich diversity of Mesomycoplasma hyopneumoniae through high-throughput sequencing.

Yin Y, Jiang J, Hu Y, Chen Y, Wei Z, Chen H.Vet Microbiol. 2024 Aug 6;297:110213. doi: 10.1016/j.vetmic.2024.110213. Online ahead of print.PMID: 39116641

Uveitis following COVID-19 vaccination in the pediatric population: Experience at a tertiary referral hospital.

Alsalman B, AlBloushi AF, Alzuabi AK, Al Tawil L.J Fr Ophtalmol. 2024 Aug 5;47(8):104265. doi: 10.1016/j.jfo.2024.104265. Online ahead of print.PMID: 39106557

A Micronemal Protein, Scot1, Is Essential for Apicoplast Biogenesis and Liver Stage Development in *Plasmodium berghei*.

Ghosh A, Mishra A, Devi R, Narwal SK, Nirdosh, Srivastava PN, Mishra S.ACS Infect Dis. 2024 Aug 9;10(8):3013-3025. doi: 10.1021/acsinfecdis.4c00362. Epub 2024 Jul 22.PMID: 39037752

Probable extinction of influenza B/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases.

Caini S, Meijer A, Nunes MC, Henaff L, Zounon M, Boudewijns B, Del Riccio M, Paget J.Lancet Microbe. 2024 Aug;5(8):100851. doi: 10.1016/S2666-5247(24)00066-1. Epub 2024 May 7.PMID: 38729197

Search for novel *Plasmodium falciparum Pf*ATP4 inhibitors from the MMV Pandemic Response Box through a virtual screening approach.

Reghunandanan K, T P A, Krishnan N, K M D, Prasad R, Nelson-Sathi S, Chandramohanadas R.J Biomol Struct Dyn. 2024 Aug;42(12):6200-6211. doi: 10.1080/07391102.2023.2232459. Epub 2023 Jul 9.PMID: 37424150

Atypical and non-classical CD45RB^{lo} memory B cells are the majority of circulating SARS-CoV-2 specific B cells following mRNA vaccination or COVID-19.

Priest DG, Ebihara T, Tulyeu J, Søndergaard JN, Sakakibara S, Sugihara F, Nakao S, Togami Y, Yoshimura J, Ito H, Onishi S, Muratsu A, Mitsuyama Y, Ogura H, Oda J, Okusaki D, Matsumoto H, Wing JB.Nat Commun. 2024 Aug 9;15(1):6811. doi: 10.1038/s41467-024-50997-4.PMID: 39122676

Engineered bacterial membrane vesicle as safe and efficient nano-heaters to reprogram tumor microenvironment for enhanced immunotherapy.

Liu K, Du S, Yang J, Li J, Wang S, Zhang Z, Luo W, Chen C, Yang J, Han X.J Control Release. 2024 Aug 7:S0168-3659(24)00547-9. doi: 10.1016/j.jconrel.2024.08.008. Online ahead of print.PMID: 39122216

Macrophages directly kill bladder cancer cells through TNF signaling as an early response to BCG therapy.

Martínez-López MF, de Almeida CR, Fontes M, Mendes RV, Kaufmann SHE, Fior R.Dis Model Mech. 2024 Aug 1;17(8):dmm050693. doi: 10.1242/dmm.050693. Epub 2024 Aug 8.PMID: 39114912

Chitosan: An overview of biological activities, derivatives, properties, and current advancements in biomedical applications.

Edo GI, Yousif E, Al-Mashhadani MH.Carbohydr Res. 2024 Aug;542:109199. doi: 10.1016/j.carres.2024.109199. Epub 2024 Jun 27.PMID: 38944980

Global epidemiological comparison of Streptococcus pyogenes emm-types associated with pharyngitis and pharyngeal carriage.

de Crombrugghe G, Botteaux A, Osowicki J, Steer AC, Smeesters PR.Clin Microbiol Infect. 2024 Aug;30(8):1074.e1-1074.e4. doi: 10.1016/j.cmi.2024.05.007. Epub 2024 May 15.PMID: 38759867

Vaccination coverage of hepatitis B and associated factors among health care workers in Gansu province.

An J, Jin N, Xie J, Ma Y, Liu H, Balajiang G, Liu S, Zhang X.Hum Vaccin Immunother. 2024 Dec 31;20(1):2383509. doi: 10.1080/21645515.2024.2383509. Epub 2024 Aug 12.PMID: 39132758

National burden of Ebola virus disease in Democratic Republic of the Congo: the urgency to act.

Ahmad B, Sagide M, Ntamwinja S, Byiringiro E, Kihanduka E, Rugendabanga E, Hangi S, Bhattacharjee P, Ali B, Nkundakozera M, Kanda MS, Guruka L, Onesime J, Tague C, Langat AK, Akilimali A.Ann Med Surg (Lond). 2024 Jun 21;86(8):4579-4585. doi: 10.1097/MS9.0000000000002213. eCollection 2024 Aug.PMID: 39118744

Herpes zoster in neuro-ophthalmology: a practical approach.

Tao BK, Soor D, Micieli JA.Eye (Lond). 2024 Aug;38(12):2327-2336. doi: 10.1038/s41433-024-03030-3. Epub 2024 Mar 27.PMID: 38538778

Expression, Sarkosyl Solubilization, DNase Activity, Purification, and SPR Binding Affinity of Recombinant Diphtheria Toxoid (rCRM197EK) Expressed in Escherichia coli BL21(DE3).

Novianti MT, Subroto T, Efendi YS, Baroroh U, Kusumawardani S, Gumilar G, Yusuf M, Gaffar S.Mol Biotechnol. 2024 Aug 6. doi: 10.1007/s12033-024-01238-y. Online ahead of print.PMID: 39107502

A Missed Opportunity: Evaluating Immunization Status and Barriers in Hospitalized Children.

Lissinna B, Gilbert C, Isaac C, Mian Q, MacDonald SE, Forbes KL.Hosp Pediatr. 2024 Aug 5:e2024007728. doi: 10.1542/hpeds.2024-007728. Online ahead of print.PMID: 39099437

Diagnostic and prophylactic potential of a stabilized foot-and-mouth disease serotype Asia1 virus like particles designed through a structure guided approach.

Aparna M, Saravanan P, Dhanesh VV, Selvaraj DPR, Shreya G, Adwitiya D, Madhusudan H, Sreenivasa BP, Tamilselvan RP, Sanyal A, Goyal S, Thiyagarajan S, Chaudhuri P.Int J Biol Macromol. 2024 Aug 3;277(Pt 4):134366. doi: 10.1016/j.ijbiomac.2024.134366. Online ahead of print.PMID: 39098702

Deciphering structural variation upon biotinylation of biotin carboxyl carrier protein domain in Streptococcus pneumoniae.

Karalia S, Meena VK, Kumar V.Int J Biol Macromol. 2024 Aug;275(Pt 1):133580. doi: 10.1016/j.ijbiomac.2024.133580. Epub 2024 Jul 1.PMID: 38960227

Foals of mares vaccinated for Hendra virus have a suboptimal response to HeV vaccination.

Carey KJ, Smith I, Barr J, Caruso S, Au GG, Hartley CA, Bailey KE, Perriam W, Broder CC, Gilkerson JR.Vet Microbiol. 2024 Aug;295:110167. doi: 10.1016/j.vetmic.2024.110167. Epub 2024 Jun 27.PMID: 38954881

Meningitis caused by Aeromonas hydrophila in Oreochromis niloticus: Proteomics and druggability of virulence factors.

Fernandes DC, Eto SF, Baldassi AC, Balbuena TS, Charlie-Silva I, de Andrade Belo MA, Pizauro JM.Fish Shellfish Immunol. 2024 Aug;151:109687. doi: 10.1016/j.fsi.2024.109687. Epub 2024 Jun 10.PMID: 38866348

How common is otogenic meningitis? A retrospective study in southern Sweden over 18 years.

Bjar N, Hermansson A, Gisselsson-Solen M.Infection. 2024 Aug;52(4):1377-1384. doi: 10.1007/s15010-024-02195-z. Epub 2024 Feb 28.PMID: 38416397

Guarding the gatekeepers: a comprehensive approach to control nosocomial measles.

Limavady A, Tu IT, Bedford H.Infection. 2024 Aug;52(4):1195-1206. doi: 10.1007/s15010-024-02186-0. Epub 2024 Feb 14.PMID: 38353874

Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy.

Jahanafrooz Z, Oroojalian F, Mokhtarzadeh A, Rahdar A, Díez-Pascual AM.Drug Dev Res. 2024 Aug;85(5):e22244. doi: 10.1002/ddr.22244.PMID: 39138855

Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity.

Bathula NV, Friesen JJ, Casmil IC, Wayne CJ, Liao S, Soriano SKV, Ho CH, Strumpel A, Blakney AK.J Control Release. 2024 Aug 8;374:28-38. doi: 10.1016/j.jconrel.2024.07.078. Online ahead of print.PMID: 39097193

Gamma-Irradiated Female Aedes aegypti Mosquitoes Exhibit Greater Susceptibility to Mayaro Virus.

Trefry SV, Aldridge RL, Sprague TR, Lowen RG, Erasmus JH, Pitt ML, Hahn DA, Nasar F, Gibson S, Linthicum KJ.Am J Trop Med Hyg. 2024 Jun 25;111(2):421-428. doi: 10.4269/ajtmh.23-0515. Print 2024 Aug 7.PMID: 38917780

Laboratory diagnosis and treatment of *Mycoplasma pneumoniae* infection in children: a review.

Gao L, Sun Y.Ann Med. 2024 Dec;56(1):2386636. doi: 10.1080/07853890.2024.2386636. Epub 2024 Aug 3.PMID: 39097794

New-onset of giant cell arteritis with ischemic optic neuropathy following the seventh-dose of COVID-19 mRNA vaccination: A case report and literature review.

Ohmura SI, Yonezawa H, Yukishima T, Gohto Y, Obana A.Mod Rheumatol Case Rep. 2024 Aug 3:rxae042. doi: 10.1093/mrcr/rxae042. Online ahead of print.PMID: 39096515

Maternal GBS vaccination for preventing group B streptococcus disease in newborns: A mini review of current evidence.

Kokori E, Olatunji G, Komolafe R, Ogieuhi IJ, Oyebiyi B, Ajayi I, Muogbo I, Ukoaka B, Samuel O, Aderinto N.Int J Gynaecol Obstet. 2024 Aug;166(2):639-643. doi: 10.1002/ijgo.15465. Epub 2024 Mar 6.PMID: 38445529

Immunoinformatic approaches for ErpY-LemA chimeric protein design for use in leptospirosis control.

Ávila-Martínez EG, Cardoso TL, Pereira IL, Caballero PS, Wozeak DR, Neto ACPS, Pinto LDS, Hartwig DD.J Appl Microbiol. 2024 Aug 5;135(8):lxae179. doi: 10.1093/jambio/lxae179.PMID: 39020252

Looking beyond vaccines: Cultural tightness-looseness moderates the relationship between immunization coverage and disease prevention vigilance.

Ma MZ, Chen SX, Wang X.Appl Psychol Health Well Being. 2024 Aug;16(3):1046-1072. doi: 10.1111/aphw.12519. Epub 2023 Dec 17.PMID: 38105555

BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial.

Messina NL, Pittet LF, McDonald E, Moore C, Barry S, Bonten M, Byrne A, Campbell J, Croda J, Croda MG, Dalcolmo M, de Almeida E Val FF, de Oliveira RD, Dos Santos G, Douglas MW, Gardiner K, Gwee A, Jardim BA, Kollmann T, Lacerda MV, Lucas M, Lynn DJ, Manning L, Marshall H, O'Connell A, Perrett KP, Post JJ, Prat-Aymerich C, Rocha JL, Rodriguez-Baño J, Wadia U, Warris A, Davidson A, Curtis N; BRACE Trial Consortium Group.J Infect. 2024 Aug 8:106245. doi: 10.1016/j.jinf.2024.106245. Online ahead of print.PMID: 39127450

Poria cocos polysaccharide-loaded Alum Pickering emulsion as vaccine adjuvant to enhance immune responses.

Gu P, Zhu Y, Xu P, Zhao Q, Zhao X, Zhao K, Wang X, Zhang W, Bao Y, Shi W.Colloids Surf B Biointerfaces. 2024 Aug 6;244:114144. doi: 10.1016/j.colsurfb.2024.114144. Online ahead of print.PMID: 39116600

The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2.

Guenthoer J, Garrett ME, Lilly M, Depierreux DM, Ruiz F, Chi M, Stoddard CI, Chohan V, Yaffe ZA, Sung K, Ralph D, Chu HY, Matsen FA 4th, Overbaugh J.PLoS Pathog. 2024 Aug 2;20(8):e1012383. doi: 10.1371/journal.ppat.1012383. Online ahead of print.PMID: 39093891

Analysis of the recombination and evolution of the new type mutant pseudorabies virus XJ5 in China.

Jiang L, Cheng J, Pan H, Yang F, Zhu X, Wu J, Pan H, Yan P, Zhou J, Gao Q, Huan C, Gao S.BMC Genomics. 2024 Aug 1;25(1):752. doi: 10.1186/s12864-024-10664-w.PMID: 39090561

Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade.

Jin C, Zhang Y, Li B, Gao T, Wang B, Hua P.Mater Today Bio. 2024 Jun 22;27:101136. doi: 10.1016/j.mtbio.2024.101136. eCollection 2024 Aug.PMID: 39015802

Investigation on the Epidemic Situation of Epidemic Hemorrhagic Fever in an Island Industrial Park in Zhoushan, China.

Tan Q, Shu J, Ye L, Zhang S, Wang Z, Zhang T, Li S, Mao Z.Vector Borne Zoonotic Dis. 2024 Aug;24(8):546-551. doi: 10.1089/vbz.2023.0131. Epub 2024 Jun 13.PMID: 38868950

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Lim YJ, Ward V, Brown A, Phillips E, Kronsteiner B, Malone T, Jennings D, Healy S, Longet S, James T, Thomson P, Farrell L, Oates M, Jackson R, Morrison A, Burns M, Carroll M, Klenerman P, Turtle L, Naisbitt D, Rhodes M, Robinson K, Gatto S, Young M, Linton K, Eyre TA, Eyre DW, Dunachie S, Barnes E, Pettitt A.Br J Haematol. 2024 Aug;205(2):440-451. doi: 10.1111/bjh.19562. Epub 2024 Jun 13.PMID: 38867615 Clinical Trial.

A lightweight xAI approach to cervical cancer classification.

Civit-Masot J, Luna-Perejon F, Muñoz-Saavedra L, Domínguez-Morales M, Civit A.Med Biol Eng Comput. 2024 Aug;62(8):2281-2304. doi: 10.1007/s11517-024-03063-6. Epub 2024 Mar 20.PMID: 38507122

COVID-19 hospitalisations in a tertiary health service during the Omicron subvariant wave.

Wanigaratne AY, Baptista M, Langham F, Stripp A, Stuart RL.Aust N Z J Public Health. 2024 Aug;48(4):100170. doi: 10.1016/j.anzjph.2024.100170. Epub 2024 Jul 29.PMID: 39079228

Restoring immune balance with Tregitopes: A new approach to treating immunological disorders.

Javidan M, Amiri AM, Koohi N, Joudaki N, Bashirrohelleh MA, Pirsadeghi A, Biregani AF, Rashno M, Dehcheshmeh MG, Sharifat M, Khodadadi A, Mafakher L.Biomed Pharmacother. 2024 Aug;177:116983. doi: 10.1016/j.biopha.2024.116983. Epub 2024 Jun 21.PMID: 38908205

Evaluation of the immunoprotective power of a multiple antigenic peptide against Aah II toxin of *Androctonus australis hector* scorpion.

Benazzouz SM, Benlouahmia N, Bouhadida K, Benlamara M, Arezki N, Sadeddine OEK, Issad M, Attal N, Mansouri K, Derrar F, Djidjik R.Vaccine X. 2024 May 25;19:100503. doi: 10.1016/j.jvacx.2024.100503. eCollection 2024 Aug.PMID: 38868522

Insertion and Anchoring of HIV-1 Fusion Peptide into Complex Membrane Mimicking Human T-cell.

Zhao M, Lopes LJS, Sahni H, Yadav A, Do HN, Reddy T, López CA, Neale C, Gnanakaran S.bioRxiv [Preprint]. 2024 Aug 4:2024.08.02.606381. doi: 10.1101/2024.08.02.606381.PMID: 39131401

The current therapeutic cancer vaccines landscape in non-small cell lung cancer.

Chen S, Cheng S, Cai J, Liu Z, Li H, Wang P, Li Y, Yang F, Chen K, Qiu M.Int J Cancer. 2024 Aug 7. doi: 10.1002/ijc.35088. Online ahead of print.PMID: 39109825

Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023).

Pérez-García C, Sempere J, de Miguel S, Hita S, Úbeda A, Vidal EJ, Llorente J, Limia A, de Miguel AG, Sanz JC, Martinón-Torres F, Ardanuy C, Domenech M, Yuste J.J Infect. 2024 Aug;89(2):106204. doi: 10.1016/j.jinf.2024.106204. Epub 2024 Jun 19.PMID: 38906265

Development of quantum dot-based immunochromatographic strip for detection of antibodies against ASFV pp62.

Zhou J, Yu W, Zhu X, Liu H, Liu D, Wang A, Zhang G.Int J Biol Macromol. 2024 Aug 9:134559. doi: 10.1016/j.ijbiomac.2024.134559. Online ahead of print.PMID: 39128749

Improving estimation efficiency of case-cohort studies with interval-censored failure time data.

Zhou Q, Wong KY.Stat Methods Med Res. 2024 Aug 6:9622802241268601. doi: 10.1177/09622802241268601. Online ahead of print.PMID: 39105419

The nuts and bolts of recombination in the generation of SARS-CoV-2 variants; from XA to XBB.

Karim B, Barary M, Fereydouni Z, Sanjari E, Hosseinzadeh R, Salehi-Vaziri M, Maleki A.Lett Appl Microbiol. 2024 Aug 5;77(8):ovae074. doi: 10.1093/lambio/ovae074.PMID: 39081071

Dynamic clade transitions and the influence of vaccination on the spatiotemporal circulation of SARS-CoV-2 variants.

Banho CA, de Carvalho Marques B, Sacchetto L, Lima AKS, Parra MCP, Lima ARJ, Ribeiro G, Martins AJ, Barros CRDS, Elias MC, Sampaio SC, Slavov SN, Rodrigues ES, Santos EV, Covas DT, Kashima S, Brassaloti RA, Petry B, Clemente LG, Coutinho LL, Assato PA, da Silva da Costa FA, Grotto RMT, Poleti MD, Lesbon JCC, Mattos EC, Fukumasu H, Giovanetti M, Alcantara LCJ, Souza-Neto JA, Rahal P, Araújo JP Jr, Spilki FR, Althouse BM, Vasilakis N, Nogueira ML.NPJ Vaccines. 2024 Aug 10;9(1):145. doi: 10.1038/s41541-024-00933-w.PMID: 39127725

Identification of two novel B cell epitopes on E184L protein of African swine fever virus using monoclonal antibodies.

Tesfagaber W, Lan D, Wang W, Zhao R, Yin L, Yang M, Zhu Y, Sun E, Liu R, Lin W, Bu Z, Li F, Zhao D.Virus Res. 2024 Aug;346:199412. doi: 10.1016/j.virusres.2024.199412. Epub 2024 Jun 11.PMID: 38838820

Construction and validation of a risk model of proteinuria in patients with omicron COVID-19: retrospective cohort study.

Teng L, Chang G, Song X, Zhang M, Han Y, Chang W, Shen Z.Ren Fail. 2024 Dec;46(2):2365979. doi: 10.1080/0886022X.2024.2365979. Epub 2024 Aug 6.PMID: 39108141

Retrospective Analysis of Dog Bite Injuries in Children with Autism Spectrum Disorder.

Mazur LE, Even KM, Krawiec C.J Autism Dev Disord. 2024 Aug 8. doi: 10.1007/s10803-024-06510-3. Online ahead of print.PMID: 39115742

Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015-April 2024.

Tohme RA, Shadaker S, Adamia E, Khonelidze I, Stvilia K, Getia V, Tsereteli M, Alkhazashvili M, Abutidze A, Butsashvili M, Gogia M, Glass N, Surguladze S, Schumacher IT, Gabunia T.MMWR Morb Mortal Wkly Rep. 2024 Aug 1;73(30):660-666. doi: 10.15585/mmwr.mm7330a1.PMID: 39088368

Transcriptome analysis of Vero cells infected with attenuated vaccine strain CDV-QN-1.

Chang X, Su H, Ma S, Li Y, Tan Y, Li Y, Dong S, Lin J, Zhou B, Zhang H.Microb Pathog. 2024 Aug;193:106786. doi: 10.1016/j.micpath.2024.106786. Epub 2024 Jul 5.PMID: 38971506

Brain -cyst-driven genes expression in Toxoplasma Gondii Tehran strain: a parasitic-immunogenicity assessment by dint of RNA-Seq.

Asadi M, Babaei Z, Afgar A, Banabazi MH, ZiaAli N, Daryani A, Aghajani E, Mahdavi M, Attari M, Zarrinkar F.Vet Res Commun. 2024 Aug;48(4):2563-2581. doi: 10.1007/s11259-023-10241-8. Epub 2024 Jun 25.PMID: 38916691

Impact of booster vaccination interval on SARS-CoV-2 infection, hospitalization, and death.

Lin DY, Xu Y, Gu Y, Sunny SK, Moore Z, Zeng D.Int J Infect Dis. 2024 Aug;145:107084. doi: 10.1016/j.ijid.2024.107084. Epub 2024 May 3.PMID: 38705567

Bactericidal human monoclonal antibody 1B1 shows specificity for meningococcal factor H binding protein variant 2 and displaces human factor H.

Veggi D, Chesterman CC, Santini L, Huang Y, Pacchiani N, Sierra J, Chen L, Laliberte J, Bianchi F, Cozzi R, Frigimelica E, Maione D, Finco O, Bottomley MJ.FASEB Bioadv. 2024 Jun 27;6(8):235-248. doi: 10.1096/fba.2023-00077. eCollection 2024 Aug.PMID: 39114449

Antigen-driven Convergent Evolution of Polysaccharide-specific "DH-less" B Cells in Glycoconjugate Immunized Mice.

Kushwaha S, Shome P, Sehgal D.Immunohorizons. 2024 Aug 1;8(8):511-526. doi: 10.4049/immunohorizons.2400055.PMID: 39093310

Detection and characterization of Brucella species in rodents: A threat for the persistence of brucellosis in livestock farms.

Dadar M, Alamian S.Res Vet Sci. 2024 Aug;176:105339. doi: 10.1016/j.rvsc.2024.105339. Epub 2024 Jun 18.PMID: 38941712

Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer.

Zucca LER, Laus AC, Sorroche BP, Paro E, Sussuchi L, Marques RF, Teixeira GR, Berardinelli GN, Arantes LMRB, Reis RM, Cárcano FM.Transl Oncol. 2024 Aug;46:102003. doi: 10.1016/j.tranon.2024.102003. Epub 2024 Jun 4.PMID: 38838438

Systematic Review: Safety and Efficacy of mRNA COVID-19 Vaccines in Pregnant Women.

Lam JN, Nehira J, Phung O, Deng B.J Pharm Pract. 2024 Aug;37(4):967-976. doi: 10.1177/08971900231196065. Epub 2023 Aug 22.PMID: 37605626

Prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction.

Hebert KJ, Matta R, Horns JJ, Paudel N, Das R, McCormick BJ, Myers JB, Hotaling JM.Int J Impot Res. 2024 Aug;36(5):521-525. doi: 10.1038/s41443-023-00687-4. Epub 2023 Mar 15.PMID: 36922696

Development of two recombinant vaccines against Clostridioides difficile infection and immunogenicity in pregnant sows and neonatal piglets.

Ramos CP, Siqueira WF, Viana LA, Cunha JLR, Fujiwara RT, Amarante VS, Souza TGV, Silva ROS.Anaerobe. 2024 Aug 8;89:102896. doi: 10.1016/j.anaerobe.2024.102896. Online ahead of print.PMID: 39127403

Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy.

Acúrcio RC, Kleiner R, Vaskovich-Koubi D, Carreira B, Liubomirski Y, Palma C, Yeheskel A, Yeini E, Viana AS, Ferreira V, Araújo C, Mor M, Freund NT, Bacharach E, Gonçalves J, Toister-Achituv M, Fabregue M, Matthieu S, Guerry C, Zarubica A, Aviel-Ronen S, Florindo HF, Satchi-Fainaro R.Adv Sci (Weinh). 2024 Aug 8:e2404159. doi: 10.1002/advs.202404159. Online ahead of print.PMID: 39116324

Newly developed peptide-ELISA successfully detected anti-IgG antibodies against Maedi-Visna virus in sheep.

Koçkaya ES, Can H, Yaman Y, Kandemir Ç, Taşkın T, Karakavuk M, Değirmenci Döşkaya A, Döşkaya M, Pehlivan E, Şireli HD, Gürüz AY, Ün C.Vet Immunol Immunopathol. 2024 Aug;274:110806. doi: 10.1016/j.vetimm.2024.110806. Epub 2024 Jul 10.PMID: 39002364

Identification of B-cell epitope on the N protein of type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using monoclonal antibody and construction of epitope-mutated virus.

Liu J, Wang X, Ren T, Qin J, Qin Y, Ouyang K, Chen Y, Huang W, Wei Z.Virology. 2024 Aug;596:110102. doi: 10.1016/j.virol.2024.110102. Epub 2024 May 10.PMID: 38749084

Targeting gut microbiota for immunotherapy of diseases.

Yu YJ, Liu XD, Liao C, Yu R, Wang X, Li M, Wang Y.Arch Toxicol. 2024 Aug;98(8):2429-2439. doi: 10.1007/s00204-024-03770-x. Epub 2024 May 9.PMID: 38722348

Meningococcal meningitis in Spain in the Horizon 2030: A position paper.

Moraga-Llop F, Andradas E, Blesa-Baviera LC, Cantón R, González Del Castillo J, Martinón-Torres F, Moya E, Trilla A, Vazquez J, Villena RJ, Ruiz-Galiana J, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Bouza E.Rev Esp Quimioter. 2024 Aug;37(4):285-298. doi: 10.37201/req/023.2024. Epub 2024 Mar 22.PMID: 38515374

Feasibility Study for the Use of Gene Electrotransfer and Cell Electrofusion as a Single-Step Technique for the Generation of Activated Cancer Cell Vaccines.

Ušaj M, Pavlin M, Kandušer M.J Membr Biol. 2024 Aug 12. doi: 10.1007/s00232-024-00320-5. Online ahead of print.PMID: 39133276

Impact of pre-existing cross-reactive antibodies on cyclic dengue outbreaks in the hyperendemic region of Bali, Indonesia.

Balingit JC, Denis D, Suzuki R, Hayati RF, Ngwe Tun MM, Takamatsu Y, Masyeni S, Sasmono RT, Morita K.Virus Res. 2024 Aug 2;348:199445. doi: 10.1016/j.virusres.2024.199445. Online ahead of print.PMID: 39089369

Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.

Albertini MR, Zuleger CL, Ranheim EA, Shiyanbola O, Sondel PM, Morris ZS, Eickhoff J, Newton MA, Ong IM, Schwartz RW, Hayim R, Kurzman ID, Turek M, Vail DM.Melanoma Res. 2024 Aug 1;34(4):307-318. doi: 10.1097/CMR.0000000000000975. Epub 2024 May 20.PMID: 38768442

The evaluation of cystatin protein vaccines based on the stress response of ticks triggered by low-temperature and toxin stress in Haemaphysalis doenitzi.

Zhang SB, Gao ZH, Wang YK, Lv WX, Dong KX, Guo FD, Wang RY, Yang XL.Pest Manag Sci. 2024 Aug;80(8):3957-3966. doi: 10.1002/ps.8099. Epub 2024 Apr 8.PMID: 38521986

A Dynamic Prognostic Model for Identifying Vulnerable COVID-19 Patients at High Risk of Rapid Deterioration.

Anand P, D'Andrea E, Feldman W, Wang SV, Liu J, Brill G, DiCesare E, Lin KJ.Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5872. doi: 10.1002/pds.5872.PMID: 39135513

Molecular epidemiology of infectious bronchitis virus in eastern and southern China during 2021-2023.

Meng X, Zhang J, Wan Z, Li T, Xie Q, Qin A, Shao H, Zhang H, Ye J.Poult Sci. 2024 Aug;103(8):103939. doi: 10.1016/j.psj.2024.103939. Epub 2024 Jun 6.PMID: 38909507

The experience of pregnant women and their families who were infected with covid-19 before vaccination: A qualitative approach within a multicenter study in Brazil.

Soeiro RE, Souza RT, Bento SF, Cecatti JG, Surita FG, Freitas-Jesus JV, Pacagnella RC, Ribeiro-Do-Valle CC, Luz AG, Lajos GJ, Nobrega GM, Griggio TB, Charles CM, Silveira C, Miele MJ, Tedesco RP, Fernandes KG, Martins-Costa SH, Peret FJ, Feitosa FE, Traina E, Cunha Filho EV, Vettorazzi J, Haddad SM, Andreucci CB, Guida JP, Correa Junior MD, Dias MA, Oliveira LG, Melo Junior EF, Luz MGD, Costa ML; REBRACO Study Group.Midwifery. 2024 Aug;135:104018. doi: 10.1016/j.midw.2024.104018. Epub 2024 Apr 23.PMID: 38729000

Active vitamin D analog and SARS-CoV-2 IgG after BNT162b2 vaccination in patients with hemodialysis.

Nakashima A, Yamamoto I, Kobayashi A, Kimura K, Yaginuma T, Nishio S, Kato K, Kawai R, Horino T, Ohkido I, Yokoo T.Ther Apher Dial. 2024 Aug;28(4):599-607. doi: 10.1111/1744-9987.14121. Epub 2024 Mar 19.PMID: 38504452

A case of hypophysitis after COVID-19 vaccination with a detection of anti-pituitary antibody, with review of literature.

Kyo C, Kobayashi T, Iwama S, Kosugi R, Sawabe F, Hayafusa R, Sakai Y, Ogawa T, Kotani M, Inoue T, Arima H, Ariyasu H.Endocr J. 2024 Aug 8;71(8):799-807. doi: 10.1507/endocrj.EJ24-0061. Epub 2024 May 3.PMID: 38710620

Analysis of seasonal H3N2 influenza virus epidemic characteristics and whole genome features in Jining City from 2018 to 2023.

Jiang Y, Dou H, Wang X, Song T, Jia Y, Yue Y, Li L, He F, Kong L, Wu Z, Huang X, Liang Y, Jiao B, Jiao B.J Med Virol. 2024 Aug;96(8):e29846. doi: 10.1002/jmv.29846.PMID: 39138641

Saudi Arabia's Middle East respiratory syndrome Coronavirus (MERS-CoV) outbreak: consequences, reactions, and takeaways.

Salomon I.Ann Med Surg (Lond). 2024 Jul 1;86(8):4668-4674. doi: 10.1097/MS9.0000000000002336. eCollection 2024 Aug.PMID: 39118758

Evaluation of longitudinal passive immunity transfer against lumpy skin disease virus in calves by different serological methods.

Samojlović M, Petrović T, Polaček V, Lupulović D, Lazić G, Rogan D, Lazić S.Vet Res Commun. 2024 Aug;48(4):2797-2804. doi: 10.1007/s11259-024-10421-0. Epub 2024 May 23.PMID: 38780823

Tartrolon D induces immunogenic cell death in melanoma.

Brito TL, Edson EA, Dias Florêncio KG, Machado-Neto JA, Garnique ADMB, Mesquita Luiz JP, Cunha FQ, Alves-Filho JC, Haygood M, Wilke DV.Chem Biol Interact. 2024 Aug 2;400:111177. doi: 10.1016/j.cbi.2024.111177. Online ahead of print.PMID: 39097071

Measles in Czech population with varying vaccination rates in 2018-2019: clinical and laboratory differences between vaccinated and unvaccinated individuals and their relevance to clinical practice.

Smíšková D, Janovic S, Kadeřávková P, Nováková L, Blechová Z, Malý M, Limberková R.Infect Dis (Lond). 2024 Aug;56(8):616-623. doi: 10.1080/23744235.2024.2339870. Epub 2024 Apr 13.PMID: 38613412

Validation of a phenotyping method to identify PRRSV-resilient sows and its impact on sow stayability.

Fraile L, Vidal A, Romero J, Abella G, Gracia J, Blanco-Penedo I, Pena RN.J Anim Sci. 2024 Aug 12:skae232. doi: 10.1093/jas/skae232. Online ahead of print.PMID: 39132682

Characteristics of Sleep Disturbance and Comparison Across Three Waves of the COVID-19 Pandemic Among Healthcare Workers.

Li DJ, Huang JJ, Hsu ST, Hsieh KY, Lin GG, Wu PJ, Liu CL, Wu HC, Chou FH.Psychiatry Investig. 2024 Aug;21(8):838-849. doi: 10.30773/pi.2024.0006. Epub 2024 Aug 8.PMID: 39111749

COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of Rituximab.

Ammitzbøll C, Thomsen MK, Bartels LE, Hansen CB, Hermansen MF, Hänel M, Klose-Jensen R, Larsen ML, Lauritsen MO, Mistegaard CE, Mikkelsen S, Olesen JBM, Næser EU, Nielsen MA, Erikstrup C, Garred P,

Hauge EM, Troldborg A.ACR Open Rheumatol. 2024 Aug;6(8):519-528. doi: 10.1002/acr2.11681. Epub 2024 Jun 23.PMID: 38923834

Incidence of laboratory-confirmed influenza and RSV and associated presenteeism and absenteeism among healthcare personnel, Israel, influenza seasons 2016 to 2019.

Azziz-Baumgartner E, Hirsch A, Yoo YM, Peretz A, Greenberg D, Avni YS, Glatman-Freedman A, Mandelboim M, MacNeil A, Martin ET, Newes-Adeyi G, Thompson M, Monto AS, Balicer RD, Levine MZ, Katz MA.Euro Surveill. 2024 Aug;29(31):2300580. doi: 10.2807/1560-7917.ES.2024.29.31.2300580.PMID: 39092531

An architecture for COVID-19 analysis and detection using big data, AI, and data architectures.

Alghamdi AM, Al Shehri WA, Almalki J, Jannah N, Alsubaei FS.PLoS One. 2024 Aug 1;19(8):e0305483. doi: 10.1371/journal.pone.0305483. eCollection 2024.PMID: 39088543

Pediatric tuberculosis in Mexico: A retrospective analysis of 100 patients.

Villarreal EG, Ramos-Barrera E, Estrada-Mendizabal RJ, Treviño-Valdez PD, Tamez-Rivera O.J Clin Tuberc Other Mycobact Dis. 2024 Apr 19;36:100441. doi: 10.1016/j.jctube.2024.100441. eCollection 2024 Aug.PMID: 38699149

Role of biomarkers and molecular signaling pathways in acute lung injury.

Niri P, Saha A, Polopalli S, Kumar M, Das S, Chattopadhyay P.Fundam Clin Pharmacol. 2024 Aug;38(4):640-657. doi: 10.1111/fcp.12987. Epub 2024 Jan 26.PMID: 38279523

Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19 pandemic was not associated with significant serotype changes.

Silva-Costa C, Gomes-Silva J, Pinho M, Friães A, Subtil-Limpo F, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections and the Portuguese Study Group of Invasive Pneumococcal Disease of the Pediatric Infectious Disease Society.J Infect. 2024 Aug 6;89(4):106242. doi: 10.1016/j.jinf.2024.106242. Online ahead of print.PMID: 39116949

Harnessing Children's Picture Books to Socialize Children About Pain and Injury: A Qualitative Study.

Wallwork SB, Nichols S, Jordan A, Noel M, Madden VJ, Lorimer Moseley G.J Pain. 2024 Aug;25(8):104520. doi: 10.1016/j.jpain.2024.03.016. Epub 2024 Apr 3.PMID: 38580100

Natural and hybrid immunity after SARS-CoV-2 infection in children and adolescents.

Rothoeft T, Maier C, Talarico A, Hoffmann A, Schlegtendal A, Lange B, Petersmann A, Denz R, Timmesfeld N, Toepfner N, Vidal-Blanco E, Pfaender S, Lücke T, Brinkmann F.Infection. 2024 Aug;52(4):1449-1458. doi: 10.1007/s15010-024-02225-w. Epub 2024 Mar 18.PMID: 38499828

Exploring the implementation of an educational film within antenatal care to reduce the risk of cytomegalovirus infection in pregnancy: A qualitative study.

Vandrevala T, Montague A, Boulton R, Coxon K, Jones CE.BMC Pregnancy Childbirth. 2024 Aug 10;24(1):524. doi: 10.1186/s12884-024-06715-5.PMID: 39127657

A cost benefit analysis of varicella vaccination in South Korea.

Lee YH, Choe YJ.Vaccine X. 2024 Jul 4;19:100521. doi: 10.1016/j.jvacx.2024.100521. eCollection 2024 Aug.PMID: 39070929

Aluminum oxyhydroxide-Poly(I:C) combination adjuvant with balanced immunostimulatory potentials for prophylactic vaccines.

Yao Z, Liang Z, Li M, Wang H, Ma Y, Guo Y, Chen C, Xue C, Sun B.J Control Release. 2024 Aug;372:482-493. doi: 10.1016/j.jconrel.2024.06.054. Epub 2024 Jun 27.PMID: 38914205

Trends in invasive Haemophilus influenzae serotype b (Hib) disease in England; 2012/13 to 2022/23.

Hani E, Abdullahi F, Bertran M, Eletu S, D'Aeth J, Litt DJ, Fry NK, Ladhani SN.J Infect. 2024 Aug 10:106247. doi: 10.1016/j.jinf.2024.106247. Online ahead of print.PMID: 39134211

Risk of healthcare visits from influenza in subjects with diabetes and impacts of early vaccination.

Horswell R, Chu S, Stone AE, Fort D, Uwaifo G, Fonseca VA, Norton EB.BMJ Open Diabetes Res Care. 2024 Aug 6;12(4):e003841. doi: 10.1136/bmjdrc-2023-003841.PMID: 39107077

A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.

Zhuang H, Tang C, Lin H, Zhang Z, Chen X, Wang W, Wang Q, Tan W, Yang L, Xie Z, Wang B, Chen B, Shang C, Chen Y.Cell Oncol (Dordr). 2024 Aug;47(4):1205-1220. doi: 10.1007/s13402-024-00921-1. Epub 2024 Feb 5.PMID: 38315287

Retrospective, Real Life Study on the Effectiveness and Safety of a Depigmented-Polymerized Subcutaneous Vaccine Containing a Mixture of Grasses and Olea europaea.

Pérez Montero A, Sanz-Rosa D, Carnés J.Int Arch Allergy Immunol. 2024 Aug 1:1-8. doi: 10.1159/000540280. Online ahead of print.PMID: 39089230

Best Practices and Lessons Learned From the Public Health Disability Specialists Program: Addressing the Needs of People With Disabilities During COVID-19.

Cree RA, Wray A, Evans A, Lyons S, Burrous H, Nilz M, Clarke C, Li J, Baio J.J Public Health Manag Pract. 2024 Aug 1. doi: 10.1097/PHH.0000000000001958. Online ahead of print.PMID: 39088586

Hepatitis B infection and immunity in migrant children and pregnant persons in Europe: a systematic review and meta-analysis.

Hobart C, Pescarini JM, Evans L, Adil HS, Adil ST, Deal A, Carter J, Matthews PC, Hargreaves S, Sanchez Clemente N.J Travel Med. 2024 Aug 3;31(6):taae094. doi: 10.1093/jtm/taae094.PMID: 38990201

Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates Between 2012 and 2023: Results From an Open Italian Cohort.

Lucente MF, Raccagni AR, Galli L, Lolatto R, Ranzenigo M, Ripa M, Ponta G, Monardo R, Gona F, Clementi N, Burioni R, Carletti S, Castagna A, Nozza S.Sex Transm Dis. 2024 Aug 1;51(8):540-544. doi: 10.1097/OLQ.0000000000001981. Epub 2024 Apr 17.PMID: 38647240

CD4⁺ and CD8⁺ T-cell multi-epitope chimeric protein associated with an MPLA adjuvant induce protective efficacy and long-term immunological memory for the immunoprophylaxis of American Tegumentary Leishmaniasis.

Moura DM, Carvalho AMRS, Brito RCF, Roatt BM, Lage DP, Martins VT, Cruz LDR, Medeiros FAC, Batista SD, Pinheiro GRG, da Costa Rocha MO, Coelho EAF, Duarte MC, Mendes TAO, Menezes-Souza D.Vaccine. 2024 Aug 2;42(21):126178. doi: 10.1016/j.vaccine.2024.126178. Online ahead of print.PMID: 39096765

Assessment of expanded programme on immunization routine data quality in the upper east region of Ghana.

Piu LJ, Owusu-Marfo J, Agyeman YN, Kolekang AS, Kissi J.BMC Health Serv Res. 2024 Aug 2;24(1):886. doi: 10.1186/s12913-024-11347-8.PMID: 39095772

Resurgence of common respiratory viruses in patients with community-acquired pneumonia (CAP)-A prospective multicenter study.

Dähne T, Bauer W, Essig A, Schaaf B, Barten-Neiner G, Spinner CD, Pletz MW, Rohde G, Rupp J, Witzenrath M, Panning M; Members of the CAPNETZ study group.J Clin Virol. 2024 Aug;173:105694. doi: 10.1016/j.jcv.2024.105694. Epub 2024 May 22.PMID: 38781632

Excess mortality in COVID-19-affected solid organ transplant recipients across the pandemic.

Yamanaga S, Shimata K, Ohfuji S, Yoshikawa M, Natori Y, Hibi T, Yuzawa K, Egawa H; Japan Society for Transplantation COVID-19 Registry Study Group.Am J Transplant. 2024 Aug;24(8):1495-1508. doi: 10.1016/j.ajt.2024.03.016. Epub 2024 Mar 20.PMID: 38514016

Toward better pandemic governance and preparedness: South Korea's whole-of-nation approach to COVID-19.

Hong SA.BMC Public Health. 2024 Aug 6;24(1):2126. doi: 10.1186/s12889-024-19655-8.PMID: 39107756

Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil.

Luna EJA, Moraes JC, Roediger MA, Miranda EJFP, Braga PE, França JID, Pacheco PHM, de Lima MA, Ragiotto L, Barros ENC; CoronaVac Effectiveness Study Group.Braz J Infect Dis. 2024 Aug 5:103856. doi: 10.1016/j.bjid.2024.103856. Online ahead of print.PMID: 39117300

Effect of active immunization with OPN5 on follicular development and egg production in quail under different photoperiods.

Zhou X, Jiang D, Zhang Z, Shen X, Pan J, Ouyang H, Xu D, Tian Y, Huang Y.Theriogenology. 2024 Aug 5;228:81-92. doi: 10.1016/j.theriogenology.2024.08.005. Online ahead of print.PMID: 39116655

Activation of Antiviral Host Responses against Avian Influenza Virus and Remodeling of Gut Microbiota by rLAB Vector Expressing rIL-17A in Chickens.

Bhowmick S, Gupta S, Mondal S, Mallick AI.ACS Infect Dis. 2024 Aug 9;10(8):3026-3041. doi: 10.1021/acsinfecdis.4c00377. Epub 2024 Jul 6.PMID: 38970488

A mathematical fractal-fractional model to control tuberculosis prevalence with sensitivity, stability, and simulation under feasible circumstances.

Farman M, Shehzad A, Nisar KS, Hincal E, Akgul A.Comput Biol Med. 2024 Aug;178:108756. doi: 10.1016/j.compbiomed.2024.108756. Epub 2024 Jun 19.PMID: 38901190

The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer.

Hsu WH, Shiau BW, Tsai YW, Wu JY, Huang PY, Chuang MH, Liu TH, Lai CC, Weng TC.J Infect Public Health. 2024 Aug;17(8):102465. doi: 10.1016/j.jiph.2024.05.053. Epub 2024 May 31.PMID: 38878678

Arginine vasopressin deficiency onset after COVID-19 vaccination with positive anti-rabphilin-3A antibodies: a case report and literature review.

Takizawa H, Goto H, Uchida T, Aoyama S, Fujisawa H, Iwata N, Suzuki A, Sugimura Y, Watada H.BMC Endocr Disord. 2024 Aug 6;24(1):143. doi: 10.1186/s12902-024-01664-8.PMID: 39107738

Knowledge of HPV vaccination and associated HNC and treatment decision-making among minority populations.

Lin ME, Ayo-Ajibola O, Davis R, Gallagher TJ, Castellanos CX, West JD, Nurimba M, Kokot NC, Chambers T.Am J Otolaryngol. 2024 Aug 3;45(6):104458. doi: 10.1016/j.amjoto.2024.104458. Online ahead of print.PMID: 39116721

The Epidemiologic and Clinical Features of Radiographic-Confirmed Community-Acquired Pneumonia Among Chinese Children: A Retrospective Hospital-Based Study.

Li Y, Liu C, Shi T, Sheng M, Chen Q, Zhu J, He N, Zhao G, Tian J, Zhang T.Pediatr Infect Dis J. 2024 Aug 5. doi: 10.1097/INF.0000000000004509. Online ahead of print.PMID: 39105527

Evaluation of a Pharmacist-Led COVID-19 Vaccination Program in a Hospital Setting.

John LL, Armbrust S, Haller IV, Renier CM, Brown A, Monson E.J Pharm Pract. 2024 Aug;37(4):895-899. doi: 10.1177/08971900231189355. Epub 2023 Aug 19.PMID: 37597002

Rabies control in Bangladesh and prediction of human rabies cases by 2030: a One Health approach.

Ghosh S, Hasan MN, Nath ND, Haider N, Jones DH, Islam MK, Rahaman MM, Mursalin HS, Mahmud N, Kamruzzaman M, Rabby MF, Kar S, Ullah SM, Ali Shah MR, Jahan AA, Rana MS, Chowdhury S, Uddin MJ, Sunil TS, Ahmed BN, Siddiqui UR, Kaisar SMG, Islam MN.Lancet Reg Health Southeast Asia. 2024 Jul 23;27:100452. doi: 10.1016/j.lansea.2024.100452. eCollection 2024 Aug.PMID: 39140082

The impact of butyrate on group B *Streptococcus*-induced intestinal barrier disruption.

Dominguez K, Pearah AN, Lindon AK, Worthington L-AM, Carter RR, John-Lewis Edwards N, Ho TTB, Darch SE, Randis TM.Infect Immun. 2024 Aug 12:e0020024. doi: 10.1128/iai.00200-24. Online ahead of print.PMID: 39133019

Cefoperazone targets D-alanyl-D-alanine carboxypeptidase (DAC) to control *Morganella morganii*-mediated infection: a subtractive genomic and molecular dynamics approach.

Ahmad V, Jamal A, Khan MI, Alzahrani FA, Albiheyri R, Jamal QMS.J Biomol Struct Dyn. 2024 Aug;42(13):6799-6812. doi: 10.1080/07391102.2023.2238088. Epub 2023 Jul 22.PMID: 37480259

COVID-19 deaths in dental occupations and other healthcare occupations among U.S. decedents in 2020.

Blackley BH, Fechter-Leggett ED, Alexander T, Panagakos F, Chipps T, Cox-Ganser JM.Am J Ind Med. 2024 Aug 9. doi: 10.1002/ajim.23645. Online ahead of print.PMID: 39119790

SARS-CoV-2 transmission in a highly vulnerable population of Brazil: a household cohort study.

Coelho LE, Luz PM, Pires DC, Jalil EM, Perazzo H, Torres TS, Cardoso SW, Peixoto EM, Nazer S, Massad E, Carvalho LM, Réquia WJ, Motta FC, Siqueira MM, Vasconcelos ATR, da Fonseca GC, Cavalcante LTF, Costa CAM, Amancio RT, Villela DAM, Pereira T, Goedert GT, Santos CVBD, Rodrigues NCP, Bormann de Souza Filho BA, Csillag D, Grinsztejn B, Veloso VG, Struchiner CJ.Lancet Reg Health Am. 2024 Jun 18;36:100824. doi: 10.1016/j.lana.2024.100824. eCollection 2024 Aug.PMID: 38993539

Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.

Chen PK, Chang SH, Chen YM, Chen HH, Huang PH, Huang CC, Yeo KJ, Lan JL, Chen DY.Clin Rheumatol. 2024 Aug;43(8):2503-2511. doi: 10.1007/s10067-024-07041-z. Epub 2024 Jul 2.PMID: 38954278

Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.

Spiliopoulos L, Sørensen AIV, Bager P, Nielsen NM, Hansen JV, Koch A, Meder IK, Videbech P, Ethelberg S, Hviid A.Am J Epidemiol. 2024 Aug 5;193(8):1106-1114. doi: 10.1093/aje/kwad225.PMID: 37981717

Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2.

Saikh KU, Anam K, Sultana H, Ahmed R, Kumar S, Srinivasan S, Ahmed H.Int J Mol Sci. 2024 Aug 1;25(15):8421. doi: 10.3390/ijms25158421.PMID: 39125989

Disparities in hepatitis B virus healthcare service access among marginalised poor populations: a mixed-method systematic review.

Li C, Thapa D, Mi Q, Gao Y, Fu X.Infect Dis Poverty. 2024 Aug 9;13(1):58. doi: 10.1186/s40249-024-01225-0.PMID: 39123232

Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD).

Round J, Kirwin E, van Katwyk S, McCabe C.Pharmacoeconomics. 2024 Aug 7. doi: 10.1007/s40273-024-01401-y. Online ahead of print.PMID: 39110389

Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV.

Gupta A, Righi E, Konnova A, Sciammarella C, Spiteri G, Van Averbeke V, Berkell M, Hotterbeekx A, Sartor A, Mirandola M, Malhotra-Kumar S, Azzini AM, Pezzani D, Monaco MGL, Vanham G, Porru S, Tacconelli E, Kumar-Singh S.J Med Virol. 2024 Aug;96(8):e29820. doi: 10.1002/jmv.29820.PMID: 39056205

Inactivation of Avian Influenza Virus Inoculated into Ground Beef Patties Cooked on a Commercial Open-Flame Gas Grill.

Luchansky JB, Porto-Fett ACS, Suarez DL, Spackman E.J Food Prot. 2024 Aug;87(8):100325. doi: 10.1016/j.jfp.2024.100325. Epub 2024 Jul 2.PMID: 38964610

Orthopedic Surgery Volume Trends During the COVID-19 Pandemic and Postvaccination Era: Implications for Healthcare Planning.

Ghoshal S, Stovall N, King AH, Miller AS, Harris MB, Succi MD.J Arthroplasty. 2024 Aug;39(8):1959-1966.e1. doi: 10.1016/j.arth.2024.03.028. Epub 2024 Mar 19.PMID: 38513749

Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.

Song XD, Yang GJ, Shi C, Jiang XL, Wang XJ, Zhang YW, Wu J, Zhao LX, Wang MM, Chen RR, He XJ, Dai EH, Shen Y, Gao HX, Dong G, Ma MJ.Int J Infect Dis. 2024 Aug 6:107198. doi: 10.1016/j.ijid.2024.107198. Online ahead of print.PMID: 39117174

SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database.

Takada K, Taguchi K, Samura M, Igarashi Y, Okamoto Y, Enoki Y, Tanikawa K, Matsumoto K.J Infect Chemother. 2024 Aug 3:S1341-321X(24)00209-5. doi: 10.1016/j.jiac.2024.07.025. Online ahead of print.PMID: 39103148

A health equity science approach to assessing drivers of COVID-19 vaccination coverage disparities over the course of the COVID-19 pandemic, United States, December 2020-December 2022.

Woolfork MN, Haire K, Farinu O, Ruffin J, Nelson JM, Coronado F, Silk BJ, Harris L, Walker C, Manns BJ.Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158. Online ahead of print.PMID: 39095277

Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project.

Spiteri G, D'Agostini M, Abedini M, Ditano G, Collatuzzo G, Boffetta P, Vimercati L, Sansone E, De Palma G, Modenese A, Gobba F, Liviero F, Moretto A, dell'Omo M, Fiordi T, Larese Filon F, Mauro M, Violán C, Mates D, Oravec Bérešová J, Monaco MGL, Carta A, Verlato G, Porru S.Infection. 2024 Aug;52(4):1347-1356. doi: 10.1007/s15010-024-02189-x. Epub 2024 Feb 7.PMID: 38326526

Seroprevalence of anti-diphtheria toxoid antibody and implications for vaccination policy in Vietnam's South-central coast: a cross-sectional study.

Le HT, Do TH, Dao TA, Hoang TT, Nguyen BT, Le TL, Nguyen DL, Yoshida LM, Le XH, Le HQ, Ton TT, Ha MJ.BMC Infect Dis. 2024 Aug 12;24(1):813. doi: 10.1186/s12879-024-09688-0.PMID: 39134980

Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity.

Runnstrom MC, Lamothe PA, Faliti CE, Cheedarla N, Moreno A, Suthar MS, Nahata R, Ravindran M, Haddad NS, Morrison-Porter A, Quehl H, Ramonell RP, Woodruff M, Anam F, Zhang R, Swenson C, Polito C, Neveu W, Patel R, Smirnova N, Nguyen DC, Kim C, Hentenaar I, Kyu S, Usman S, Ngo T, Guo Z, Wu H, Daiss JL, Park J, Manning KE, Wali B, Ellis ML, Sharma S, Holguin F, Cheedarla S, Neish AS, Roback JD, Sanz I, Eun-Hyung Lee F.J Allergy Clin Immunol. 2024 Aug;154(2):435-446. doi: 10.1016/j.jaci.2024.03.029. Epub 2024 Jun 13.PMID: 38878020

An Analysis of the Knowledge Among Midwifery Students at Medical University-Pleven Regarding Human Papillomavirus (HPV) and HPV-Associated Diseases.

Petkova EY, Kamburova MS, Mineva-Dimitrova EN.Cureus. 2024 Aug 5;16(8):e66154. doi: 10.7759/cureus.66154. eCollection 2024 Aug.PMID: 39105201

Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China.

Jiang M, Zhang H, Yao X, Wang Y, Lai X, Fang H.Vaccine. 2024 Aug 1:126150. doi: 10.1016/j.vaccine.2024.07.051. Online ahead of print.PMID: 39095276

Factors affecting the intention to use COVID-19 contact tracing application "StaySafe PH": Integrating protection motivation theory, UTAUT2, and system usability theory.

Ong AKS, Prasetyo YT, Tapiceria RPKM, Nadlifatin R, Gumasing MJJ.PLoS One. 2024 Aug 1;19(8):e0306701. doi: 10.1371/journal.pone.0306701. eCollection 2024.PMID: 39088508

Factors associated with acceleration of clinical development for infectious diseases: a cross-sectional analysis of 10-year EMA registration data.

de Jong HK, Hermans SM, Schuitenmaker SM, Oli M, van den Hoven MA, Grobusch MP.Lancet Reg Health Eur. 2024 Jun 24;43:100983. doi: 10.1016/j.lanepe.2024.100983. eCollection 2024 Aug.PMID: 39027897

De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.

Gudesblatt M, Bumstead B, Buhse M, Zarif M, Morrow SA, Nicholas JA, Hancock LM, Wilken J, Weller J, Scott N, Gocke A, Lewin JB, Kaczmarek O, Mendoza JP, Golan D.Adv Ther. 2024 Aug;41(8):3059-3075. doi: 10.1007/s12325-024-02902-0. Epub 2024 Jun 11.PMID: 38861218

Severe acute respiratory syndrome coronavirus 2 infection in hematopoietic stem cell transplant recipients in Mexico City.

Martinez-Rivera N, Franco D, Acosta-Maldonado BL, Alatorre-Fernandez P, Islas-Muñoz B, Perez-Jimenez C, Martin-Onraet A.Transpl Infect Dis. 2024 Aug;26(4):e14274. doi: 10.1111/tid.14274. Epub 2024 Apr 4.PMID: 38576133

Patients With Inflammatory Bowel Disease Are at Increased Risk of Hospitalization Due to Respiratory Syncytial Virus.

Smith RA, Desai A, Barnes EL, Hayney M, Kochhar GS, Hashash JG, Farraye FA, Caldera F.Am J Gastroenterol. 2024 Aug 1;119(8):1545-1554. doi: 10.14309/ajg.0000000000002682. Epub 2024 Feb 6.PMID: 38318981

Treatment and management of coenurosis by Taenia multiceps: field data from outbreaks in endemic regions and literature review.

Abbas I, Tamponi C, Madau G, Cavallo L, Varcasia A, Scala A.Parasit Vectors. 2024 Aug 9;17(1):335. doi: 10.1186/s13071-024-06430-2.PMID: 39123250

Uncommon high distribution of HPV-16, HPV-54, and HPV-56 in female referred to a laboratory in Karaj, Iran: indications of a paradigm shift in HPV genotypes?

Letafati A, Motlaghzadeh S, Ardekani OS, Memarpour B, Seyedi S, Bahari M, Farahani AV, Khoshravan A, Sarrafzadeh S, Vasmehjani AA, Pournaseri M, Bahrami Y, Talebi F.Virol J. 2024 Aug 9;21(1):182. doi: 10.1186/s12985-024-02457-0.PMID: 39123176

Metabolites profiling and cheminformatics bioprospection of selected medicinal plants against the main protease and RNA-dependent RNA polymerase of SARS-CoV-2.

Lanrewaju AA, Enitan-Folami AM, Nyaga MM, Sabiu S, Swalaha FM.J Biomol Struct Dyn. 2024 Aug;42(13):6740-6760. doi: 10.1080/07391102.2023.2236718. Epub 2023 Jul 18.PMID: 37464870

Potential antivirulence and antibiofilm activities of sub-MIC of oxacillin against MDR S. aureus isolates: an in-vitro and in-vivo study.

Omar A, El-Banna TE, Sonbol FI, El-Bouseary MM.BMC Microbiol. 2024 Aug 9;24(1):295. doi: 10.1186/s12866-024-03429-8.PMID: 39123138

Factors associated with SARS-CoV-2 infection among people living with HIV: Data from the Balearic cohort (EVHIA).

Artigues Serra F, Pinecki Socias S, Fanjul FJ, Peñaranda M, Homar F, Sorni P, Serra J, Rey A, Ventayol L, Macia MD, Ribas MÀ, Riera M.PLoS One. 2024 Aug 7;19(8):e0308568. doi: 10.1371/journal.pone.0308568. eCollection 2024.PMID: 39110761

Gender transformative innovation: Women's inclusion in livestock vaccine systems in northern Ghana.

Njiru N, Galiè A, Omondi I, Omia D, Loriba A, Awin P.Agric Syst. 2024 Aug;219:104023. doi: 10.1016/j.agsy.2024.104023.PMID: 39113677

Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study.

Lapadula G, Mezzadri L, Lo Cascio G, Antolini L, Malandrin S, Ranzani A, Limonta S, Cavallero A, Bonfanti P.Infection. 2024 Aug;52(4):1499-1509. doi: 10.1007/s15010-024-02250-9. Epub 2024 Apr 23.PMID: 38652224

Survival of Critically Ill COVID-19 Patients in Sweden During the First Two and a Half Years of the Pandemic.

Santosa A, Oras J, Li H, Nwaru C, Kirui B, Nyberg F.Crit Care Med. 2024 Aug 1;52(8):1194-1205. doi: 10.1097/CCM.0000000000006271. Epub 2024 Mar 28.PMID: 38546287

Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals.

Quek AML, Wang S, Teng O, Shunmuganathan B, Er BGC, Mahmud NFB, Ng IXQ, Gupta R, Tan ISL, Tan NY, Qian X, Purushotorman K, Teoh HL, Ng KWP, Goh Y, Soon DTL, Tay SH, Teng GG, Ma M, Chandran NS, Hartono JL, MacAry PA, Seet RCS.J Infect. 2024 Aug 7:106238. doi: 10.1016/j.jinf.2024.106238. Online ahead of print.PMID: 39121971

Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.

Wan EYF, Wong ZCT, Yan VKC, Chui CSL, Lai FTT, Li X, Wong ICK, Chan EWY.Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15830. Online ahead of print.PMID: 39109461

Cyclization increases bactericidal activity of arginine-rich cationic cell-penetrating peptide for *Neisseria gonorrhoeae*.

John CM, Otala SA, Jarvis GA.Microbiol Spectr. 2024 Aug 6:e0099724. doi: 10.1128/spectrum.00997-24. Online ahead of print.PMID: 39105587

Impact of COVID-19 monoclonal antibodies on outcomes of COVID-19 infection in hematopoietic stem cell transplant and chimeric antigen receptor therapy recipients.

Hahn EH, Li H, Sauter CS, Mossad SB.Transpl Infect Dis. 2024 Aug;26(4):e14322. doi: 10.1111/tid.14322. Epub 2024 Jun 27.PMID: 38937864

Anti-Spike IgG antibodies as correlates of protection against SARS-CoV-2 infection in the pre-Omicron and Omicron era.

Seekircher L, Astl M, Tschiderer L, Wachter GA, Penz J, Pfeifer B, Huber A, Afonso PM, Gaber M, Schennach H, Siller A, Willeit P.J Med Virol. 2024 Aug;96(8):e29839. doi: 10.1002/jmv.29839.PMID: 39105391

Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: A study using data from the UK Biobank.

Xiang Y, Feng Y, Qiu J, Zhang R, So HC.Int J Infect Dis. 2024 Aug;145:107080. doi: 10.1016/j.ijid.2024.107080. Epub 2024 May 2.PMID: 38701913

Factors associated with the uptake of COVID-19 vaccination, testing and medical care among Myanmar migrants in Japan: a cross-sectional study.

Thandar MM, Iwamoto A, Hoshino HA, Sudo K, Fujii M, Kanda M, Ikeda S, Fujita M.Trop Med Health. 2024 Aug 6;52(1):53. doi: 10.1186/s41182-024-00621-4.PMID: 39107852

Prevalence and factors associated with hepatitis B susceptibility among men who sex with men on HIV pre-exposure prophylaxis in Northeastern Brazil: a cross-sectional study.

Vechi HT, de Freitas CHS, de Lira Nunes Paulino F, de Moura MGM, de Sant'anna JGFC, Bay MB, de Lima KC.BMC Infect Dis. 2024 Aug 8;24(1):795. doi: 10.1186/s12879-024-09698-y.PMID: 39118019

Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021.

Kao S-YZ, Nycz E, Benoit TJ, Clarke KEN, Jones JM.Microbiol Spectr. 2024 Aug 6;12(8):e0012324. doi: 10.1128/spectrum.00123-24. Epub 2024 Jun 13.PMID: 38869287

Total cost of care of Medicare Advantage beneficiaries participating in an appointment-based model in a national pharmacy chain.

Luder H, Lawrence J, Musich S, Friderici J, Andrade K, Reed C, Ren J, Halpern R.J Manag Care Spec Pharm. 2024 Aug;30(8):782-791. doi: 10.18553/jmcp.2024.30.8.782.PMID: 39088333

A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).

Michael A, Wilson W, Sunshine S, Annels N, Harrop R, Blount D, Pandha H, Lord R, Ngai Y, Nicum S, Stylianou L, Gwyther S, McNeish IA, Hackshaw A, Ledermann J.Int J Gynecol Cancer. 2024 Aug 5;34(8):1225-1231. doi: 10.1136/ijgc-2023-005200.PMID: 38760075 Clinical Trial.

Enteric coronavirus nsp2 is a virulence determinant that recruits NBR1 for autophagic targeting of TBK1 to diminish the innate immune response.

Jiao Y, Zhao P, Xu LD, Yu JQ, Cai HL, Zhang C, Tong C, Yang YL, Xu P, Sun Q, Chen N, Wang B, Huang YW.Autophagy. 2024 Aug;20(8):1762-1779. doi: 10.1080/15548627.2024.2340420. Epub 2024 Apr 16.PMID: 38597182

Pneumococcal vaccination, but not influenza vaccination, is negatively associated with incident dementia among Japanese older adults: The JAGES 2013-2022 prospective cohort study.

Iwai-Saito K, Sato K, Fujii M, Kondo K.Brain Behav Immun. 2024 Aug;120:452-463. doi: 10.1016/j.bbi.2024.06.020. Epub 2024 Jun 24.PMID: 38925416 Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people.

Taylor K, Eastwood S, Walker V, Cezard G, Knight R, Al Arab M, Wei Y, Horne EMF, Teece L, Forbes H, Walker A, Fisher L, Massey J, Hopcroft LEM, Palmer T, Cuitun Coronado J, Ip S, Davy S, Dillingham I, Morton C, Greaves F, Macleod J, Goldacre B, Wood A, Chaturvedi N, Sterne JAC, Denholm R; Longitudinal Health and Wellbeing and Data and Connectivity UK COVID-19 National Core Studies; CONVALESCENCE study; OpenSAFELY collaborative.Lancet Diabetes Endocrinol. 2024 Aug;12(8):558-568. doi: 10.1016/S2213-8587(24)00159-1.PMID: 39054034

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([01.08.2024 TO 12.08.2024]) *as the publication date 52 records.*

1.4410304ANTIKREBSIMPFSTOFFZUSAMMENSETZUNG MIT PEPTIDEN AUS TUMORASSOZIIERTEM ANTIGEN UND ADJUVANS AUS LIPOPEPTID UND IMMUNAKTIVEM STOFF SOWIE VERWENDUNG DAVON

EP - 07.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 22873232Solicitante CHA VACCINE RES INSTITUTE CO LTDInventor/a YUM JUNG SUN

The present invention pertains to: an anti-cancer vaccine composition comprising [peptides derived from a tumor-associated antigen (TAA)] and [an adjuvant consisting of a lipopeptide and an immunoactive substance]; and a use thereof. Specifically, the peptides derived from a tumor-associated antigen specifically bind to a human leukocyte antigen (HLA), a combination of the peptides having the above characteristics is mixed with the adjuvant in an optimal ratio to prepare a vaccine composition, and the vaccine composition is used for preventing or treating cancer.

2.4410305IMPFSTOFFZUSAMMENSETZUNG GEGEN KREBS MIT HSP90-ANTIGENPEPTID UND VERWENDUNG DAVON

EP - 07.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 22876850Solicitante ASTON SCI INCInventor/a KANG JIN HO

The present disclosure relates to an anticancer vaccine composition including a peptide of SEQ ID NO: 1 and a peptide of SEQ ID NO: 2, which are epitopes of HSP90, and the vaccine composition according to the present disclosure may effectively inhibit the growth of tumors in an animal model of tumor cell line transplantation without severe adverse effects, and thus may be useful for treating cancer or preventing cancer recurrence.

3.4408483COVID19-MRNA-IMPFSTOFF

EP - 07.08.2024

Clasificación Internacional A61K 48/00Nº de solicitud 22877397Solicitante UNIV TEXASInventor/a HU HAITAO

A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein (S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and/or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N/mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.

4.WO/2024/161361MODIFIED BCG VACCINE

WO - 08.08.2024

Clasificación Internacional A61K 39/04Nº de solicitud PCT/IB2024/050966Solicitante UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventor/a KANA, Bavesh Davandra

The present invention relates to a recombinant Mycobacterium bovis BCG strain comprising a plasmid having a short guide RNA (sgRNA) target sequence for knockdown of the Mb3739 gene. Also provided are vaccine compositions for eliciting an immune response against Mycobacterium tuberculosis comprising the recombinant Mycobacterium bovis BCG strain engineered to activate the NOD-1 pathway. The recombinant Mycobacterium bovis BCG strain or the vaccine compositions may be useful in methods of eliciting an immune response against Mycobacterium tuberculosis. The invention also relates to methods of obtaining the recombinant Mycobacterium bovis BCG strain.

5.202402613 87RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE

US - 08.08.2024

Clasificación Internacional A61K 39/155Nº de solicitud 18394486Solicitante Vernagen, LLCInventor/a Baek KIM

Provided herein are a respiratory syncytial virus (RSV) vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding RSV mutant F B strain protein, and optionally a mRNA including an ORF encoding RSV mutant F A strain protein, and a method of inducing immune response against RSV by administering an effective amount of the RSV vaccine composition to a subject in need thereof. Provided herein are also a respiratory syncytial virus (RSV) and human metapneumovirus virus (hMPV) vaccine composition including a mRNA including an ORF encoding RSV mutant F A strain protein, a mRNA including an ORF encoding RSV mutant F B strain protein, and a mRNA including an ORF encoding hMPV F protein, and a method of inducing immune response against RSV and hMPV by administering an effective amount of the RSV and hMPV vaccine composition to a subject in need thereof.

6.WO/2024/163092RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE

WO - 08.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2023/085663Solicitante VERNAGEN, LLCInventor/a KIM, Baek

Provided herein are a respiratory syncytial virus (RSV) vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding RSV mutant F B strain protein, and optionally a mRNA including an ORF encoding RSV mutant F A strain protein, and a method of inducing immune response against RSV by administering an effective amount of the RSV vaccine composition to a subject in need thereof. Provided herein are also a respiratory syncytial virus (RSV) and human metapneumovirus virus (hMPV) vaccine composition including a mRNA including an ORF encoding RSV mutant F A strain protein, a mRNA including an ORF encoding RSV mutant F B strain protein, and a mRNA including an ORF encoding hMPV F protein, and a method of inducing immune response against RSV and hMPV by administering an effective amount of the RSV and hMPV vaccine composition to a subject in need thereof.

7.WO/2024/156912ANTI-ABETA VACCINE THERAPY

WO - 02.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud PCT/EP2024/052002Solicitante AC IMMUNE SAInventor/a STREFFER, Johannes

A liposomal vaccine composition comprising a !-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of Aβ, a peptide comprising a universal T-cell epitope and an adjuvant comprising monophosphoryl lipid A (MPLA) is used for inducing an anti-Aβ immune response in a human subject without inducing a serious adverse event. The !-amyloid (Aβ)-derived peptide antigen (SEQ ID NO: 1) is administered in an amount of 300-2000 µg. The liposomal vaccine composition is administered intramuscularly or subcutaneously.

8.WO/2024/163918MRNA VACCINE FOR HERPES SIMPLEX VIRUS

WO - 08.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2024/014282Solicitante UNIVERSITY OF HOUSTON SYSTEMInventor/a ZHANG, Shaun

This invention relates to an mRNA-based vaccine composition for strains of herpes simplex virus (HSV), such as herpes simplex virus-2 (HSV-2). The mRNA vaccine composition comprises a combination of herpesvirus glycoprotein D (gD) and gB-pf mRNA, either alone or in combination with gE and/or gC mRNA.

9.202402526 06PHOSPHORYLATED POLYPEPTIDE ANTIGEN VACCINE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

US - 01.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 17059665Solicitante CHANGCHUN BCHT BIOTECHNOLOGY CO.Inventor/a Wei KONG

The present invention discloses a phosphorylated polypeptide antigen vaccine, comprising at least two polypeptide fragments or conservatively modified variants thereof from human full-length Tau protein, wherein the polypeptide fragments or conservatively modified variants thereof contain phosphorylation sites. The present invention also discloses a complex vaccine formed by coupling a phosphorylated polypeptide antigen vaccine with a carrier. The polypeptide antigen vaccine and the complex vaccine can be used for preventing and/or treating tauopathy comprising Alzheimer's disease (AD).

10.20240261398ADJUVANT AND VACCINE CONTAINING ADJUVANT

US - 08.08.2024

Clasificación Internacional A61K 39/39Nº de solicitud 18634012Solicitante The University of TokyoInventor/a Yoshihiro KAWAOKA

The present invention is intended to provide an adjuvant having high safety to living bodies and an action to sufficiently reinforce immune function, and a vaccine comprising the adjuvant. Specifically, the present invention relates to 34 novel adjuvant candidate compounds, which have been identified by screening 145 food additives and 51 injection additives, using, as indicators, an increase in the antibody titer against influenza virus and a protective effect against infection with influenza virus, and then selecting those having the function of increasing the antiviral antibody titer in blood and the protective effect against viral infection. In addition, the present invention also relates to a vaccine comprising these adjuvant candidate compounds.

11.20240261383RECOMBINANT FUSION PROTEIN VACCINE CONTAINING CLOSTRIDIOIDES DIFFICILE FLIC AND FLID

US - 08.08.2024

Clasificación Internacional A61K 39/08Nº de solicitud 18390057Solicitante University of South FloridaInventor/a Xingmin Sun

A novel vaccine and methods of preventing and treating *C. difficile* infection in a patient is described. The vaccine is comprised of a fusion protein (denoted FliCD) comprised of the FliC and FliD from *C. difficile* and joined by a linker sequence. Administration of the vaccine, as well as anti-FliCD serum, has been shown to prevent *C. difficile* infection as well as treat existing infections.

12.WO/2024/163138RECOMBINANT FUSION PROTEIN VACCINE CONTAINING CLOSTRIDIOIDES DIFFICILE FLIC AND FLID

WO - 08.08.2024

Clasificación Internacional A61K 38/16Nº de solicitud PCT/US2024/010819Solicitante UNIVERSITY OF SOUTH FLORIDAInventor/a SUN, Xingmin

A novel vaccine and methods of preventing and treating *C. difficile* infection in a patient is described. The vaccine is comprised of a fusion protein (denoted FliCD) comprised of the FliC and FliD from *C. difficile* and joined by a linker sequence. Administration of the vaccine, as well as anti-FliCD serum, has been shown to prevent *C. difficile* infection as well as treat existing infections.

13.WO/2024/159517HEPATITIS B MRNA AND VACCINE AND USE THEREOF

WO - 08.08.2024

Clasificación Internacional C12N 15/51Nº de solicitud PCT/CN2023/074384Solicitante SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGYInventor/a WANG, Peng

Provided are a hepatitis B mRNA and a vaccine and use thereof. A protein encoded by an mRNA molecule contains at least one of a hepatitis B PreS1 antigen protein, a hepatitis B core antigen protein, a hepatitis B polymerase, and a polymerase T cell epitope enriched fragment. The use of an mRNA-LNP vaccine for immunizing healthy and HBV model mice can induce strong humoral immune response and wide cellular immune response, and can significantly improve viral serological indicators of HBV model mice, thus indicating that the vaccine has the potential of clinical functional cure of HBV.

14.20240252627MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAME

US - 01.08.2024

Clasificación Internacional A61K 39/39Nº de solicitud 18629427Solicitante Longeveron Inc.Inventor/a Joshua M. HARE

The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.

15.20240261386COXSACKIEVIRUS 83 VACCINE

US - 08.08.2024

Clasificación Internacional A61K 39/125Nº de solicitud 18165762Solicitante KING FAISAL UNIVERSITYInventor/a JAWHAR GHARBI

The Coxsackievirus B3 (CVB3) vaccine including a mutant strain of Coxsackievirus B3 (CVB3) (SEQ ID NO: 1) has specific double mutations introduced in the Internal Ribosome Entry Segment (IRES) region of the wild type Coxsackievirus B3 (CVB3) genome in the nucleotide positions 473 (in which uracil is substituted for cytosine) and 475 (in which cytosine is substituted for uracil). The resulting double mutant (SEQ ID NO: 1) demonstrates a significant decrease in its replicative capacity and a drastic decrease in its translation efficiency compared to the wild-type Coxsackievirus B3 (CVB3) strain.

16.20240252616LIVE-ATTENUATED VIRUS VACCINE

US - 01.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18016137Solicitante GRIFFITH UNIVERSITYInventor/a Surendran Mahalingam

This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-COV-2 comprising a partly codon deoptimized viral genome, SARS-COV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.

17.20240261391TLR7 AGONIST CONJUGATED PEPTIDE-BASED NOVEL CORONAVIRUS NANOEMULSION VACCINE AND PREPARATION THEREOF

US - 08.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18565013Solicitante SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventor/a Xinxin ZHANG

The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test. The nanoemulsion vaccine of the present invention is fast and convenient to prepare, and can realize large-scale production in a short term for coping with the novel coronavirus outbreak.

18.20240252620COMBINED AGONIST ADJUVANT FOR CORONAVIRUS VACCINE

US - 01.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18564263Solicitante THE REGENTS OF THE UNIVERSITY OF MICHIGANInventor/a Pamela Wong

The disclosure is directed to compositions and methods for inducing an immune response against a coronavirus, which involve a coronavirus vaccine and an adjuvant composition. The adjuvant composition comprises a nanoemulsion, an agonist of retinoic acid-inducible gene I (RIG-I), and/or an agonist of a toll-like receptor.

19.WO/2024/160088USE OF AESCIN AND/OR SALT COMPOUND THEREOF AS ADJUVANT IN VACCINE

WO - 08.08.2024

Clasificación Internacional A61K 39/39Nº de solicitud PCT/CN2024/073565Solicitante SICHUAN UNIVERSITYInventor/a SUN, Xun

The present invention provides a use of aescin and/or an aescin salt compound as an adjuvant in a vaccine. The results of animal experiments show that the combination of aescin and an antigen can increase the antibody levels of sera IgG, IgG1, and IgG2a, i.e., enhance both humoral and cellular immune responses, and can be used as an adjuvant in a vaccine.

20.WO/2024/160956ANTI-TUBERCULOSIS VACCINE TARGETING SELECTED MYCOBACTERIUM TUBERCULOSIS PROTECTIVE ANTIGENS TO DENDRITIC CELLS

WO - 08.08.2024

Clasificación Internacional A61K 39/04Nº de solicitud PCT/EP2024/052500Solicitante INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventor/a LEVY, Yves

There is an urgent need for an efficient therapeutic vaccine against tuberculosis (TB), which remains a major public health issue. Current "classic" strategies under development failed or are not optimal, and to reach the World Health Organization's 2035 End TB Strategy, more efficacious vaccines are needed. The inventors have generated a post-exposure/therapeutic TB vaccine candidate (CD40.TB), consisting in an antibody directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain is conjugated to 3 pertinent Mycobacterium tuberculosis (Mtb) antigens, and prone to induce strong anti-TB humoral and cellular immunity.

21.20240261390VACCINE FOR PREVENTION OR TREATMENT OF VIRAL INFECTION

US - 08.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18563019Solicitante LEMONEX INC.Inventor/a CHEOL HEE WON

A nucleic acid molecule of RBD-(L)n-X sequence, wherein, RBD is a sequence of at least a partial region including the receptor-binding domain of the spike protein, L is a linker sequence, n is 0 or 1, and X is the nucleotide sequence of SEQ ID NO: 1 may be used in a vaccine composition against various viral infections.

22.20240261393SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE

US - 08.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18612698Solicitante HDT Bio Corp.Inventor/a Steven Gregory Reed

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.

23.20240252622NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

US - 01.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18615472Solicitante INSTITUT PASTEURInventor/a Etienne SIMON-LORIERE

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

24.4408459DNA-IMPFSTOFF ZUR VERWENDUNG BEI DER THERAPEUTISCHEN UND/ODER PROPHYLAKTISCHEN BEHANDLUNG VON TUMORERKRANKUNGEN

EP - 07.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 22793599Solicitante UNIV DEGLI STUDI DI TORINOInventor/a NOVELLI FRANCESCO

The invention relates to a recombinant expression vector suitable for use as a prophylactic or therapeutic vaccine against tumor diseases. In addition to a promoter and any additional transcription regulatory elements, the recombinant expression vector of the invention comprises a nucleotide sequence encoding an immunogenic synthetic peptide resulting from the fusion of two or more of the amino acid sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:9 of the human EN01

protein, excluding peptides that correspond to fragments of the native human EN01 protein. The recombinant vector of the invention, or the immunogenic synthetic peptides encoded thereby, are useful as a prophylactic or therapeutic vaccine against tumor diseases.

25.WO/2024/163912VACCINE AND THERAPEUTIC PROTEIN DELIVERY COMPOSITIONS COMPRISING FUSION PROTEINS

WO - 08.08.2024

Clasificación Internacional A61K 39/145Nº de solicitud PCT/US2024/014273Solicitante THE CHILDREN'S MEDICAL CENTER CORPORATIONInventor/a MCCARTHY, Kevin R.

Provided herein are compositions comprising a polypeptide molecule, or a nucleic acid encoding such a polypeptide molecule, comprising an ectodomain polypeptide of interest and an ectodomain liberation sequence (ELS) that, when cleaved, separates the polypeptide of interest into a soluble ectodomain and a transmembrane domain. Methods of use of such polypeptides or nucleic acids encoding them are also described, including, for example generation and/or delivery of vaccine antigens and, for example, delivery of therapeutic polypeptides.

26.4410969REKOMBINANTER LEBENDER ABGESCHWÄCHTER RSV-IMPFSTOFFSTAMM UND HERSTELLUNGSVERFAHREN DAFÜR

EP - 07.08.2024

Clasificación Internacional C12N 7/00Nº de solicitud 22876926Solicitante SK BIOSCIENCE CO LTDInventor/a SEO KI-WEON

The present invention provides a recombinant attenuated respiratory syncytial virus (RSV) comprising i) a nucleic acid encoding an F protein of a stabilized pre-fusion respiratory syncytial virus (RSV) or its analogue, variant, or fragment; or ii) a nucleic acid encoding a G protein of vesicular stomatitis Indiana virus (VSV) or its analogue, variant, or fragment, and provides a genome of the recombinant RSV, and a recombinant vector comprising the genome. The recombinant attenuated RSV can be provided as a live vaccine strain which is safe and has excellent stability while maintaining infectiousness.

27.WO/2024/162788ANTIGEN FOR SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS, AND HIGH-EFFICACY VACCINE COMPOSITION COMPRISING SAME

WO - 08.08.2024

Clasificación Internacional C07K 14/005Nº de solicitud PCT/KR2024/001524Solicitante KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventor/a KIM, Seong Jun

In the present invention, an antigen exhibiting higher antigenicity by being fused with a human LRRC24 protein-derived transmembrane domain peptide (LRRC24p) has been discovered, and it has also been identified that a neutralizing antibody is more well-formed even in actual animal experiments. It has been identified that, after inoculation with a recombinant antigen, excellent protective immunity is induced in all mice in a post-immunization challenge test in which SFTSV infection occurs. By using the recombinant antigen exhibiting these results, a vaccine for prevention of SFTSV, which exhibits lethal risk, can be developed.

28.WO/2024/159030HUMAN PAPILLOMAVIRUS, VARICELLA-ZOSTER VIRUS, AND RABIES VIRUS ANTIGENS AND USES THEREOF IN CANCER IMMUNOTHERAPY

WO - 02.08.2024

Clasificación Internacional Nº de solicitud PCT/US2024/012976Solicitante THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventor/a CUBURU, Nicolas

Provided herein are varicella-zoster virus vaccine, human papillomavirus vaccine, and Rabies vaccine antigens, compositions thereof, and uses thereof in cancer immunotherapy and cancer treatment.

29.20240252670ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

US - 01.08.2024

Clasificación Internacional A61K 47/68Nº de solicitud 18560288Solicitante TSINGHUA UNIVERSITYInventor/a Xuebin LIAO

Disclosed are an antibody drug conjugate, a preparation method therefor and an application thereof, which are in particular, a conjugate of an anti-PD-L1 antibody and a TLR7 and/or TLR8 agonist, a pharmaceutical composition thereof, a preparation method therefor and an application thereof. In the present invention, a modified anti-PD-L1 antibody having mutated cysteine is obtained by means of gene editing, basically retains the structure of the original antibody, and may be used for the construction of antibody drug conjugates. By means of anti-tumor experiments, it has been discovered that the obtained antibody drug conjugate has good activity, such as strong anti-tumor activity, which may significantly improve the survival rate of tumor-bearing animals, and significantly reduce toxicity. Moreover, the antibody drug conjugate is less burdensome on the bodies of test animals, which greatly reduces the minimum effective dose of small molecular drugs when used alone, expands the therapeutic window thereof, is expected to be used in the development of therapeutic drugs for various diseases (such as tumors, viral diseases such as hepatitis B, etc.), and has good application prospects and value.

30.20240262876RECOMBINANT VACCINE AGAINST HELMINTHS IN PICHIA PASTORIS AND METHODS FOR PRODUCING AND PURIFYING PROTEINS FOR USE AS VACCINES AGAINST HELMINTHS

US - 08.08.2024

Clasificación Internacional C07K 14/435Nº de solicitud 18443739Solicitante Fundacao Oswaldo CruzInventor/a Miriam TENDLER

The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in *Pichia pastoris*. More specifically, the invention describes the production of Sm14 *Schistosoma mansoni* recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of *Pichia pastoris* promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, *Pichia pastoris* strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from *P. pastoris* cells, which can be escalated for their industrial production, were also improved.

31.WO/2024/159105METHODS OF TREATING CANCER COMPRISING ADMINISTRATION OF INTRATUMORAL DCS IN COMBINATION WITH SYSTEMIC IGG MONOCLONAL ANTIBODY

WO - 02.08.2024

Clasificación Internacional A61K 35/15Nº de solicitud PCT/US2024/013120Solicitante H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor/a CZERNIECKI, Brian

Disclosed are combination therapies comprising a semaphoring vaccine and dendritic cell vaccine and methods of their use in the treatment of cancer.

32.20240252608PEPTIDE ANALOGS CAPABLE OF ENHANCING STIMULATION OF A GLIOMA-SPECIFIC CTL RESPONSE

US - 01.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 18342884Solicitante University of Pittsburgh - Of the Commonwealth System of Higher EducationInventor/a Hideho OKADA

The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.

33.WO/2024/157221PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS GLYCOPROTEIN C, GLYCOPROTEIN D, AND GLYCOPROTEIN E ANTIGENS AND RELATED METHODS

WO - 02.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/IB2024/050751Solicitante BIONTECH SEInventor/a GÜLER, Alptekin

The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).

34.WO/2024/156908LIPOSOMAL CONSTRUCT

WO - 02.08.2024

Clasificación Internacional A61K 9/00Nº de solicitud PCT/EP2024/051996Solicitante AC IMMUNE SAInventor/a DI BONAVENTURA, Ivan

A liposomal construct comprises a liposome, at least one adjuvant; and a peptide containing at least one T-cell epitope which comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4 or an analogue thereof that retains alanine at position 2 and does not contain any methionine residues. The peptide preferably has the amino acid sequence of SEQ ID NO: 6. The liposomal construct may be used to generate a liposomal vaccine composition that additionally comprises at least one antigenic peptide displayed on the surface of the liposome. The liposomal vaccine compositions are useful in therapy. Methods of manufacture are also described.

35.WO/2024/160126TANDEM DESIGN METHOD AND APPARATUS FOR MULTI-EPITOPE VACCINES, DEVICE, AND STORAGE MEDIUM

WO - 08.08.2024

Clasificación Internacional G16B 30/10Nº de solicitud PCT/CN2024/074020Solicitante SHENZHEN NEOCURNA BIOTECHNOLOGY CORPORATIONInventor/a WAN, Ji

The present invention relates to the technical field of bioinformatics. Disclosed are a tandem design method and apparatus for multi-epitope vaccines, a device, and a storage medium. The method comprises: acquiring multiple sequence alignment data and a sequence feature matrix of candidate vaccine sequences; performing calculation according to the multiple sequence alignment data and the sequence feature matrix to obtain an initial PSSM for feature encoding, so as to obtain action feature information; at the same time, performing local feature extraction on the sequence feature matrix to obtain local feature information; obtaining an enhanced PSSM on the basis of the local feature information and the action feature information; then calculating predicted lysis probabilities of sites of the candidate vaccine sequences according to the enhanced PSSM and the sequence feature matrix; and finally constructing a mixed integer linear programming problem for optimization solution to obtain multiple multi-epitope vaccines. Thus, local hidden patterns and features of adjacent amino acid residues of the candidate vaccine sequences can be extracted, and the initial PSSM is corrected to obtain a more accurate enhanced PSSM to participate in subsequent epitope tandem design, thereby improving the accuracy and reliability of the designed multi-epitope vaccines.

36.WO/2024/159101METHODS FOR IDENTIFYING DISSEMINATED CANCER CELLS IN BREAST CANCER PATIENTS

WO - 02.08.2024

Clasificación Internacional A61K 35/15Nº de solicitud PCT/US2024/013114Solicitante H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor/a CZERNIECKI, Brian

Disclosed are methods for the detection and isolation of disseminated cancer cells and the used of tumor antigen pulsed type 1 dendritic cell vaccine for the treatment and prevention of metastasis and abscopal tumors.

37.4408462PANCORONAVIRUS-IMPFSTOFFE

EP - 07.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud 22877654Solicitante GRITSTONE BIO INCInventor/a GITLIN LEONID

Disclosed herein are vaccine compositions that include Pancorona receptor binding domain (RBD) encoding cassettes and/or MHC epitope-encoding cassettes. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

38.20240252554TREATMENT AND PREVENTION OF NEUROPATHOLOGY ASSOCIATED WITH NEURODEGENERATIVE DISEASES

US - 01.08.2024

Clasificación Internacional A61K 35/74Nº de solicitud 18633352Solicitante ILiAD Biotechnologies, LLCInventor/a Keith Rubin

Administering a live, attenuated *Bordetella pertussis*-based vaccine to a subject at risk for developing a neurodegenerative disease featuring Aβ brain plaques can prevent or reduce the amount of Aβ brain plaques that would have developed in the subject without such treatment.

39.WO/2024/164014RSV F VACCINE FORMULATIONS

WO - 08.08.2024

Clasificación Internacional C07K 14/135Nº de solicitud PCT/US2024/014509Solicitante NOVAVAX, INC.Inventor/a PATEL, Nita

Disclosed herein are RSV F glycoproteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

40.WO/2024/163969MODULAR EVALUATION OF IMMUNOGENICITY USING MULTI-PLATFORM HUMAN IN VITRO SYSTEMS

WO - 08.08.2024

Clasificación Internacional A61K 31/739Nº de solicitud PCT/US2024/014350Solicitante THE CHILDREN'S MEDICAL CENTER CORPORATIONInventor/a VAN HAREN, Simon, D.

Provided herein are methods for characterizing population- specific immunogenicity of immunomodulatory agents including small molecule adjuvants and adjuvanted vaccines. The provided methods are useful for determining the activity and mechanism of action of such agents and may be used, for example, to further characterize previously known vaccine adjuvants, facilitate discovery and development of new immunomodulatory agents, and define biomarkers of their safety and efficacy.

41.WO/2024/158722SARS-COV-2 VACCINE CONSTRUCTS

WO - 02.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2024/012464Solicitante RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventor/a ANDERSON, Stephen

The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.

42.WO/2024/161017AVIAN-SPECIFIC VIRAL VACCINE VECTORS

WO - 08.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2024/052645Solicitante HENNRICH, Alexandru AdrianInventor/a HENNRICH, Alexandru Adrian

The present invention relates to a nucleic acid molecule comprising, in expressible form, a glycoprotein (G) gene deleted genome of a negative single-strand RNA virus of the order Mononegavirales, preferably a VSV rhabdovirus, wherein said genome comprises, as additional elements, an (Envelope) Env gene of an avian leukosis virus (ALV) and one or more sequences encoding one or more immunogenic proteins or peptides.

43.20240252621VIRUS-LIKE PARTICLE VACCINE FOR CORONAVIRUS

US - 01.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18565728Solicitante Icosavax, Inc.Inventor/a Niranjan Kanesa-Thasan

The present disclosure relates to targeting SARS-CoV-2, in particular, prevalent strains of SARS-CoV-2, and methods of using such vaccines to induce neutralizing antibody levels against SARS-CoV-2.

44.WO/2024/159313VACCINE FOR STREPTOCOCCUS EQUI SUBSP. ZOOEPIDEMICUS

WO - 08.08.2024

Clasificación Internacional A61K 39/09Nº de solicitud PCT/CA2024/050111Solicitante UNIVERSITY OF SASKATCHEWANInventor/a COSTA, Matheus

Provided herein is a composition comprising a live strain of *S. zooepidemicus* and a pharmaceutically acceptable carrier, wherein the live strain of *S. zooepidemicus* contains a mutated M protein trans-acting positive regulator (MGA) gene that results in impaired DNA binding. Also provided are methods and uses to eliciting an immune response against an infection by *S. zooepidemicus* in a subject, comprising administering to the subject an effective amount of the composition described herein. Also provided is a method of generating strains of *S. zooepidemicus* with reduced virulence.

45.WO/2024/163508METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE

WO - 08.08.2024

Clasificación Internacional A61K 39/145Nº de solicitud PCT/US2024/013595Solicitante ARCTURUS THERAPEUTICS, INC.Inventor/a SULLIVAN, Brian

Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.

46.4408886BEHANDLUNG MIT NICHTIMMUNOGENER RNA ZUR ANTIGENIMPFUNG UND PD-1-ACHSEN-BINDENDEN ANTAGONISTEN

EP - 07.08.2024

Clasificación Internacional C07K 16/24Nº de solicitud 22800119Solicitante BIONTECH SEInventor/a SAHIN UGUR

The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. These methods and agents are, in particular, useful for the treatment of diseases characterized by diseased cells expressing an antigen the immune effector cells are directed to. In some embodiments, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or polypeptide comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) a PD-1 axis binding antagonist such as an anti-PD-1 antibody and/or an anti-PD-L1 antibody.

47.20240252610A BROADLY PROTECTIVE PROPHYLACTIC VACCINE AGAINST PSEUDOMONAS AERUGINOSA

US - 01.08.2024

Clasificación Internacional A61K 39/104Nº de solicitud 18562170Solicitante UNIVERSITY OF KANSASInventor/a Wendy L. PICKING

Disclosed are compositions comprising a fusion polypeptide comprising i) a fusion of a needle tip protein or an antigenic fragment thereof and/or a translocator protein or an antigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria and ii) the A1 subunit of the labile toxin (LTA1) from enterotoxigenic *Escherichia coli* or cholera toxin, and methods of their use.

48.20240262869POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-COV-2, AND IMPLEMENTATIONS THEREOF

US - 08.08.2024

Clasificación Internacional C07K 14/005Nº de solicitud 18004065Solicitante Indian Institute of ScienceInventor/a Raghavan VARADARAJAN

The present disclosure discloses the polypeptide fragment having an amino acid sequence with at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6. The present disclosure also discloses

nucleic acid fragment encoding the polypeptide fragment as described herein. Moreover, the present disclosure also discloses recombinant construct, recombinant vector and recombinant host cells. Also disclosed herein is an immunogenic composition comprising the polypeptide fragment as described herein, and a method for preparing the said immunogenic composition. The immunogenic composition is in form of vaccine. The polypeptide fragment and/or immunogenic composition is capable of eliciting protection against severe acute respiratory syndrome coronavirus 2. A kit comprising the polypeptide, or the immunogenic composition as described herein is also disclosed.

49.20240262891HYBRIDOMA CELL LINE FOR SECRETING ANTI-RABIES VIRUS M PROTEIN MONOCLONAL ANTIBODY AND APPLICATION THEREOF

US - 08.08.2024

Clasificación Internacional C07K 16/10Nº de solicitud 17294414Solicitante ZHEJIANG UNIVERSITYInventor/a Jiyoung ZHOU

The present invention discloses a hybridoma cell line for secreting monoclonal antibody against rabies virus M protein and application thereof, relates to the field of biotechnology. A classification of the hybridoma cell line is named as hybridoma cell line 4A1, and the hybridoma cell line was deposited on Apr. 1, 2019 in the China Center for Type Culture Collection, Wuhan University, Wuhan, China, with a deposit number CCTCC NO: C201947. The monoclonal antibody prepared by the hybridoma cell line has high titer, good specificity and excellent biological characteristics. The present invention identifies the variant antigen epitope recognized by the RABV M protein, the hybridoma cell line can be used to distinguish Flury strain and other RABV strains, prepare kit for detecting rabies virus RABV, detect RABV infection and differential diagnosis vaccine Flury strain and other RABV strains.

50.20240261394COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES AGAINST CLASS I FUSION PROTEIN VIRUSES

US - 08.08.2024

Clasificación Internacional A61K 39/225Nº de solicitud 17924963Solicitante University of Virginia Patent FoundationInventor/a Steven L. Zeichner

Provided are modified bacteria and derivatives thereof that express nucleotide sequence encoding an antigen of a viral family selected from the group comprising Retroviridae (e.g., HIV, including a HIV Fusion Peptide antigen), Orthomyxoviridae, Paramyxoviridae, Arenaviridae, 5 Filoviridae, and/or Coronaviridae (e.g., an SARS-CoV, SARS-CoV-2 Fusion Peptide, and/or PEDV). In some embodiments, the bacterium has a reduced genome and induces an enhanced immune response against the viral antigen of interest when administered to a subject. In some embodiments, the viral (e.g., SARS-CoV, 10 SARS-CoV-2, PEDV, and/or HIV) antigen is expressed on a surface of a bacterium. Also provided are method for producing antibodies against viral antigens, vaccine compositions, methods for vaccinating subjects, methods for treating viral infections in subjects, and expression vectors for expressing viral antigens including but not limited to coronavirus (e.g., SARS-CoV, SARS-CoV-2, and/or PEDV) antigens and/or HIV antigens on the surface of reduced 15 genome bacteria.

51.WO/2024/157026RH5-INTERACTING PROTEIN (RIPR) EGF DOMAIN (RIPR EGF) ANTIGEN-BASED MALARIA VACCINE

WO - 02.08.2024

Clasificación Internacional A61K 39/015Nº de solicitud PCT/GB2024/050210Solicitante OXFORD UNIVERSITY INNOVATION LIMITEDInventor/a DRAPER, Simon J

The present invention relates to antigens, antibodies and vaccines for treatment or prevention of malaria.

52.2024204962METHODS FOR ENHANCING EFFICACY OF A VACCINE BY ADMINISTERING AN IL-4R ANTAGONIST

AU - 01.08.2024

Clasificación Internacional Nº de solicitud 2024204962Solicitante Regeneron Pharmaceuticals, Inc.Inventor/a Evans, Robert

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES

CUBA